Acute ischaemic stroke-multimodal imaging and stroke outcomes by Cheripelli, Bharath kumar
Cheripelli, Bharath kumar (2020) Acute ischaemic stroke-multimodal 
imaging and stroke outcomes. MD thesis. 
http://theses.gla.ac.uk/81736/ 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
1 
 
 
 
 
 
 
      Acute Ischaemic Stroke- 
     Multi modal Imaging and  
           Stroke outcomes  
 
           Dr Bharathkumar Cheripelli 
              MBBS, MRCP, CCT (Neurology)   
 
 
     A thesis which fulfils the requirements of the University of 
            Glasgow for the degree of Doctorate of Medicine 
                
                  Institute of Neuroscience and Psychology 
                             University of Glasgow 
                                    October 2019                                                                               
 
 
 
 
 
 
  2 
 
Abstract 
 
Introduction 
Acute stroke Imaging plays a crucial role in understanding the cerebral tissue 
states and multimodal imaging with perfusion, collaterals and vessel occlusion 
provides more information on tissue dynamics in individual patient which can be 
useful for tailored treatments and prognosis. Perfusion parameters and their 
validation are important in achieving clinical practicality. A novel tissue 
parameter, Capillary transit time heterogeneity has been suggested to identify 
micro vascular flow patterns. The clinical utility of this is not yet established.  
Stroke outcome is dependant not only on the imaging parameters but also on 
patient demographics, co morbidities and probably on complex socio-economic 
and other unidentified patient factors. 
Methods 
 
Using a database of single centre multi modal imaging I derived perfusion metrics 
in commercial software (MIstar). I conducted a few different analyses on: 
penumbra relationship with time, collaterals; haemorrhage, oedema relationship 
with recanalisation; Safety in Stroke Thrombolysis (SITS) registry Stroke outcomes; 
Deriving a new perfusion parameter called ‘Capillary transit time heterogeneity 
(CTTH)’ and comparing the values in different tissue compartments.    
 
Results 
In a cross-sectional sample imaged within 6h, neither the proportions of 
penumbral tissue nor “target mismatch” varied by time from onset. A trend for 
reducing penumbra proportion only among those with poor collaterals may have 
pathophysiological and therapeutic importance. 
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Among patients treated with IV thrombolysis, 24h recanalisation was not 
independently associated with significant early (24h) vasogenic oedema or 
significant haemorrhage, although incidence of HI/HI2 ICH was higher. Large 
ischaemic core was associated with both significant brain oedema and poor 
outcome. There was no interaction of recanalisation and large core lesions for any 
imaging outcomes. Early major clinical improvement as a marker of probable early 
reperfusion was associated with lower incidence of both significant haemorrhage 
and oedema. 
In SITS registry study, poorer 90 day outcomes after IV thrombolysis occurred 
frequently at a hospital (Southern General Hospital) that accepted secondary 
transfer patients compared to a hospital in the same city (Western Infirmary 
Glasgow) that did not routinely take such patients.  
Capillary transit time heterogeneity (CTTH) voxel wise maps were derived 
successfully using “vascular model” in Brain Lab, Arhus, Denmark. The CTTH 
values are closely related with MTT. There is no significant difference of CTTH 
between Core, penumbra.  
Conclusion 
Multimodal imaging can provide us with valuable information on understanding 
ischemic brain tissue, predict patient outcomes in stroke. Patient imaging and 
clinical outcomes depend on recanalisation, and patient factors. A novel perfusion 
parameter, CTTH has been successfully derived and its utility and validity is yet to 
be evaluated. 
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Definitions/Abbreviations 
 
4D          4 Dimensional  
ACA       Anterior Cerebral Artery coefficient 
ADC       Apparent diffusion coefficient 
AF           Atrial Fibrillation  
AIF          Arterial Input Function  
AIS           Acute Ischaemic Stroke  
ANOVA       Analysis of Variance  
ASPECTS   Alberta Stroke Program Early CT Score  
ATP          Adenosine Triphosphate  
ATTEST     Alteplase – Tenecteplase Trial Evaluation for Stroke Thrombolysis  
BBB          Blood Brain Barrier  
BKCR        Bohr-Kety-Crone-Renkin 
BP            Blood Pressure  
CTTH        Capillary transit time heterogeneity 
CBF          Cerebral Blood Flow  
CBV           Cerebral Blood Volume  
CI             Confidence Interval  
CMRglu      Cerebral Metabolic Rate of Glucose  
CMRO2      Cerebral Metabolic Rate of Oxygen  
COV          Coefficient of variation 
CPP           Cerebral Perfusion Pressure  
CSF           Cerebro-Spinal Fluid  
CT             Computed Tomography  
CTA            CT Angiography  
CTP           CT Perfusion  
CVR            Cerebrovascular Resistance  
DEFUSE     Diffusion and Perfusion Imaging Evaluation for Understanding Stroke 
Evaluation  
DICOM        Digital Imaging and Communications in Medicine  
DWI            Diffusion Weighted Imaging (MRI)  
DSA            Digital Subtraction Angiography  
DT              Delay Time  
ECASS        European Cooperative Acute Stroke Study EIC (Early Ischaemic changes) 
EPITHET     Echoplanar Imaging Thrombolytic Evaluation Trial  
ESCAPE      Endovascular Treatment for small Core and Anterior Circulation 
Proximal Occlusion with Emphasis on Minimising Computed Tomography to 
Recanalisation Times  
EXTEND     Extending the Time for Thrombolysis in Emergency Neurological Deficits  
FLAIR         Fluid-Attenuated Inversion Recovery imaging (MRI)  
FMSIO        F18-fluormisonidazole 
FOV           Field of View  
GRE           Gradient Echo (MRI)  
HI               Haemorrhagic Infarction  
HU             Hounsfield Unit  
IA               Intra-arterial  
ICA            Internal Carotid Artery  
ICH            Intra cerebral Haemorrhage  
IQR            Inter quartile Range  
IST3           International Stroke Trial 3  
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IV               Intravenous  
LACS          Lacunar stroke 
LMF           Leptomeningeal collateral flow 
LMA           Leptomeningeal collateral arteries 
MASIS            Multicentre Acute Stroke Imaging Study  
MCA              Middle Cerebral Artery  
MIP                Maximum Intensity Projection  
MR CLEAN      Multicenter Randomized Clinical Trial of Endovascular Treatment for 
Acute    Ischemic Stroke in the Netherlands  
MRI             Magnetic Resonance Imaging  
MR RESCUE Mechanical Retrieval and Recanalisation of Stroke Clots Using 
Embolectomy  
mRS           modified Rankin Scale  
MTT           Mean Transit Time  
NCCT         Non-Contrast Computed Tomography  
NCCP         Non-core-non-penumbra 
NIFTI         Neuroimaging Informatics Technology Initiative 
NIHSS         National Institute of Health Stroke Scale  
NINDS        National Institute of Neurological Disorders and Stroke  
NMDA         N-methy1-D-asapartate  
NNT           Number Needed to Treat  
NVD           Neurovascular dysfunction 
OCSP         Oxfordshire Community Stroke Project 
OEF           Oxygen Extraction Fraction   
OR              Odds Ratio 
oSVD           Circular Singular value decomposition 
OTT            Onset-to-treatment Time  
PACS            Partial anterior circulation stroke 
PCA             Posterior Cerebral Artery  
PDF             Probability density function 
PET             Positron Emission Tomography  
PH               Parenchymal Haemorrhage  
POCS            Posterior circulation stroke 
POSH            Post Stroke Hyperglycaemia  
PRACTISE      Penumbra and Recanalisation Acute Computed Tomography in 
Ischaemic Stroke Evaluation  
PROBE           Prospective Randomised Open Blinded End-point  
PWI               Perfusion Weighted Imaging (MRI)  
RAPID           Rapid Processing of Perfusion and Diffusion 
RCT               Randomised Controlled Trial  
REVASCAT Randomized Trial of Revascularization with Solitaire FR Device versus 
Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation 
Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset   
ROI              Region of Interest  
rtPA             recombinant tissue Plasminogen Activator  
SD                Standard Deviation 
SGH              Southern General Hospital 
SI                   Source images 
SICH             Symptomatic Intra-cerebral Haemorrhage  
SITS               Safety in stroke thrombolysis 
SITS-MOST    Safe Implementation of Thrombolysis in Stroke Monitoring Study 
SPECT          Single Photon Emission CT  
SWI              Susceptibility Weighted Imaging (MRI)  
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SWIFT-PRIME Solitaire with intention for Thrombectomy as Primary Endovascular 
Treatment  
sSVD            Standard Singular Value Decomposition  
TACS           Total anterior stroke 
TEMPIS        Telemedicine Pilot Project for Integrative Stroke Care 
TIA              Transient Ischaemic Attack  
TICI             Thrombolysis in Cerebral Infarction  
TIMI            Thrombolysis in Myocardial Infarction  
Tmax          Time to Maximum  
TNK            Tenecteplase  
TOAST        Trial of ORG 10172 in Acute Stroke Treatment  
TOF           Time of Flight Imaging (MRA)  
tPA             Tissue Plasminogen Activator  
TTP            time to peak 
UK              United Kingdom 
VM                 Vascular model  
VOF               Venous Output Function  
WAKE-UP        Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke 
WGI                Western general Infirmary 
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Chapter 1 Introduction 
 
1.1 Acute Ischaemic stroke (overview) 
Stroke represents a substantial socioeconomic burden globally. It is the second 
most common cause of mortality worldwide and the leading cause of adult 
disability1. In UK prevalence is 518 per 100,000 and annual incidence is around 
110 per 100,000.  
Despite a decline in incidence and mortality over the past three decades, stroke 
continues to be a disabling disease, with one half having residual hemi paresis, 
one third unable to walk or requiring institutional care at six months. In the UK 
societal costs are estimated at £8.9 billion per year2-4. Ischemic stroke accounts 
for 87% of all strokes while primary intra cerebral haemorrhage accounts for 10% 
5. A Stroke registry study in 1712 ischaemic stroke patients showed prevalence of 
atherothrombosis (23.7%), Cardio-embolic (26.5%), small vessel disease (22.9%), 
cryptogenic (14.7%), two causes (4.7%) and not sufficiently studied (6.4%)6. 
TOAST (a set of criteria originally developed for the Trial of Org 10172 in Acute 
stroke treatment) classification was suggested to classify ischemic stroke based 
on the aetiology7. A German stroke registry study in stroke patients using TOAST 
criteria showed prevalence of atherothrombosis (20.9%), cardio-embolic (25.6%) 
and small vessel disease (20.5%)8. SSS-TOAST is a modified TOAST criteria using 
imaging, cardiovascular, historical, laboratory information to assign the 
mechanism with certainty9. This classifies stroke aetiology as:  
 Large artery atherosclerosis (evident-probable-possible) 
 Cardiac embolism 
 Small vessel occlusion 
 Stroke of other determined aetiology 
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 Stroke of undetermined aetiology  
 Unknown-cryptogenic embolism 
 Unknown-other cryptogenic 
 Unknown-incomplete evaluation 
 Unclassified 
The most commonly affected territory in ischemic stroke is middle cerebral 
artery (46.6%), followed by posterior cerebral artery (10.7%), basilar artery (8%), 
anterior choroidal artery (6.2%), cerebellar arteries (4.8%) and anterior cerebral 
artery (3.2%)6.  
Intravenous thrombolysis within 4.5 hours has been the mainstay of treatment 
since publication of the National Institute of Neurological Disorders and Stroke 
(NINDS) 10 and third European Co-operative acute stroke study (ECASS-III)11 trials. 
Intra arterial thrombectomy (IAT) has been proven to be beneficial in selected 
patients with proximal large artery occlusions as an adjunct to intra venous 
thrombolysis12,13.  IAT is now considered as an adjunctive treatment to IV 
thrombolysis  for a selected population in the UK14 . Multimodal Imaging has 
played a crucial role in patient selection, both in research settings and in routine 
clinical practice. Tissue level imaging with perfusion metrics has been studied in 
research trials15-17. Large artery recanalisation does not reflect the tissue and 
clinical outcomes. Among many other factors, a possible explanation is the role 
of “microcirculation” with incomplete reperfusion at microcirculatory level18,19. 
There is potential role of the microcirculation in acute ischemic stroke and how 
this may play a role in tissue fate20-22. Of important development in this area is 
“capillary transit time heterogeneity”23.   
In this thesis, I looked at the 3 month stroke outcomes between UK centres (2 
hospitals in Glasgow, and rest of the UK) using Safety in Stroke Thrombolysis 
(SITS) stroke registry. I then looked at the cross sectional variation in penumbra 
volumes over time (within 6 hours of stroke) and role of collaterals in this 
relation of penumbra with time. I also investigated the effect of recanalisation 
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in respect to haemorrhage and oedema occurrence after IV thrombolysis. I 
investigated a novel approach in deriving perfusion maps by incorporating 
“capillary transit time heterogeneity” using vascular model to understand and 
investigate the tissue states.  
1.2 Pathophysiology 
Ischaemic stroke is caused by a critical reduction of regional cerebral blood flow 
beyond a critical duration. This can be caused by atherothrombosis, cardiac or 
large artery embolism or small vessel occlusion. The extent of ischaemic 
infarction depends on the site of vessel occlusion, compensatory capacity of 
vascular bed (fig.1-1). Large artery occlusion with poor collateral flow can cause 
large Middle cerebral artery (MCA) territory infarction where as with good 
collateral flow the extent of infarction can be less 24. Border zones can be 
affected with critical stenosis of large arteries, whereas, lacunar infarctions are 
caused by different mechanisms: embolism from the heart, carotid artery; 
atheroma of parent artery or perforating arterioles;  intrinsic small vessel 
disease (lipohyalinosis or fibrinoid necrosis)25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Arterial occlusion site and extent of Cerebral infarction 
a. Total territorial infarct b. Core infarct c. Territorial infarct in centre of supply area, due to branch 
occlusion d. Border zone infarction in watershed areas e. Lacunar infarction due to small vessel 
disease. Reproduced with permission from Textbook of stroke medicine (p. 4), Brainin M and Heiss 
W-D(eds), 2010, Cambridge University press.  
 
  22 
 
1.2.1 Cellular pathology of ischaemic stroke 
Ischaemia is defined as reduction in cerebral blood flow causing altered cellular 
function. The reduction in cerebral blood flow is not uniform throughout the 
ischaemic territory, there is gradient of reducing blood flow from periphery to 
the core26. A normal adult brain comprises of 130 billion neurons (21 billion in 
neo cortex)27 comprising only 2% of body weight, but consumes approximately 
20% of the body’s total oxygen consumption. The brain’s oxygen consumption is 
almost exclusively used for oxidative metabolism of glucose28. Approximately 
70% of metabolic demand is due to the N-K ATPase pump that maintains the ion 
gradient across neuronal membranes. Ischaemia causes depletion of ATP, leading 
to influx of calcium, sodium and efflux of potassium. Cerebral blood flow 
thresholds below the requirement for the ATP synthesis are established within a 
few minutes of ischaemia29. The mechanism of death in this tissue is thought to 
be necrosis. The consequence of membrane depolarisation is Glutamate 
release30 . This leads to calcium influx 31in nearby neurons by stimulation of N-
methyl-D-aspartate receptors32. This calcium influx causes “excito-toxicity” and 
ultimately contributes to cell death33. Further, a cascade of oxidative34, nitrate 
stress32, inflammation35 cause “apoptosis”36, and necrosis. In parallel to 
molecular events above, a physiological process, “Cortical spreading depressions 
or depolarisation” (CSD)37, a sustained depolarisation spreading out from core in 
adjacent neuronal membranes is also identified as a stroke mechanism. CSD has 
been demonstrated in patients suffering from ischaemic stroke38. 
1.2.2 Cerebral haemodynamics in response to ischaemia  
Relative Cerebral Blood Flow (rCBF) values of approximately 50ml/100gm/min is 
maintained for a wide range of Cerebral Perfusion Pressure (80-150 mmHg, 
CPP)39. This is due to autoregulation mediated through changes in Cerebral 
Vascular Resistance (CVR). The relationship between CBF and CVR is known with 
an equation rCBF = r CPP/ r CVR . r CPP represents the difference between 
arterial pressure forcing blood into the cerebral circulation and the venous back 
pressure. When CBF falls below 20ml/100gm/min impairment in  function, and 
below 8ml/100g/min infarction develops26. A three stage model of 
haemodynamic change is commonly accepted in response to reduction in CPP40 
(fig.1-2). In stage 0,  CPP is normal, Cerebral Blood Volume (CBV), Mean Transi 
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Time (MTT) are not elevated, while r CBF response to vasodilatory stimulus is 
normal. In stage 1, vasodilation of arterioles occurs to maintain a constant rCBF 
when CPP falls. So, CBV, and MTT increase (MTT= (CBV/CBF)), but Oxygen 
Extraction Fraction (OEF) remains the same. In stage 2, autoregulatory capacity 
for compensatory vasodilatation is exceeded. Further reductions in CPP now 
produce decrease in CBF. While oxygen supply is diminished due to decreasing 
CBF, there is an increase in OEF to maintain Cerebral Metabolic Rate of Oxygen 
(CMRO2).  
If CPP continues to fall CBF will progressively decline until the increase in OEF is 
no longer adequate to supply the energy needs of the brain41. Clincial evidence 
of brain dysfunction now appears and this may be reversible if circulation is 
rapidly restored. In the oligaemic phase CMRO2 is normal but in ischaemia 
CMRO2 is decreased. 
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Figure 1-2 Changes in Cerebral variables with cerebral perfusion pressure reduction 
Illustration of the changes in cerebral variables during a progressive decrease in cerebral perfusion 
pressure and progression through various stages of impaired cerebral circulation. The stages are 
referenced to the changes in OEF. Stage I (Perfusion pressure >60), OEF is unchanged. Stage II 
(perfusion pressure 30-60), OEF begins to increase. Stage III (perfusion pressure <30), OEF 
declines again. Solid lines show changes that are known and dashed lines, those that are 
postulated. Reproduced with permission from “Cerebral haemodynamics in ischaemic 
cerebrovascular disease”, by Powers et al
40
, 1991, Ann Neurol, 29 (3),231-240. 
 
1.3 Types of Cerebral oedema 
The initial type of oedema following cerebral ischemia is cytotoxic oedema. 
Cytotoxic oedema is the result of cells being unable to maintain ATP-dependent 
Na-K membrane pumps which are responsible for high extracellular and low 
intracellular Sodium (Na) concentration42. When energy fails, these pumps cease 
to operate and Sodium accumulates in the cells, drawing with it chloride (Cl-), 
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and water along an osmotic gradient. Cytotoxic oedema is blood flow threshold 
dependant. At flow values of approximately 30% of control, anaerobic 
metabolism causes increase of intra cellular osmolality and hence osmotic 
swelling. At levels below 20% of control, anoxic depolarisation and equilibration 
of ion gradients further enhance intracellular osmolality and swelling43. This 
occurs due to osmotic gradient created by influx of Na. The movement of ions 
and water into cells causing cytotoxic oedema results in depletion of these 
constituents from extracellular space44. In absence of blood flow, cell swelling 
occurs at the expense of extracellular fluid but net water content is unchanged. 
The shift of fluid is reflected by decrease in Apparent diffusion coefficient (ADC) 
of water, causing increased Diffusion-weighted (DWI) signal in MRI 45. However, 
if there is residual flow, the net water content increases, resulting in brain 
swelling, “Ionic oedema”.  
In Ionic oedema, an earliest phase of endothelial dysfunction, there is transport 
of Sodium across the Blood Brain Barrier (BBB), generating an electrical gradient 
for Cl- and osmotic gradient for water, replenishing Na+, Cl-, and water in the 
extracellular space42. This ionic oedema is responsible for tissue swelling and 
precedes vasogenic oedema by approximately 6 hours 46. With advancing cell 
necrosis and degradation of the vascular basal lamina, the blood brain barrier 
breaks down47 . After 4-6 hours serum proteins leak from the blood into brain. 
This initiates a vasogenic oedema that reaches its peak in 1-2 days48, enhancing 
total water content. SUR1-TRMP4 an ion channel is up regulated by all cell types 
in the neurovascular unit after ischaemia49. In rats, this channel blockade 
reduces oedema and haemorrhage50. Molecule therapy with glyburide is effective 
in blocking this channel49. This agent was studied in pilot phase II study of 
humans to evaluate safety and feasibility51. 
1.4 Haemorrhagic Transformation (HT) in Ischaemic 
stroke 
The disruption of BBB and impairment of the auto regulatory capacity of 
cerebral vasculature predisposes to blood extravasation when ischaemic tissue is 
reperfused52.  The degree of this disruption appears highly on the duration of 
ischaemia. It is proposed that IV tPA may augment matrix metalloproteinase 
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(MMP) dysregulation, IV tPA may degrade the extracellular matrix integrity and 
increase the risk of BBB leakage, oedema and haemorrhage53. 
Haemorrhagic transformation (HT) is a known complication of Ischaemic stroke, 
especially after thrombolytic therapy54.HT can be divided into Haemorrhagic 
Infarction (HI) and Parenchymal Haematoma (PH). HI is a heterogeneous 
hyperdensity occupying a portion of an ischaemic infarct zone on CT, whereas 
PH refers to a more homogeneous dense haematoma with mass effect. The 
subtypes are: HI1, HI2, PH1 and PH2. HI1- small petechiae, HI2- more confluent 
hyperdensity (no mass effect), PH1- <30% Infarct zone, PH2 >30% Infarct zone 
(both PH1, PH2 have homogeneous hyperdensity and mass effect) 
The incidence depends on many factors, such as age, blood glucose level, 
thrombolytic agent used, route of administration, time window of therapy55,56. 
There is positive correlation between Infarct area and incidence of HT57. AF and 
cerebral embolism are associated with increased risk of HT58. Hypergylcemia has 
a major role in post Ischemic HT.  
In experimental transient MCAO model, acute hyperglycemia resulted in HT. 
Human trials also revealed this association59. Poor collaterals may result in a 
high frequency of HT with worsened clinical neurological status60. IV-tPA is 
independently associated with HT in major studies. Prognosis of HT depends on 
the type: PH2 is found to be significant predictor of neurological deterioration 
and high mortality.  
 
1.5 Evidence from animal studies  
Experimental animal models have provided us with important insights into 
ischemia. Different animal models exist; global61 or focal ischaemia62,63. Global 
ischaemia is achieved by four vessel occlusion61. Focal ischaemia models can be 
transient where the Middle cerebral artery (MCA) occlusion with intra luminal 
thread placement which is reversed in 2-3 hours; or permanent, where the 
irreversible MCA occlusion is achieved by diathermy, surgical section or 
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photocoagulation. Focal ischaemia is more useful as this is translatable into 
human stroke; however it is not without pitfalls. 
Focal ischaemia in the territory of MCA is the dominating cause of clinical 
stroke. This is reflected by predominantly MCA occlusion models in animal 
experiments. In these models, occlusion of MCA at its origin including 
lenticulostriate arteries- end arteries supplying basal ganglia that suffer severe 
reduction of blood flow, whereas cortex exhibits a gradient of blood flow with 
decrease from periphery to central parts64 . Trans-orbital MCA occlusion was 
initially applied in monkeys65 , but later experimented in cats, dogs, rabbits and 
rats. In this model, there is no retraction of brain; however, removal of the eye 
ball can cause functional disturbances, and vasospasm66. Trans- cranial 
approaches were commonly used for mice since the MCA originates close to brain 
surface67 . Filament occlusion of MCA is most widely used technique, described 
by Koizumi 68. A nylon suture with acryl thickened tip is placed in the origin of 
MCA. This method commonly affects large part of MCA territory often resulting 
in oedema, therefore, usually after 1-2 hours filament is withdrawn although it 
may be left in produce permanent ischaemia.  
1.5.1 Multimodal imaging of tissue outcomes in focal ischaemia 
animal models  
Consecutive cryostat section of brain can be analysed using pictorial methods 
that can give a good regional resolution69. Bio-luminescence methods are 
available to identify ATP 70, glucose71, lactate72 . Loss of ATP on bioluminescent 
images is the “core” of hypoperfused tissue. “Penumbra” can be identified by 
mismatch between acidosis, inhibition of protein synthesis (which occurs at high 
flow thresholds) and ATP (i.e. core. Fig.1-3) 73. Other invasive methods apply 
fluorescence (NADH for tissue acidosis74) or mapping gene expression75.  
Non-invasive imaging in animal studies mainly employs Positron emission 
tomography (PET) or Magnetic resonance Imaging (MRI). The parameters 
commonly used for imaging of ischaemia are cerebral blood flow (CBF), 
metabolic rate of oxygen (CMRO2) and glucose consumption (CMRGl), Oxygen 
extraction fraction (OEF)76 and binding of ligands such as Flumazenil which is a 
marker for neuronal cell bodies with benzodiazepine receptors77. With declining 
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cerebral blood flow, blood OEF rises to cover oxygen needs of aerobic 
metabolism. At flows approximately <50% of control, oxygen consumption 
declines and anaerobic glycolysis begins. With further lower flow rates this also 
fails, energy metabolism fails and flumazenil do no longer bind to their 
receptors. So, ischaemic core can be delineated by reduction of oxygen, glucose  
consumption or by loss of flumazenil binding77 where as ischaemic penumbra has 
increased glucose utilisation78 or increased oxygen extraction79.  
 
 
 
Figure 1-3 Biochemical imaging of "core" and "penumbra" 
The core is identified by ATP depletion and the penumbra by the mismatch between the 
suppression of protein synthesis and ATP depletion (top) or by the mismatch between tissue 
acidosis and ATP (bottom). The mismatch areas are highlighted by projecting the outlines of the 
biochemical disturbances on the corresponding autoradiogram of cerebral blood flow. Reproduced 
with permission from “Multimodal mapping of the ischemic penumbra in animal models” in Informa 
Helath care (p. 77-92), by  Donnan GA et al, 2007, NewYork:Mercel Dekker
73
. 
 
1.5.2 Evidence for irreversible (Core) and reversible (Penumbra) 
ischaemia and evolution over time  
Different energy requirements and flow thresholds exist for maintenance of 
membrane function, preservation of neuronal function (functional threshold) and 
morphological integrity29. Some function of CBF reduction and its duration 
probably defines threshold for irreversible infarction. Symon et al, in baboons 
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(trans-orbital or retro-orbital approach MCA occlusion), showed the linear 
relationship of local blood flow reduction and degree of neurological 
impairment80. The tissue that lost its electrical function but no release of 
potassium characterises tissue death80. This functionally silent but viable tissue 
regained function if occlusion was removed. In this model, core of ischaemia was 
located in the basal ganglia and sylvian opercula, penumbra stretching almost 
entire lateral aspect of cerebral hemisphere 81. The area between these two 
thresholds is structurally viable and was termed as penumbra (analogy to moon 
eclipse, since this area is between infracted and normal tissue)26. Since viability 
of brain tissue requires maintenance of energy-dependant metabolic processes, 
the penumbra may be defined as region of constrained blood supply in which 
energy metabolism is preserved82 .  
Different brain regions have variable thresholds for ischaemic cell damage, 
white matter being more resilient than grey matter. The key concept is distinct 
compartments in hypoperfused tissue; tissue that is irreversibly damaged (core), 
tissue that will survive (oligaemia), and tissue that may survive (penumbra) if 
reperfusion occurs in time( fig. 1-4)83. 
 
 
Figure 1-4 Hypoperfused brain compartments in MCA territory ischaemic stroke. 
Reproduced with permission from “Imaging of acute stroke”, by Muir et al, 2006,. Lancet 
Neurology,5 (9),755-68
83
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Jones et al, first reported the dynamic nature of “penumbra”84. In their study in 
awake monkeys, within 3 hrs a very little penumbra survived (fig.1-5). Baron et 
al,85 defined penumbra as a tissue that exists between threshold of infarction 
and penumbra threshold. Operationally, penumbral tissue must satisfy the 
criteria of being 1) functionally impaired hypoperfused tissue with undetermined 
fate that is at risk of infarction if not salvaged 2) contributing to clinical deficit 
3) its resolution is associated with proportional recovery of neurological 
function. Oligaemic tissue surrounds critically ischaemic tissue where the 
decreased CPP is compensated by collaterals86,87. 
 
Figure 1-5 Dynamic penumbra  
The time course of infarct growth at the expense of penumbra, from the situation immediately 
following MCA occlusion (top left) , to 3h later (bottom right). The oligaemia is not at risk of 
infarction. Reproduced with permission from “Mapping the ischemic penumbra with PET: 
Implications for acute stroke treatment”, by Baron et al
88
, Idealised diagram  of baboon’s brain. 
(using data from Jones et al
84
), 1999,Cerebrovasc Dis,9 (4),193-201.  
 
1.5.3 Tissue Thresholds 
Biochemical and functional changes were correlated with CBF values in several 
studies. The normal value for CBF is 50-60 ml/100g/min in grey matter. This is 2-
3 times less in white matter. Protein synthesis was completely suppressed at CBF 
of 35ml/100g/min89. Glucose utilisation sharply declines below CBF of 
35ml/100g/min90 . This corresponds to beginning of acidosis and accumulation of 
lactate91 . At flow rates below 26ml/100g/min tissue acidosis becomes 
pronounced and ATP begins to decline. This is the threshold for energy failure92. 
Na-K ratio of brain increases at flows below 10-15ml/100g/min66 and 
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extracellular ion changes occur at rates between 6 and 15 ml/100g/min  29,93,94. 
This is the threshold for anoxic depolarisation (pump failure). In animal studies, 
Cerebral Blood flow (CBF) values of less than 20ml/100g/min results in impaired 
neural function (electric failure) but temporarily intact tissue integrity, defining 
penumbra, and, early, irreversibly damaged tissue had CBF values of 6-10 
ml/100gm/min 26,29,95,96. 
Suppression of EEG activity occurs at rates between 15 and 23 ml/100g/min29,97. 
In cats, neuronal firing stops at flows of 18 ml/100g/min96. Narcotized baboons 
lose somato-sensory evoked potentials when CBF falls below 15ml/100g/min 98. 
In contrast to biochemical and functional changes, histological changes require 
sometime before being visible. Studies determining the dynamic changes in CBF 
thresholds indicate that thresholds may change with time (fig.1-6). 
 
Figure 1-6 Dynamic ischaemic thresholds during permanent vascular occlusion.  
CBF thresholds increase with duration of ischaemia for ATP, glutamate, unit rate but static for 
protein synthesis. Reproduced with permission from “Variability thresholds and the penumbra of 
focal ischaemia”, by Hossmann K-A
82
, 1994, Ann Neurol, 36 (4),557-565.  
 
The prototype of the penumbra definition is focal ischemia through MCA 
occlusion in which blood flow gradually declines from periphery to the core 
region. Jones et al, in awake monkeys showed that blood flow thresholds for 
Infarction are higher with longer duration of occlusion84. CBF threshold for 
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neurological symptoms was 23 ml/100g/min. When this fell below 
8ml/100g/min, neurological deficit became permanent. Moderate CBF 
(15ml/100g/min) was tolerated for 2-3 hours. After 2-3 hours, CBF below 10-12 
ml/100g/min resulted in infarction, whereas with permanent occlusion CBF 
below 17ml/100g/min resulted in infarction84 (fig.1-7). 
 
Figure 1-7 CBF thresholds for Ischaemia in awake monkey  
Reproduced with permission from “Thresholds for focal cerebral ischaemia in awake monkeys, by  
Jones et al
84
,1981, J Neurosurg, 54 (6),773-82. 
 
The tissue outcome is shown to depend on severity of flow reduction and 
duration was also reported by others99,100. Using high contrast PET, serial 
functions were measured over 24 hours after permanent MCA occlusion in cats99. 
A dynamic nature of penumbra with progressive increase in core size was found. 
In six cats, they showed gradual changes (at 3 time points of <1 hr, 1-4 hr, 24 hr) 
in metabolic parameters. CBF fell to 40% of control immediately and very 
gradually to 20%; whereas CMRO2 fell to 55% and then to 20% of control 
gradually. Areas of increased OEF moved from the centre to periphery. The 
interaction of severity and duration of ischaemia in tissue outcome was studied 
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in cats by recording neuronal activity and blood flow101. Possible combinations of 
residual cerebral blood flow and duration of ischaemia and neuronal recovery is 
shown in Fig.1-8102. CBF threshold that define irreversibly damaged tissue 
increases with time.  
 
Figure 1-8 CBF thresholds for preservation of function and morphology of brain tissue 
changes with time 
The activity of individual neurons is blocked when flow decreases below a certain threshold 
(dashed line) and returns when flow is raised above this threshold. The solid line separates 
structurally damaged from functionally impaired but morphologically intact tissue, the penumbra. 
Reproduced with permission from “The ischemic Penumbra: Correlates in Imaging and Implications 
for treatment of Ischemic stroke”, by Heiss WD, 2011, Cerebrovascular Dis,32 (4),307-320
102
. 
 
Tolerance to focal cerebral ischemia is clearly related to residual CBF which -
must be provided by collateral circulation103. In non-anaesthetised macaque 
monkeys, the extent of CBF reduction correlated well with infarct size: when 
CBF fell below 12ml/100g/min for 2 hours or longer, a larger infarction occurred 
and at higher residual CBF a smaller infarction occurred; good collaterals led to 
little or no infarction  where as poor collaterals produced fatal infarction98 
Volume of brain infarct after 3 hours of temporary MCA occlusion is same as 
after permanent ligation104. Lassen et al, concluded that penumbra remains 
viable for only one or perhaps a few hours but not longer86. After 2 hours of 
permanent MCA occlusion in rats, the ratio of restricted diffusion lesion (DWI) 
volume to ATP depleted lesion declines to 1.4 and after 7 hours these are 
congruent69. Blood flow remains stable throughout this initial ours of ischemia 
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which excludes the possibility of the infarct growth due to progression of 
ischemia. The reason for the expansion of tissue injury into penumbra may be 
due to peri-infarct depression like depolarisations37,105. PET studies in baboons 
showed that tissue with misery perfusion escaped infarction if vessel reopened 
within 6 hours but infarcted with permanent occlusion106-110. Jones et al, study in 
awake monkeys, moderate to large infarction was seen in 2-3 hrs84. Heiss et al, 
study in cats also showed faster (within 6-8 hrs) demise of penumbra99.  
Animal models do not translate directly to human stroke. Focal ischemic models 
did not have any change in hemodynamic parameters (respiration, pulse etc.) 
which is not the case in human stroke. Moreover, stroke in humans is 
heterogeneous and has associated co morbidities, which make it difficult to 
translate animal models to Humans. Successful translation of animal 
experiments should reflect human co-morbidities and variability in mechanism of 
stroke111. However, this would mean increased sample size. 
1.6 Human Positron Emission Tomography (PET) studies 
PET introduction allowed the repeated quantitative determination of 
physiological variables in brain. PET with oxygen-15 tracers became the gold 
standard for evaluation of pathophysiological changes in early ischaemic 
stroke112.  PET studies provided the data on flow and metabolic variables 
predicting final infarction. Relatively preserved CMRO2 indicated maintained 
neuronal function in regions with severely reduced CBF “misery perfusion”. OEF 
is increased up to 80% in this area. 
PET study using oxygen-15-steady state technique in humans showed the 
existence of penumbra in one third of patients imaged between 5 and 18 hours 
and detected penumbra as late as 16 hours in some patients 88. Another 
prospective study showed existence of penumbra (in 10 out of 11 patients) up to 
18 hours113. They have also showed that neurological recovery was proportional 
to the volume of penumbra that is rescued. Using multi-tracer PET, viable tissue 
in the border zone of ischaemia was seen up to 48 hours114. In another study, all 
8 eligible subjects had substantial volume of tissue with CMRO2 values above 
threshold for tissue viability115. These voxels constituted 10%-52% (mean 32%) of 
the final infarct volume. Read et al, using18F fluoromisonidazole to  identify 
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hypoxic tissue found that on average 45% of  total hypoxic tissue volume survived 
in those patients studied up to 51 hours116. Another study using18F 
fluoromisonidazole in patients up to 48 hrs, spontaneously surviving proportion 
of hypoxic tissue (median 46%) was not significantly different between two time 
epochs (≤ 12 hrs or >12 hrs) , and also showed that survival of penumbra has a 
definite neurological benefit117. However, PET imaging although useful in 
understanding pathophysiology, it is not feasible in clinical practice. 
1.7 Acute stroke imaging in Humans 
 
1.7.1 Non-contrast CT (NCCT) 
In the National Institute of Neurological Disorders and Stroke (NINDS) study, only 
NCCT was the requirement before inclusion of subjects for IV thrombolysis10. 
NCCT is commonly used to exclude contraindications such as haemorrhagic 
stroke before thrombolysis118. If established hypodensity or early ischemic 
changes in >1/3 MCA territory, the risk of haemorrhage with thrombolysis is 
greater119. Early ischemic changes include hypodensity because of combination 
of cytotoxic oedema and reduced blood volume, and loss of grey-white matter 
differentiation. In patients with known stroke onset time of <4.5 hours, if NCCT 
is normal or showing only subtle early ischemic changes, or <1/3 MCA territory 
hypodensity, IV thrombolysis is deemed safe 120.  
Early ischemic changes (EIC) can give a positive diagnosis but are not really 
helpful in indicating the time since stroke onset in acute stage. If there is no 
major hypodensity, however, it is possible that onset is <4.5 hours. This is an 
inclusion criterion for a currently ongoing randomised, Tenecteplase in wakeup 
ischemic stroke trial (TWIST clinicaltrials.gov NCT03181360). In hyper acute 
stage, the Na-K channel failure in ischaemic brain tissue leads to cytotoxic 
oedema without any net increase of water. The Hounsfield Unit (HU) attenuation 
is directly proportional to the tissue water content, therefore proportional to 
the degree of vasogenic oedema but not cytotoxic oedema: for every 1% increase 
in tissue water content , X-ray attenuation decreases by 3-5%, which corresponds 
to a drop of 2.5 HU on NCCT images121. Early ischemic changes described on 
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NCCT encompass both decreased attenuation (e.g. obscuration of basal ganglia, 
loss of grey white differentiation) or localised tissue swelling ( hemispheric 
sulcal effacement in the cortex)122,123. These appearances represent different 
patho-physiological processes123,124. Hypo attenuation represents an increase in 
tissue water content which results in reduction of tissue density. This occurs 
following a series of compartmental fluid shifts 
(intravascular>interstitial>intracellular) that ultimately result in additional 
water within the brain125. Hypo attenuated regions represent irreversibly injured 
tissue that is destined for infarction126,127. Isolated sulcal effacement results 
from the compensatory increase in the cerebral blood volume (CBV) that occurs 
in penumbral tissue127-129. Tomura et al, reported that in embolic middle 
cerebral artery or internal carotid artery distribution ischemic stroke patients, 
the earliest sign was obscuration of the lentiform nucleus due to cytotoxic 
oedema130.  
In European Cooperative Acute Stroke Study (ECASS; n=620), NCCT had limited 
sensitivity (40-70%) to detect acute ischemic changes within the first 6 
hours131,132. A systematic review of the literature showed the sensitivity for early 
ischemic signs on NCCT in subjects presenting <6hrs varied from poor to 
moderate133. The sensitivities varied as the number of subjects in these studies 
are small, problems in clinician experience in detecting subtle early 
parenchymal changes and different definitions of early ischemic signs. 
Moderately good inter observer agreement (mean 82%-84%) was observed 
between neuro-radiologists for detection of acute hypo density within 6 hrs134. 
Inter-rater agreement and sensitivity of ischemic signs on CT in <7 hrs is 
imperfect in other studies that compared CT with MRI135-138. 
1.8 Perfusion Imaging 
The goal of acute stroke therapies is to normalise perfusion to preserve maximal 
amount of penumbral tissue139. In acute ischaemic stroke, patient tailored 
treatment approaches need information on core and penumbra. CT perfusion 
(CTP) is widely available and provides similar pathophysiological information as 
MRI140.  
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1.8.1 CT perfusion (CTP) 
Most commonly, imaging for CTP consists of 4-8 slices of brain each with 10-
20mm thickness at level of basal ganglia. Approximately 7-10 sec after IV 
Iodinated contrast injection, series of scans acquired for about 50sec. These 
temporally acquired images are reconstructed and post processed using one of 
the several algorithms. 
CTP imaging has been used to evaluate the infarct core and potentially 
salvageable penumbra141.  Without early reperfusion, core can expand 142-144,   
and with early reperfusion penumbra can be rescued 145,146, hence the need for 
assessing these acutely. Selection of perfusion parameters and thresholds to 
identify core, penumbra remain a challenge147. Studies using different post 
processing software reported different parameters and different thresholds for 
accurately identifying core and penumbra141,148.  
Bolus tracking CTP149 generates maps of Cerebral blood flow (CBF), Cerebral 
blood volume (CBV), Time to Peak(TTP) and Mean transit time (MTT) (fig 1-14). 
CBV is defined as the total volume of flowing blood in a given volume of the 
brain (millilitres of blood in 100g of brain); CBF is defined as the volume of blood 
passing through the given volume of brain per unit time (millilitres of blood in 
100g of brain); MTT represent the average time for blood transiting through the 
given brain region (in seconds); TTP is an index of time between the beginning of 
blood perfusion and maximum enhancement in the given region. Depending on 
mathematical model, Tmax (time to the peak of the residual function) or DT 
(delay time to the peak of the residual function) can be generated instead of 
TTP. 
In CTP, thresholds for both core and penumbra have to be derived unlike in MRI. 
In MRI acute DWI lesion volume has been reported to be highly correlated to 
core150. When quantitative interpretation of all CTP maps was performed and 
compared to final infarct volume using the Alberta Stroke Program early CT 
score (ASPECTS) 127, CBV maps were close predictors of outcome lesion extent in 
subjects with major reperfusion by 24 hrs, while MTT and CBF were predictive of 
the infarct extent in those who did not have major reperfusion151. Reduced CBV 
has therefore been considered a marker for infarct core, whereas prolonged MTT 
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with normal CBV being a marker for ischemic tissue at risk of infarction140. 
Wintermark et al, using ROC curve analysis using follow-up MRI as a gold 
standard (each pixel in selected CT perfusion parameter and selected threshold 
is categorised (TP true positive, FP false positive, TN true negative, FN false 
negative against reference MR images).  Wintermark group showed in case of 
persistent arterial occlusion, relative MTT (AUC 0.962) predicted penumbra, with 
an optimal threshold >145% and absolute CBV (AUC 0.927) in cases of large 
artery recanalisation predicted the core, with an optimal threshold <2 
ml/100gm/min 141. The software relies on central volume principle as contrast 
injection rates were slow. Non iterative deconvolution was applied to derive 
MTT map. CBV is calculated from area under the time enhancement curve. CBF 
is derived from central volume principle (CBF=CBV/MTT). In CTP, with ROC curve 
analysis using more stringent criteria including volumetric (mean difference 
between CTP lesion and 2h DW lesion volumes) and clinical validation (24 h and 
90 day clinical outcomes), relative CBF threshold (rel. CBF< 40%) most 
accurately predicted the core (AUC 0.95) and relative delay time (r DT)>2 sec 
accurately predicted penumbra (AUC 0.86)  in a study by Bivard et al148. The 
commercial software MiStar (Apollo Medical Imaging Technology, Australia) used 
singular value decomposition with delay or dispersion correction. This 
methodology produced Delay time than Tmax.  Relative CBF volume thresholds 
in hypoperfused tissue have been found to be similar to those found in Single 
Photon emission CT (SPECT) studies 151 152. MTT and TTP maps are found to be 
more sensitive to ischemia than CBF or CBV maps153. It is observed that TTP 
lesion volumes are closely related to final infarct volume in those who do not 
recanalise154. The penumbra not progressing to infarction was predictive of 
clinical recovery154. Additional studies have confirmed good correlations of CBF 
values on CTP maps compared with PET 155 or Xenon CT156.  
 There are several other parameters, either alone, or in combination in 
predicting the tissue states. Threshold derivation from other groups showed a 
product of CBF and CBV was the best predictor of core pixels for white 
matter157. Each CT scanner manufacturer use different algorithms for deriving 
the parameters, which complicates the uniform interpretation, and 
standardisation of CTP parameters.  
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Marked variability across different post processing software limit any 
generalisation of perfusion parameter threshold maps between platforms. rMTT, 
a most accurate predictor of penumbra by Wintermark et al, might not be 
generalisable to newer, longer CTP acquisition protocols or CTP maps generated 
by different post processing platforms for example new “delay corrected” 
algorithms158.  
 
1.8.2 Post acquisition CT perfusion processing 
Two commonly applied mathematical methods for CT perfusion are maximum 
slope and deconvolution methods.  These are first pass bolus tracking 
techniques. Non diffusible tracer (iodinated contrast) is injected into ante 
cubital fossa and its concentrations repeatedly measured during its first pass 
through an intracranial vessel. Contrast transit through the vasculature produces 
a change in time attenuation. These changes can be graphed as time attenuation 
curves for each voxel in brain tissue. These are also called tissue concentration 
curves (CTC).  Tissue perfusion measurements using CTP was first reported by 
Axel in 1980 159. Maximum slope model assumes no venous outflow. For this, a 
very high rate of contrast injection (10ml/s) is required160 which cannot be 
achieved routinely in practice. This method yields relative rather than absolute 
values. Both deconvolution, non-deconvolution techniques apply Fick’s principle 
(fig.1-9).  
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Figure 1-9 Fick's principle.  
Conservation of mass to a given region of interest within the brain parenchyma. Reproduced with 
permission from  “Theoretic basis and technical implementations of CT Perfusion in Acute Ischemic 
Stroke, Part1
161
: Theoretic Basis” , by A.A. Konstas et al, 2009, AJNR, 30 (4), 662-668. 
 
1.8.2.1 Maximum slope model: 
As contrast  enters the area being imaged, the signal intensity of the time-
concentration curve, measured in HU rises linearly (fig.1-10)159. The amount of 
accumulated contrast material Q(t) is the product of CBF and the difference on 
arterio-venous concentration: 
Q (t) =CBF•
T 
0 
[C artery (t) – Cvein (t)] dt 
In order to make the CBF calculation less complicated, it is assumed that the 
output from the capillary bed into the venous system is zero, termed the no 
venous outflow assumption. To satisfy this assumption, injection rates must be 
very rapid. Using these assumptions, the equation can be simplified as 
Q (t) =CBF•
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T 
0 
C artery (t) dt 
The equation is known as the Mullani-Gould formulation162. The rate of contrast 
accumulation is related to the CBF and the arterial concentration at time (t) and 
from the Mullani-Gould equation the peak rate of contrast accumulation will 
occur when arterial concentration is maximum: 
[dQ(t) /dt] max = CBF•[C artery (t)] max 
The ratio of the maximal slope of Q (t) to the maximal arterial concentration 
can therefore be used to measure CBF. 
 
 
Figure 1-10 Maximum slope method.  
CBF can be calculated from the ratio of maximal slope of Q (t) to the maximal arterial 
concentration. Different maximal slopes in different ROIS reflect different CBF values. Reproduced 
with permission from “Theoretic basis and technical implementations of CT perfusion in acute 
ischemic stroke, part 2: technical implementations”, by Konstas A.A. et al, 2009. AJNR,30 (5),885-
92”
163
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However, this equation relies upon assumptions which may influence calculation 
of CBF. Specifically it is assumed there is no venous flow of contrast flow before 
the peak arterial enhancement which in turn requires that injection rates of 10-
20ml/sec are used to reduce the possibility of venous contamination163. In 
clinical practice these rates are not achievable and therefore CBF calculations 
may be inaccurate164. As rates of injection for IV contrast material are typically 
no more than 5ml/sec alternative methods to interpret the time – concentration 
curves must be considered. 
 
1.8.2.2 Deconvolution model:  
Deconvolution is a commonly applied post-processing mathematical process 
whereby the brain tissue contrast concentration-time curves from each pixel are 
‘scaled’ to the tissue concentration-time curve from a feeding artery (arterial 
input function, AIF). This gives each pixel a residual function tissue 
concentration-time curve that is used to measure parameters such as CBF, Tmax 
and DT. Crucial physiological information from perfusion imaging is obtained by 
conversion of concentration time curve (CTC) into reliable estimates of CBF, CBV 
and MTT. Assumption for rapid contrast injection does not hold true, therefore 
MTT cannot directly be obtained from normalised CTC. So, Tracer kinetic 
method applies that observed CTC is the convolution of AIF with a residue 
function, scaled by CBF (Fig.1-13). 
Considering a bolus of contrast tracer material injected into a tissue voxel of 
interest, we can define the concentration (C tissue (t)) of tracer in the tissue in 
terms of two functions: 1) Residue function, R (t): a fraction of tracer is still 
present in the voxel of interest at time t following an ideal instantaneous unit 
bolus injection. R (t) is unit less and is equal to 1 at t=0165. 2) Arterial Input 
function (AIF), C artery(t): concentration of tracer in the feeding vessel to the 
voxel of interest at time t. Calculation of CBF requires measurement of the 
temporal shape of both the arterial input and the tissue-time-attenuation 
curves166. The true input into the tissue voxel of interest cannot be measured 
directly; in practice, the AIF is estimated from a major artery, with the 
assumption that this represents the exact input to the tissue of interest. Any 
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delays or dispersion from AIF to the tissue of interest will introduce errors in 
quantification of CBF167. The observed tissue-time-attenuation curve represents 
a combination the effects of the AIF and the inherent tissue properties. Thus, to 
fit the model, the effects of the AIF on the tissue concentration curve must be 
removed by using a mathematic process known as “deconvolution” to derive 
R(t), which is dependent only on the haemodynamic properties of the voxel 
under consideration. R(t) demonstrates an abrupt rise, a plateau of duration 
equal to the minimum transit time through the tissue of interest and then decay 
towards baseline (fig.1-11 & 1-12 ). The impulse residue function is the idealized 
tissue time attenuation curve that would result if the entire bolus of contrast 
material was administered instantaneously into the artery supplying given area 
of brain. The plateau of the impulse residue function reflects the length of time 
during which the contrast material is passing through the capillary network. 
Assuming the contrast remains within the vascular space, the shape of the 
impulse residue function will be as below (fig.1-11)168. The venous output 
function serves as a reference against which the CTP parametric values are 
normalized and scaled.  This should have least amount of partial volume 
averaging. CBV values are affected by the chosen venous output function. 
 
Figure 1-11 Impulse Residue function 
Schematic representing the impulse residue function R(t) in a vascular network where the tracer 
remains intravascular. Reproduced with permission  from “CT perfusion scanning with 
deconvolution analysis: pilot study in patients with acute middle cerebral artery stroke” 
168
, by 
Eastwood et al, 2002, Radiology, 222 (1):227-36 
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Figure 1-12 Residue function. 
The residue function R(t) is the fraction of tracer still retained in tissue at time t after injection. 
Shape of the residue function depends on the vasculature of the tissue voxel. Q is amount of 
contrast agent in tissue (mmol), Ca Concentration of contrast agent in the artery (mmol/l), Cv 
concentration of contrast agent in Vein (mmol/l) F flow (ml/min). 
 
Use of deconvolution to derive perfusion measures does not rely on the 
assumption of no venous outflow, but instead considers outflow in the 
calculation. In deconvolution, attenuation values of an artery are integrated 
with time-attenuation curves of brain tissue on a voxel-by-voxel basis in 
mathematical operation called deconvolution (fig.1-13). C(t)=CBF.[Ca(t)*R(t)]  
C(t) is the tissue attenuation curve; Ca(t) is the arterial time –attenuation curve; 
R(t) is the impulse residue function, * is the convolution operator. C(t) and Ca(t) 
can each be measured and deconvolution produces CBF.R(t) which is plotted 
over time. CBF is obtained from the peak height of the curve, while CBV is the 
area under the curve. Once CBF, CBV are derived, MTT can be derive according 
to the central volume principle169: CBF= CBV/MTT (fig. 1-14). Other delay 
metrics such as T max, TTP, DT can be derived similar to MTT.  
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Figure 1-13 The tracer kinetics 
Tissue concentration time curve in Tracer kinetic equation: observed CTC is the convolution of AIF 
with a residue function, scaled by CBF. Ca: Concentration of agent in the artery at time t. Ct: 
Concentration agent in the tissue at time t. CBF (perfusion)(ml/100g/min). R(t) is residue function.  
 
 
Figure 1-14 Delay metrics 
a:The measured tissue concentration time curve (tissue curve) gives rise to various measures of 
the transit time that all depend on the local shape of the AIF. The arrival time (AT) of the bolus 
mainly reflects collateral circulation. The time to peak, to some extent, reflects tissue transit time 
(rTTP) and, if arrival delay is included, also reflects collateral circulation (TTP). The first moment 
(the centre of gravity) and the full width at half maximum (FWHM) of the tissue concentration time 
curve mainly depend on tissue MTT. b: Deconvolution of the curves in (a) removes the 
dependence on the arterial input curve and produces the deconvolved tissue curve. In the 
presence of arterial delays, the deconvolved curve is not maximal at t 0, but instead is maximal (the 
tissue impulse response function) after a certain delay (Tmax). CBF is usually taken as the curve 
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height of the deconvolved curve at time Tmax. MTT is calculated as CBV/CBF, where CBV is 
determined as the area under the deconvolved curve (b) or the tissue curve (a). However, 
calculation of CBV from the tissue curve requires laborious corrections for tracer recirculation. 
Reproduced with permission from “Principles of cerebral perfusion imaging by bolus tracking” 
170
, 
by Leif Ostegard et al, 2005, Journal of Magnetic resonance Imaging, 22(6),710-7. 
 
Several methods to deconvolve equation and hence solve for CBF.R(t) have be 
proposed and are divided into two main categories: Parametric (vascular model) 
and non-parametric methods. With parametric method a specific analytic 
expression for R(t) is assumed. Assuming a specific shape for R(t) imposes 
assumptions on the inherent tissue properties that cannot be known priori with 
sufficient precision166,171.  
Since non-parametric methods do not assume a shape for R(t), they are 
commonly used. Deconvolution equation is unstable, oscillations (i.e. noise) is 
produced in computation of the solution for R(t). There are two methods of 
dealing with the noise172: 1) Fourier transformation 2) singular value 
decomposition (SVD). Predominant technique for estimating CBF is based on 
deconvolving the AIF with the CTC using Singular Value Decomposition (SVD)  to 
estimate the CBF.R(t) (called impulse response)) 166,173. SVD yielded the most 
robust results from all the deconvolution methods used to map CBF171. The 
creation of accurate quantitative maps of CBF, CBV, MTT using deconvolution 
methods has been validated in a number of studies156,174.  
SVD algorithm by Østergaard171 et al is susceptible to dispersion and delay of 
measured AIF. In setting of major disease this may underestimate CBF, therefore 
overestimate MTT (i.e. penumbra) by including benign oligaemic tissue175,176.  
Despite this, it is reported to be better in tissue state prediction177. Fourier 
transformation makes this insensitive to delay but sensitive to noise, thus 
unsuitable for CBF calculation. Block circular decomposition matrix SVD (oSVD) 
method, a tracer –arrival timing insensitive technique was introduced by Wu et 
al173. This technique basically removed the causality assumption (i.e. that the 
tissue of interest signal intensity cannot arrive before the AIF) built into SVD.    
A new approach, “parametric (vascular) model” was suggested which assumes 
the physiological model of exponentially decreasing tracer kinetics178. This 
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model, in addition the standard parameters, also provides capillary transit time 
heterogeneity (CTTH). The tissue residue function that denotes proportion of 
contrast that remains in vasculature at a given time (t) is directly related to 
vascular transit times h(t), hence to CTTH177. The shape of residue function 
reflects micro vascular retention of tracer and thereby distribution of capillary 
velocities177.  
Estimated residue function has oscillations. This compromises their physiological 
interpretation (i.e. fraction of contrast agent as a function of time, after an 
impulse injection, is a decreasing function of time173 and estimation of flow 
heterogeneity difficult. So model free deconvolution approaches are not 
adequate. SVD cannot delineate between dispersion to increased transit times. 
Gaussian process deconvolution produces smoother estimate of the residue 
function 179. Regularisation steps of model free deconvolution approaches 166,173,  
may stabilise CBF 179-181, but, they are not optimised to detect salient features of 
the residue function. Hence, Parametric (vascular) model (fig.1-15) was 
suggested177,182. CTTH, OEF max can be calculated in addition to macroscopic 
perfusion markers178. Gamma variate distribution of probability density function 
(pdf) was used to describe the transit time distributions. Fraction of particles 
distributed to tube (i) is h(i).By increasing number of tubes to t, h(t) represent 
continuous pdf for transit times t (transit time distribution). The mean of this 
pdf is MTT and standard deviation is CTTH. In this parametric method, alpha and 
beta are the parameters. MTT is derived as product of alpha and beta, where as 
CTTH is square root of this product (fig.1-16).  Modelling the dynamics of micro 
vasculature, a smooth monotonically decreasing residue function is derived. 
Bayesian system identification approach183 based on Levenberg-Marquart type 
Expectation-Maximisation (EM) algorithm, was applied. A monte-carlo simulation 
study showed it does not underestimate high flows and unaffected by low signal 
to noise ratio. It is also robust to delays between AIF and CTC. Blood flow, 
oxygen binding to haemoglobin, capillary transit time heterogeneity can 
influence the oxygen delivery. Flow heterogeneity can be derived from the slope 
of deconvolved tissue curve along with CBF177. Putative effects of increased 
CTTH were reported in stroke, ischemic heart disease, and dementia in a series 
of papers by Ostergaard184-186. Tissue with abnormal flow heterogeneity is shown 
to correlate with final infarct in ischaemic stroke  21,187. 
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Figure 1-15 "Vascular model" a schematic representation 
Blood is delivered to the tissue with a delay δ relative to the measure arterial Input function. Within 
the tissue, particles are distributed to a number of tubes (N), each with a different transit time Ti. 
The fraction of particles distributed to tube i is hi. The hi’s form an empirical density function for the 
transit times which characterises the microvasculature. This indicated by the histogram on the right 
hand side. By increasing the number of tubes, the histogram will converge and represent an 
estimate of the underlying continuous density function h(t) for the transit times t. Modelling the 
dynamics of  microvasculature a smooth monotonically decreasing residue function is derived .  
MTT = ab
 
Figure 1-16 Residue function modelled from a family of gamma variate functions. 
MTT is the distribution of transit time mean value (αβ) whereas variance (√αβ) is the CTTH.  
Reproduced from”Bayesian estimate of cerebral perfusion using a physiological model of 
microvasculature”, by Kim Mouridsen et al, 2006, Neuroimage, 33(2),570-9.
178
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1.9 Role of capillaries in haemodynamic regulation 
Neurovascular coupling is an intrinsic brain microcirculation regulatory 
mechanism that adapts local cerebral blood flow (CBF) in accordance with 
underlying neuronal activity188. 
Normal regulation of CBF to meet metabolic demands of brain tissue is deranged 
in conditions predisposing to stroke such as, ageing, hypertension, and 
diabetes189. This “neurovascular dysfunction (NVD)” is characterised by reduced 
response of CBF in response to neuronal activity and the mechanism is not fully 
understood but thought to be related to depletion of nitrous oxide (NO), as 
superoxide anions189 from endothelium react with NO to form peroxy nitrite 190 . 
Peroxy nitrite disturbs the smooth muscle contractility 191 and inactivates tissue 
plasminogen activator 192. This dysfunction is not restricted to blood vessels that 
affect CBF. This was also seen in capillary level 193. Capillary flow patterns have 
been speculated to affect oxygen delivery194. In studies of direct microscopy in 
animals 195 and perfusion MRI in Humans21,23 it was found that capillaries do 
undergo changes in ischaemia.  
Increase in Capillary transit time heterogeneity (CTTH) was shown to reduce the 
maximum oxygen availability (OEF max) for a given CBF and oxygen tension23. 
This effect was thought be caused by increasing proportion of erythrocytes 
passing too fast to effectively extract oxygen. This can affect the way CBF can 
support the metabolic needs, and, accordingly abnormal capillary responses can 
contribute to abnormal CBF responses seen in NV dysfunction and to metabolic 
derangements seen in penumbra, where tissue survival depends on the effective 
oxygen extraction196 . 
Relationship of CBF to oxygen availability was described by Classical flow-
diffusion (Bohr-Kety-Crone-Renkin (BKCR)) equation 197, but it assumes 
homogenous flow in capillaries. In a human study, it is found that any degree of 
heterogeneity of capillary flow will lead to reduction of tissue oxygen 
utilisation21,177. Heterogeneity of capillary flow velocities can be caused by 
capillary wall disturbances or blood cell morphology and this reduces oxygen 
utilisation. Changes in number, diameter, and endothelial adhesion are known to 
affect the distribution of capillary flow across capillary bed. Low grade 
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inflammation and infection is shown to disturb flow patterns and result in 
shunting of erythrocytes through capillary bed 198. Also shedding of glycocalyx 
from endothelium in inflammation seems to affect the microcirculatory 
haemodynamics199. Extending the classic flow diffusion equation,  capillary blood 
mean transit time (MTT) and capillary transit time heterogeneity (CTH) together  
determines the maximum OEF that can be achieved for a given tissue oxygen 
tension. Extended BKCR equation23 shows that oxygen availability is determined 
partly by MTT of erythrocytes across all capillaries and partly by heterogeneity 
(CTTH) of these transit times (fig.1-17). Probability density function of capillary 
transit times h(t) is parameterised by gamma-variate function ( parameters α 
and β). CTTH is parameterised by the standard deviation of gamma-variate 
capillary transit time distribution (σ=√αβ) (fig.1-18)23. Vascular mean transit 
time μ is then determined as αβ (μ= αβ). 
 
 
Figure 1-17 Roles of CBF, CTTH, Oxygen tension in brain oxygentation 
Oxygen extraction as a function of capillary transit time. (A) The maximum attainable oxygen 
extraction fraction versus transit time is shown. Note that oxygen extraction becomes inefficient 
toward short mean transit times, μ=CBV′/CBF. The same principle applies to individual transit times 
along separate paths in the capillary tree. However, the effect is nonlinear, and because of the 
concave nature of the curve, a broad capillary transit time distribution (illustrated here by two 
populations with transit times μ−σ/2 and μ+σ/2) yields considerably lower OEF max (indicated by 
the asterisk) for this distribution than the corresponding homogenous distribution, where all 
capillary transits have identical transit time μ. The same phenomenon may result in a decreased 
net oxygen extraction despite an increased net flow: in (B), maximum CMRO2 is plotted versus 
flow using our model, and here the green line indicates the flow and associated CMRO2max from a 
homogeneous population of capillaries with a net flow Fhom. A slightly larger flow Fhet>Fhom, 
indicated by the red line is now accommodated by the same capillary bed, but divided into two 
populations, where one population has flow f1 and the other f2, f1+f2=Fhet. However, the net 
oxygen extraction in this case (intersection of the dashed diagonal line with the red vertical line) is 
in fact smaller than that obtained for the homogenous, lower flow case, as indicated by the double 
asterisk. Reproduced with permission from “The roles of cerebral blood flow, capillary transit time 
  51 
 
heterogeneity, and oxygen tension in brain oxygenation and metabolism”, by Jespersen et al 
23
,2012, J Cereb Blood Flow Metab, 32(2),264-277. 
 
 
 
Figure 1-18 Model overview with single capillary (top) and multiple capillaries (bottom) 
Single capillary model  has three compartments, oxygen bound to haemoglobin, oxygen in plasma, 
and oxygen in tissue. Oxygen in plasma is assumed to be in equilibrium with oxygen bound to 
haemoglobin, their concentrations related by Hill’s equation. Transfer of oxygen across the capillary 
membrane is modelled as first-order exchange process with the rate constant k. The capillary has 
length L, and blood moves with velocity v resulting in transit time t=L/v. The capillary bed below is 
then obtained as a collection of capillaries modelled as described, with different transit times t 
taken from the transit time distribution h(t). Reproduced with permission from “The roles of cerberal 
blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and 
metabolism”, by Jespersen et al, 2012, JCBFM, 32 (2), 264-77. 
23
 
 
The oxygen extraction is compared between to homogenous and heterogeneous 
capillary flow is shown in fig.1-19. 
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Figure 1-19 Effects of capillary flow heterogeneity on oxygen extraction 
Compare the extraction of oxygen from individual capillaries according to BKCR kinetics when the 
same flow is distributed across the same number of capillary paths with homogenous (B) capillary 
flow velocities (arrows), and heterogeneous flow velocities (A), respectively. Transit times in 
resting, heterogeneous cases were obtained by sampling gamma distribution with parameters 
corresponding to recordings of mean and standard deviation of transit times in a rat
200
. Notice the 
heterogeneity of capillary flows, in spite of identical total blood flows and number of open 
capillaries. Reproduced with permission from “The roles of cerberal blood flow, capillary transit time 
heterogeneity, and oxygen tension in brain oxygenation and metabolism”, by Jespersen et al,2012, 
JCBFM,32 (2), 264-77. 
23
. 
 
 
Oxygen extraction efficacy (OEF max) always increases with increasing MTT and 
with decreasing CTH. During functional activation, the reduction in CTH occurs 
in parallel with the arteriolar dilation partly maintaining the oxygen extraction 
efficacy during hyperaemia. During resting phase, along some capillary paths, 
flow velocities are so high that little oxygen is extracted from blood. In normal 
brain, hyperaemia is accompanied by a reduction in CTH (homogenisation). This 
homogenisation decreases number of capillary paths with high flow and limited 
oxygen extraction, causing net oxygen availability to increase as a function of 
CBF. 185  
CMRO2 max and thereby tissue oxygen availability always increases with 
decreasing flow heterogeneity. Haemodynamic states above a threshold are 
unique that in that increases in the CBF (reductions in MTT) will lead to states of 
lower tissue oxygen availability. These states are referred as to as malignant 
CTTH. The metabolic consequence of increased CBF with vasodilatation without 
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concomitant reductions in CTTH (i.e. homogenisation) would not lead to a net 
increase in availability of oxygen in tissue 185.  
There is a need for robust estimation of CTH, MTT, OEFmax to test the above 
hypotheses further. This will inform to what extent CBF or CTH, or both 
contribute to oxygen availability.  
 
1.10 Magnetic Resonance Imaging (MRI) 
MRI can provide information on time-sensitive pathophysiological changes and 
therefore potentially act as an indicator of time since onset of ischaemia. In 
hyper-acute ischemic stroke Sodium-potassium channel failure causes a shift of 
fluid and potassium from extracellular to intracellular compartment (cytotoxic 
oedema) after a latency of only a few minutes201. Cytotoxic oedema leads to 
narrowing of extracellular matrix and, thus, to a reduction of Brownian 
molecular motion in the extracellular space. This phenomenon can be measured 
with diffusion weighted sequence (DWI) in minutes  202-204.Cerebral oedema 
increases gradually with shift of water from extracellular space to intra-cellular 
space, and only after 4 hours, disruption of the Blood-Brain Barrier(BBB) was 
noted in animal studies 205,206. This initial phase of cytotoxic oedema is not seen 
on T2 weighted fast spin echo images207. Conventional MRI sequences (T1, T2) 
show abnormalities based on vasogenic oedema which occurs only after BBB 
breakdown, therefore, less sensitive to identify hyper acute infarcts202,203. 
Tissues with increased water content appear hyper intense on T2 sequence. 
Cerebrospinal fluid (CSF) also appears bright and, to improve delineation from 
pathology, an inversion pulse can be used to attenuate signal from pure water 
(FLAIR).  
FLAIR imaging has been proposed as a “tissue clock” – a means of judging stroke 
onset time when this cannot be ascertained from history208-210. The lack of FLAIR 
hyper intensity with positive DWI  allocated ischemic lesions within 3hrs or less 
with a high specificity (0.93) and positive predictive value (0.94) , whereas 
sensitivity (0.48) and specificity (0.43) were low 208. In this study the sensitivities 
were 27% (FLAIR alone) 50% (with knowledge of DWI) ≤3hrs increased to 56.7% 
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(FLAIR alone) 93.3% (with knowledge of DWI) after 3-6 hrs. The PRE-FLAIR study 
showed DWI-FLAIR mismatch (a positive DWI lesion, and no marked FLAIR hyper 
intensity) could identify strokes with <4.5 hrs onset with 62% sensitivity, 80% 
specificity and 83% positive predictive value and 54% negative predictive 
value210.   Using this principle of the DWI-FLAIR match as surrogate for time of 
stroke onset, a randomised trial of IV thrombolysis resulted in significantly 
better functional outcome in unknown time of onset ischemic stroke patients211.  
 
1.10.1 MRI for penumbra identification 
Reduced Apparent diffusion (ADC) of water approximately corresponds to 
core212. In acute stroke patients, the area with perfusion abnormalities is 
generally larger than the DWI hyper intensity area213,214. It was suggested that 
this perfusion-diffusion mismatch may reflect ischemic penumbra214,215. Lesion 
growth between early and late imaging time points corresponds with degree of 
mismatch between diffusion and perfusion216,217. In Human MRI studies, 
successful recanalisation led to salvage of penumbra with neurological 
improvement218.   This assumption is disputed however219 . It was shown that 
ADC decline starts before energy metabolism fails . Moreover, PWI-detectable 
flow decreases are relevant only at flow values that interfere with adequate 
oxygen supply to tissue. Therefore PWI/DWI mismatch often may include normal 
viable tissue, therefore PWI-DWI mismatch-defined penumbra may overestimate 
the extent of infarction at follow up146. 
DWI lesion representing unique physiological parameter with echo planar 
imaging was studied  in human stroke 220. Baird et al,221 suggested, penumbra 
can be operationally defined as mismatch between the lesion volume detected 
by Perfusion abnormality and DWI lesion. However, this was thought to be an 
oversimplification, and in some studies DWI lesion is shown to reverse with 
reperfusion and therefore this mismatch model may overestimate the 
irreversible infracted tissue222. This may overestimate the tissue at risk by 
including oligaemic tissue83,223. There are uncertainties with DWI lesion 
physiological accuracy and what parameters to define the tissue at risk224,225. 
Hypothesis of mismatch is correlated with penumbra is challenged by combined 
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PET and MRI studies showing DWI lesion contained penumbra226, and mismatch 
contained oligaemic tissue223.   
Perfusion weighted Imaging (PWI) uses a bolus tracking technique after 
application of paramagnetic intravascular contrast agent. Maps of Time to peak 
(TTP) provide a robust estimate of hypo perfusion. Normalised TTP (rel.TTP) are 
comparable among individuals and different imaging facilities225. However, delay 
of tracer arrival is not necessarily accompanied by reduction in CBF (for example 
in chronic carotid occlusion) and renders delayed TTP values to potentially be 
false positive and susceptible to collateral circulation227. For better tissue 
identification, a deconvolution method is applied166,171. Tmax reflects the bolus 
delay between Arterial input function and tissue228. Hypoperfusion with Tmax was 
measured in various studies229 230,231. There is no consensus on which perfusion 
parameter best identifies hypo perfusion and predicts infarct growth. Clinical 
studies reported the following range of thresholds for hypo perfusion: rel. TTP: 
>2 to >8 s; rel.MTT: >4s to >8s; CBF: <20 to 42 ml/100gm/min; Tmax >2 s to >8 
s217,232-234.  
A comparative MRI and PET study showed large variability in mismatch volume 
depending on thresholds applied, mostly overestimating penumbra225. In an MRI 
validation with PET study in 26 stroke patients, penumbral flow thresholds were 
MTT > 5.3 s; CBF <21.7 ml/100g/min, TTP >4.2 sec, CBV <1.5ml/100gand T max 
5.5 s 235. Quantification of PWI maps remains a major source of heterogeneity. 
The type of deconvolution171,173 and placement of AIF 236,237 lack a 
standardisation definition across studies. Variability in PWI/DWI mismatch 
definition was used in different studies and this can influence the mismatch 
volumes225,238 239. Adding to this, predictive power of PWI changes with time 
from onset and site of tissue imaged (grey matter vs. White matter), degree of 
reperfusion and age240,241. A comparison of various perfusion software packages 
found substantial differences in the calculated volume of hypoperfusion for maps 
of MTT, CBF, and Tmax among three tested software packages
242.   
Schlaug and colleagues using MRI demonstrated penumbra comprises about 40% 
of the total ischemic territory in patients with any vessel occlusion studied 
within 24 hours215. This was also reported by others231,243,244. This “mismatch” 
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pattern is seen in 70% of patients with anterior circulation stroke scanned <6 h 
214. Its resolution on reperfusion was associated with neurological recovery244.  
Volume of mismatch depends on the definition applied and no standardisation 
exists245. It is unclear what mismatch ratio justifies therapy. Arbitrary volumetric 
difference in a ratio of >1.2 (DW: PWI) was used initially in studies without being 
evaluated246. Recent late thrombolysis trials (EXTEND, ECASS-IV) used 
hypoperfusion to core volume ratio of >1.2 to include for randomisation. In 
DEFUSE-2 trial, SWIFT-PRIME chose target mismatch of 1.8 whereas EXTEND-IA 
chose 1.2. Kakuda et al, described DWI: PWI ratio of 2.6 to predict optimal 
response to thrombolysis247. Heterogeneity arises from the definition itself, 239 
but also from choice of PWI and post processing 245 software. If different 
mismatch definitions are applied to same patient, variability can easily result in 
mismatch exceeding 20%245. A few randomised thrombolysis studies used the 
mismatch concept for patient selection15,246,248. A meta-analysis  concluded that 
mismatch based delayed thrombolysis was not beneficial249. But the studies 
differed in conceptual issues and therefore mismatch concept is still a valid idea 
in current situation. Further randomised trials of IV alteplase were done using 
mismatch concept between 4.5- 9 hours250,251. A recent meta-analysis of late 
time window thrombolysis studies (EPITHET, ECASS-4, EXTEND) was reported 
showing that those with salvageable tissue had better functional outcomes with 
IV alteplase than those given placebo. 36% patients in alteplase group and 29% in 
the placebo group had achieved excellent functional outcome at 3 months 
(adjusted OR 1.86 (1.15-2.99), p=0.011). However, the rate of symptomatic Intra 
cerebral haemorrhage was higher in alteplase group (5% in alteplase 1% in 
placebo group)252.  
1.10.2 NCCT vs. MRI 
NCCT is more easily available and has rapid acquisition time. It is better 
tolerated by unwell, uncooperative patients than MRI. Some patients may not be 
suitable for MRI (e.g. those with pacemakers, aneurysm clips). Kucinski et al,253 
showed in a cohort of 25 patients who were imaged with NCCT and MRI between 
1.3-5.4 hours, ADC decrease was almost complete within 1.5 hours, whereas 
NCCT density was a continuous linear decrease. Sensitivity of NCCT when 
compared to MRI in identifying acute ischemic lesion is only 42-63% (average 
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time for CT 2.6 hrs, MRI 5.1 hrs)254. NCCT has lower sensitivity (75%) to acute 
ischemic changes whereas DWI had 100% sensitivity137. In a single centre, blind 
comparison of CT with MRI in acute stroke referrals, relative to the final clinical 
diagnosis, MRI had sensitivity of 83% (181/217) and CT of 26% (56/217) for the 
diagnosis of any acute stroke255.  DWI has greater inter observer and intra 
observer reliability than NCCT202,203,256,257. Wintermark et al, showed in 42 stroke 
patients imaged within 3 to 9 hours, a good correlation between multimodal CT 
(CT, CTP, CTA) and MRI for infarct size, cortical involvement and occlusion 
site258. Ischaemic Core defined by CBV threshold closely matched DWI lesion 
volume and penumbral tissue plus core on CT perfusion matched the MTT 
lesion259. 
1.11 Non-core-non-penumbral Infarction:  
There is variability in early neurological outcomes between individuals with 
anterior circulation stroke. Alawneh et al, hypothesized that clinically silent 
tissue reflected as “non-core-non-penumbral” may succumb to infarction260. 
Voxel-wise analysis was done to map acutely silent but infracted tissue (acute 
CT perfusion or MR perfusion in comparison to MRI at 1 month). Acutely silent 
but infarcted tissue was seen in most patients although much smaller volumes 
than salvaged penumbra volumes. In around 10% subjects the volume of acutely 
silent but infracted tissue was substantial. In a multivariate regression model, 
even after correcting for the effect of salvaged penumbra, the infarction of 
acutely silent tissue negatively influenced the clinical course. 
1.12 Intravenous thrombolysis (IVT): 
Intravenous thrombolysis with alteplase, a recombinant tissue plasminogen 
activator is established as the standard of care for patients with acute ischaemic 
stroke presenting within 4.5h of symptom onset. The chances of independent 
survival decline steeply with time to treatment delivery, reflecting a limited 
tolerance of the brain to ischemia (Fig. 1-20). Standards accordingly emphasise 
optimization of patient pathways to minimize onset-to-treatment times. 
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Figure 1-20 Effect of time delay on intravenous  thrombolysis outcomes 
Effect of timing of alteplase treatment on good stroke outcome (mRS 0–1).The solid line is the best 
linear fit between the log odds ratio for a good stroke outcome for patients given alteplase 
compared with those given control (vertical axis) and treatment delay (horizontal axis; 
pinteraction=0·016). Estimates are derived from a regression model in which alteplase, time to 
treatment, age, and stroke severity (handled in a quadratic manner) are included as main effects 
but the only treatment interaction included is with time to treatment. Only 198 patients (159 from 
IST–3) had a time from stroke onset to treatment of more than 6 h. The white box shows the point 
at which the estimated treatment effect crosses 1. The black box shows the point at which the 
lower 95% CI for the estimated treatment effect first crosses 1·0. mRS=modified Rankin 
Scale.Reproduced with permission from “The effect of treatment delay, age, and stroke severity on 
the effects of intra venous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis 
of individual patient data from randomised trials”, by Emberson et al, 2014, Lancet,384 
(9958),1929-35 
261
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In 1995, the landmark National Institutes of Neurological Disorders and Stroke 
(NINDS) rt-PA Stroke Trial was the first to demonstrate significant benefit of IV 
alteplase given within 3h of symptom onset, with a 16% absolute increase in the 
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proportion of patients making excellent recovery (modified Rankin Scale of 0 or 
1) at 3 months. NNT was 3 for any improvement in modified Rankin scale.  Rates 
of symptomatic intra-cerebral haemorrhage (SICH) within 36 hours of stroke 
onset were higher in the alteplase treatment group (6.2% vs. 0.6% in placebo 
group)10, using a very conservative definition of SICH. A number of other 
randomised controlled trials131,262 of IV alteplase throughout the 1990s failed 
individually to show benefit for treatment, but all had longer time windows for 
treatment initiation, and average onset to treatment (OTT) time exceeded the 
latest times for treatment in NINDS. The NINDS trial uniquely enforced very early 
treatment delivery by permitting centres to randomise a patient in the 91-180 
minute window only if they also had randomized a patient in the 0-90 minute 
window, a strategy not replicated in any subsequent study.  An individual 
patient data pooled analysis of six major alteplase trials in 2004 included 2,775 
patients and identified potential benefit extending out to 4.5h from onset263, a 
finding subsequently confirmed by the third European-Australasian Cooperative 
Stroke Study (ECASS-III) for the 3-4.5h time window120. A further systematic 
review and meta-analysis of nine trials in 2012 by Wardlaw.et al also 
strengthened the benefit of IV alteplase264. 
A large randomized, controlled trial, the third International Stroke Trial (IST-
3)265 reported effect sizes consistent with previous trials, but inclusion of 
patients with very different age and severity in different time windows rendered 
interpretation of the trial difficult in isolation. Interestingly, elderly people (>80 
yrs) seem to benefit as much as younger population. A meta-analyses of 
individual patient data, including IST-3 and 8 other RCTs of IV alteplase included 
6,756 patients and concluded that alteplase given within 4.5 hours of onset 
significantly increases both survival free of dependence and excellent outcome 
(recovery with no or minimal symptoms) at 3 months, with no difference in 
mortality at final follow-up despite an increase in SICH, responsible for a  slight 
excess of deaths within the first 7 days (fatal ICH risk 2.7% with alteplase 
compared to 0.4% among controls)261. Overall, there was an absolute increase in 
disability-free survival of 10% for patients treated within 3h and of 5% for those 
treated between 3 and 4.5h. 
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1.13 Using imaging for treatment selection 
Advanced imaging with MRI or CT using probabilistic perfusion thresholds allows 
assessment of the extent of viable (penumbral) and non-viable (core) tissue, and 
it has been hypothesised that this may allow individualised  treatment decisions, 
including  delayed intervention in individuals with favourable brain imaging 
features266. Five completed IV thrombolysis studies 15,246,248,267-269 have used 
penumbral “mismatch” (i.e. the penumbra volume exceeds core volume by an 
arbitrarily defined ratio) to select patients, predominantly in extended time 
windows between 3 and 9 hours. A meta-analysis218,249 of these studies found 
that favourable imaging features at baseline were associated with increased 
recanalisation, reperfusion and attenuated infarct growth compared to 
unfavourable imaging features. However, functional outcomes were not better 
than control (placebo) groups, and treatment was associated with increased 
mortality and risk of ICH. Mechanical Retrieval and Recanalisation of Stroke 
Clots Using Embolectomy (MR RESCUE) study269, a randomised-controlled trial 
designed to examine whether MRI features predicted benefit from delayed Intra 
arterial thrombectomy, found no imaging – treatment effect interaction: 
outcomes were good in those with good scans, and poor in those with poor 
scans, but the intervention had no effect. In contrast, MRI profile and response 
to endovascular reperfusion in the non-randomised second Diffusion and 
Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE-2) 
study268 found that patients with favourable “target mismatch” had better 
outcomes following intra-arterial treatment. The populations in these two 
studies had very different characteristics (e.g. median core volume in MR 
RESCUE was 60ml compared with 15ml in DEFUSE-2), indicating very different 
selection biases. Imaging parameters to define core and penumbra remain highly 
heterogeneous in published literature147 . Recent thrombectomy trials used 
target mismatch population after 5 hours for inclusion in their studies16,17,270,271. 
Further Intra arterial thrombectomy studies with extended time window 
included target mismatch population272,273. Better validated and platform-
independent software tools274,275 are not yet in widespread use. RAPID software 
(iSchema View, Menlo Park, CA)276 has been used in recent trials testing IV 
alteplase between 4.5 -9 hrs including target mismatch patients 250 277. 
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Advanced imaging within 4.5h may offer stratification and improve safety by 
excluding  stroke mimics278 and patients with high risk of ICH or poor outcome 
15,279, and including patients with minor stroke or rapidly improving symptoms 
who exhibit high risk of deterioration based on imaging features280 . Whether 
these hypothetical gains outweigh the detriment of additional delay in 
treatment delivery is being evaluated in a randomised controlled trial, the 
Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke 
Evaluation (PRACTISE) trial which will compare NCCT and multimodal CT (NCCT, 
CT perfusion and CTA)281. 
1.14 Intra arterial therapy (IAT) 
 Intra-arterial treatment (IAT) with thrombolytic drugs or mechanical devices 
offers an alternative treatment option to IV thrombolysis (IVT) in patients with 
contraindications. In addition, IAT as an adjunctive treatment to IVT is effective 
in large artery occlusions, which exhibit low rates of recanalisation after IVT and 
for basilar artery thrombosis. The earlier  randomised trials have found no 
difference in outcomes in the IAT arms, whether as a direct comparator to IVT 
under 4.5h 282; additional to IVT compared with IVT alone 283; or with MRI-based 
imaging selection compared to  best medical treatment, including IVT in the 
majority284.   
Several trials were published in recent past which have all showed benefit of IAT 
as an adjunct to IVT compared to IVT alone in large artery occlusion16,17,270,271,285. 
These trials were run efficiently with selective target population with proximal 
large vessel occlusion. Moreover, the stent retrievers were different to the 
earlier studies. An individual patient meta analysis showed that number needed 
to treat to have one additional patient to have reduced disability of at least 1 
score on modified Rankin score at 90 days was 2.613. These trials included only 
patients with modified Rankin score of 2 or less. Most studies used identification 
of salvageable tissue on imaging as an inclusion criteria (Extending the time for 
thrombolysis in Emergency Neurological Deficits- Intra-Arterial (EXTEND-IA), 
Randomized Trial of Revascularization with Solitaire FR Device versus Best 
Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation 
Large Vessel Occlusion Presenting within Eight Hours of Symptom 
Onset (REVASCAT), Solitaire with intention for Thrombectomy as Primary 
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Endovascular Treatment (SWIFT-PRIME), Endovascular Treatment for small Core 
and Anterior Circulation Proximal Occlusion with Emphasis on Minimising 
Computed Tomography to Recanalisation Times ( ESCAPE)) whereas Multi- Centre 
Randomised Clinical Trial of Endovascular treatment for Acute Ischemic Stroke in 
the Netherlands (MR CLEAN) did not. The trials varied in onset to endovascular 
treatment for a maximum from 6hrs-12 hrs. All the trials with extended time 
windows required a favourable profile of salvageable brain tissue for inclusion. 
Hence, thrombectomy based on CT/CTA alone, commencing procedure after 5 
hours has no proven benefit. An NIHSS score of 6 or more was inclusion criteria 
for all these trials.  
Diffusion-Weighted Imaging or Computerized Tomography Perfusion Assessment 
with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes 
Undergoing Neuro-intervention (DAWN) trial in time window of 6-24 hrs after 
symptom onset showed in target mismatch group using automated RAPID 
software, thrombectomy has a strong treatment effect272. The Endovascular 
Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE-3) trial was 
stopped early due to positive results from DAWN study273.  
 
1.15 Cerebral angiogram 
The vessel status is not available in routine cerebral parenchymal imaging with 
CT or MRI. Hyper dense artery sign (HAS) on CT is highly specific and moderately 
sensitive for intracranial arterial obstruction by thrombus286.  Stroke imaging 
protocol can include imaging of both extra cranial and intracranial vessels either 
using MRA or CTA. If proximal large arterial occlusion is found, intra arterial 
thrombectomy can be considered. Recent positive endovascular trials all 
selected patients with proximal anterior circulation occlusion17,270,271. In minor or 
rapidly improving stroke a vessel occlusion or intra cranial stenosis may predict 
later deterioration280. CTA can be done only with a contrast injection using a 
bolus tracking method. MRA can be done without contrast (Time of flight (TOF) 
MRA) or with gadolinium contrast. Contrast enhanced (CE) MRA can show low 
flow state in stenotic areas whereas TOF may show complete occlusion 287. 
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Contrast examination has high signal to noise ratio but both have low spatial 
resolution than CT angiogram.  
 
1.16 Cerebral Collateral circulation 
The collateral circulation refers to the vasculature that compensate cerebral 
blood flow when normal blood flow is impaired or restricted due to severe 
stenosis or occlusion of the principal supplying arteries288. Single phase CTA or 
multi-phase CTA gives complete collateral information. Disadvantage of 
conventional CTA is that it is single snap shot in time of contrast filled blood 
vessels. There is risk of misclassifying patients with good collaterals as poor if 
image acquisition is too early289. Multi-phase CTA generates time resolved 
cerebral angiograms of the brain vasculature from skull base to vertex289. 
Collaterals are recruited to protect ischemic tissue,  and wide variations in 
clinical features and the extent of recovery can be partly attributed to the 
collateral network comprised of the circle of willis and leptomeningeal 
vessels288,290,291. Several studies have demonstrated that in patients with good 
collaterals, clinical outcomes are better292-297 . The extent of cerebral infarction 
is dependent on collateral vessels. Good collaterals are associated but not 
invariably with large penumbra and maintaining it by limiting core expansion297. 
Final Infarct volumes were smaller in patients with good collaterals296. Subjects 
with proximal vessel occlusion with diminished collaterals experienced increased 
risk of worsening and death295. If poor collaterals are demonstrated, risk of 
haemorrhage may be increased with thrombolysis treatment298. When 
revascularisation was achieved benefit was less observed in patients with poor 
collaterals.  
A recent systematic review and meta analysis showed evidence of impact of pre 
treatment collateral circulation on the outcome of patients with IV 
thrombolysis299. A favourable role of good collateral circulation was 
demonstrated with favourable functional outcome, lower risk of symptomatic 
intra cerebral haemorrhage. Such findings may be attributable to lower NIHSS 
score and smaller infarct volume in patients with better collateral circulation. 
No significant correlation was found between collateral status and recanalisation 
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or reperfusion. Some authors reported that good collaterals have more 
protective role even in those who do not recanalise293,300. Bang et al., showed 
patients with good collaterals achieved more benefit of  endovascular therapy24. 
In a systematic review and meta analysis to investigate the effect of collateral 
status on outcomes after endovascular therapies , pre treatment good collaterals 
status was associated with slightly better recanalisation, reperfusion rates301; 
lower risk of symptomatic intra cerebral haemorrhage, more favourable 
functional outcomes and reduced risk of death302. 
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Chapter 2 Study Population and Methods 
2.1 Study population 
Study population for this thesis work included a database of three different 
studies: Alteplase versus Tenecteplase in Stroke Thombolysis (ATTEST)303, 
Pathophysiology of acute post-stroke hyperglycemias in relation to brain perfusion 
and arterial patency (POSH, unpublished), the multicentre Acute Stroke Imaging 
Study (MASIS)304. Safety in Stroke Thrombolysis (SITS) study in chapter 8 included 
the SITS registry database from May 2003- March 2013.  
The multicentre Acute Stroke Imaging Study (MASIS)304 (n=83): This study purpose 
was to investigate the role of multimodal Imaging in acute stroke. Patients under 
6 hours of stroke symptoms onset were recruited and followed up to 3 months 
(Fig.2-1). Feasibility of imaging with CT and MRI at different time-points was 
examined as part of the MASIS study. In summary, acute stroke patients admitted 
to the three participating stroke centres (Aberdeen Royal Infirmary, Western 
General Hospital, Edinburgh and Institute of Neurosciences, Southern General 
Hospital, Glasgow) between August 2008 and March 2010 were prospectively 
screened for recruitment to MASIS, an observational study examining clinical, 
imaging and blood biomarkers of salvageable tissue and outcome after ischemic 
stroke.  
 
             
  
 
 
 
 
Figure 2-1 Flow chart of MASIS study subjects included in  thesis 
 
93 patients recruited 
• 83 eligible patients 
• CT CTP CTA n=63  
• MRI n=20 
 
• Follow up Imaging 
• CT n=17 
• MRI n=60 
• no Imaging n=6 
 
• MRI 
contraindicated 
n=4 
• Non ischaemic 
stroke n=6 
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Pathophysiology of acute post-stroke hyperglycemias in relation to brain 
perfusion and arterial patency (POSH unpublished): Primary hypothesis was, 
whether there is difference in growth of irreversibly damaged tissue after stroke 
between patients in whom blood glucose is normal, in whom blood glucose is 
increased early (<6hrs), in whom blood glucose is normal early but increases later 
(>6hrs). Patients with stroke within 6 hrs were recruited in Southern General 
Hospital, Glasgow. They had CT, CTA, and CTP at admission and follow up CT at 
24-48 hrs. Additionally in those with occlusion on admission CTA also had repeat 
CTA. Patients were followed to 30 days (Fig.2-2). 
 
 
  
 
 
                          Figure 2-2 Flow chart of POSH study population included in thesis 
 
Alteplase versus Tenecteplase in Stroke Thombolysis (ATTEST)303: Pilot phase 
Prospective Randomised Open label Blinded End-point (PROBE) study compared 
markers of biological activity to inform the design of larger definitive trial 
comparing the efficacy and safety of Alteplase and Tenecteplase as thrombolytic 
agents in eligible patients with acute ischemic stroke. Patients eligible for 
thrombolysis under current standards are randomised to receive either Alteplase 
or Tenecteplase between January 2012 and September 2013. This was a single 
centre study carried out in Institute of Neurological sciences, Southern General 
Hospital, Glasgow. The primary outcome is amount of penumbral tissue salvaged 
between the two treatment arms. All patients underwent CT, CTA and CTP on 
admission and CT, CTA at 24hours. Patients were followed to 3 months (Fig.2-3). 
 
 
 
113 Consented 
Ischaemic Stroke n=108 
  CTP usable n=104 
Non stroke n=5 
CTP unusable n=4 
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                                Figure 2-3 Flow chart of ATTEST study subjects 
 
2.2  Imaging 
2.2.1 Imaging acquisition 
Imaging was performed on a Philips Brilliance 64 multi detector scanner. Whole 
brain NCCT was acquired first, (5 mm slice thickness FOV 218 x 218 mm, 120 kv, 
171 mA or 0·9 mm slice thickness, FOV 250x250  mm, 120 kV, 404 mA) followed by 
CTP with 40 mm slab coverage from the basal ganglia (8x5 mm slices, FOV 25 cm, 
80 kVp, 476 mA, 2 second cycle time, 30 cycles) using a 50 ml contrast bolus 
administered at 5 mls per second (350 Xenetix) via a large-gauge cannula. A CTA 
covering aortic arch to the top of the lateral ventricles (0·67 mm slice thickness, 
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120 kV, 475 mA) was acquired during the first arterial past of contrast (Xenetix 
350, 60 mls, followed by 30 mls of saline bolus, both given at 5 ml per second). 
Follow up brain imaging consisted of whole brain non-contrast CT followed by 
intracranial CTA from base of skull to the top of vertex. Follow up CTA was only 
performed in patients with an arterial occlusion on initial CTA. 
2.2.2 Imaging processing and analysis  
Study imaging records were transferred from clinical scanners or radiology 
archives after removal of individual identifiers from the Digital Imaging and 
Communications in Medicine (DICOM) file and were identified with the study 
number. All imaging analysis was undertaken on separate secure computer 
workstations using a commercially available software package MiStar (Apollo 
Medical Imaging Technology, Melbourne, 
Australia   http://www.apollomit.com/products.htm). Imaging studies were 
anonymised, and analysed independently by two research fellows (BC, XH) blinded 
to treatment allocation after the recruitment completion to minimise the odds of 
recognising scans with treatment allocation. The images are assigned randomly 
(non consecutive subjects) when performing the analysis.  Inter-observer 
agreement was assessed for all parameters analysed. Volumetric analysis was 
carried out by each research fellow twice. The average of the four readings was 
taken as the final reading for analysis. Disagreements in categorical readings were 
resolved by the consensus of experienced neurologists or neuro-radiologists 
blinded to treatment allocation.  
The inter-rater agreements were assessed initially in test set of scans and then 
evaluated in the full set of the scans. The test scan set (n=18) was randomly 
selected from our Imaging archive. The inter-rater agreements for continuous 
variables were assessed with an intra-class correlation coefficient (Tables 2.1 & 
2.2) and categorical variables were examined with weighted kappa using stats 
direct. 
Table 2-1 Test set inter-rater agreement in continuous variables 
 Kappa  95% CI 
Ischaemic core     0.87 (-9.95-23ml) 
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Penumbra volume  
 
0.92 (20.8-11.3ml) 
Co registered Infarct 
volume 
0.8  
 
(-31-73.4ml) 
Total infarct volume 0.94  
 
(-22.2-70.2ml) 
 
Weighted kappa for arterial patency (n=20) was 0.46 (95% CI 0.2-0.7). 
 
 Table 2-2 Study scans Inter-rater agreement in continuous variables  
 kappa 95% CI 
Core volume 0.96 (16.2-19.9 ml) 
Penumbra volume 0.91 (-30.2-30.1ml) 
 
Co registered Infarct 
volume 
0.91 (-57.3-26.4 ml) 
 
Total infarct volume 0.91 (-92.9-47.3ml) 
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The weighted kappa for baseline occlusion site was 0.63 (95%CI 0.49-0.77); 
Arterial patency at 24-48 hrs kappa=0.68 (95% CI 0.48-0.89) with TIMI and 
kappa=0.7 (95%CI 0.5-0.89) with TICI. Brain swelling at 24-48 hrs –kappa= 0.5 
(95%CI 0.36-0.65). Classification of ICH according to ECASS-III kappa= 0.75 (95%CI 
0.6-0.91). Hyper dense vessel sign on baseline NCCT kappa=0.6 (95%CI 0.42-0.8). 
ASPECT score baseline NCCT kappa=0.41(95%CI 0.29-0.53) on follow-up CT 
kappa=0.69 (95%CI 0.57-0.81). 
Given the low agreement in categorical variables, the discrepancies in baseline 
occlusion and recanalisation were resolved by referencing the reports of 
radiologist who were not aware of the treatment allocation. The ICH classification 
was adjudicated by experienced external readers from the University of Calgary 
(Dr Andrew Demchuk, Prof Michael Hill). Any remaining categorical parameter 
disagreements were settled by Prof Keith Muir. 
The MiStar software package provides four parameters when processing CTP: 
cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), 
and delay time (DT) (Fig. 2-4). In summary, deconvolution of tissue enhancement 
curves and arterial input function (AIF) selected from the contra-lesional anterior 
cerebral artery was performed using modified singular value decomposition (SVD) 
with compensation for the effects of arterial delay and dispersion. Venous Output 
function was manually selected from superior sagittal sinus. Motion correction was 
applied automatically using package provided options. A noise elimination 
technique “close clustering” of <5mm2 was used to minimise the small artifactual 
pixels probably induced by noise305. After arterial input function (AIF) and Venous 
Output function (VOF) selection, a Hounsfield Unit filter was applied in order to 
mask CSF (15 HU) and bone (700 HU), leaving only brain parenchyma as far as 
possible (fig.2-5 &2-6). Voxels with CBV values >90 cm3/100g were then masked 
(fig.2-7), as arterial voxels mimic tissue areas of high perfusion and their exclusion 
improves the accuracy of CTP relative to PET155.  
A series of delay time values, DTi ranging from 0 to Tmax were applied and for 
each delay time value a modelled arterial transport function was convolved with 
the measured global AIF to produce the AIFi which was used for SVD deconvolution 
of the tissue curve to produce an impulse residue function IRFi with its maximum 
appearing Tmax(i). DT was determined as the minimal DTi value which produces 
Tmax (i) =0.Cerebral Blood Flow (CBF) and Cerebral Blood Volume (CBV) were 
calculated from the peak height and area under tissue enhancement curves 
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respectively, and Mean Transit Time (MTT) = CBV/CBF (central volume 
theorem)169.  
Ischaemic core was defined as tissue with reduced CBF (relative CBF <40% of 
contra lesional hemisphere) and prolonged delay time (relative DT >2 sec); 
penumbra volume was defined as tissue with relative DT >2 sec but relative CBF ≥ 
40% of contra lateral 148.  
 
 
Figure 2-4 CTP maps 
CTP maps generated with MIStar software (Top four panels: CBV, CBF, MTT, angiography: Lower 
four panels: penumbra map, DT, contrast CT, and time-attenuation curve for arterial input function 
(AIF, red), and venous output function (VOF, blue) 
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Figure 2-5 CTP maps thresholding 
CT maps as in fig. 2-4 with insert showing selection of thresholds for core, penumbra 
 
 
Figure 2-6 CTP maps with bone, CSF masking 
CTP maps as in fig.2-6 after applying core, penumbra thresholds and masking CSF and bone 
(bottom panel second from right, bone is excluded) 
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Figure 2-7 CTP maps with thresholding for CBV 
 CTP maps as in fig.2-6 after applying thresholds masking voxels with CBV value >90cm
3
/100g 
 
Because of the limited coverage of CTP, the co-registered infarct volume was 
calculated for penumbral salvage. Both follow up CT and CTP scans were loaded 
side by side into a fusion tool using MIStar (fig.2-8). A rigid body 3D transformation 
was used to register the follow up structural imaging to the perfusion scan. 
Structural CT sequences were reformatted manually and visually verified to match 
the orientation of the original CTP (fig.2-9). Reformatted structural CT slices 
resulting from co-registration were used to measure the final infarct volume with 
manually drawn ROIs using visual inspection (fig. 2-10 & 2-11). The combination of 
the co-registered infarct volume and the infarct volume beyond the co-registered 
slices produces the total infarct volume.  
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Figure 2-8 CTP, CT coregistration step 1 
 Left hand side maps as in fig.2-4, right hand side follow up NCCT images 
 
To minimise the opportunity of including false positive pixels, ROIs drawn for final 
infarct volume measurement were transposed onto the corresponding CTP slice 
(Fig.2-13). Manual adjustment was applied when necessary in order to match to 
the same anatomical region. The penumbra volume that was infarcted was 
calculated from the ROI on the corresponding CTP slice. The following equations 
were used to determine relevant values:  
 
-registered infarct volume - Core volume  
– penumbra volume that 
infarcted;  
ercentage of penumbra salvaged = (penumbra salvage/penumbra volume) x100  
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Figure 2-9 CTP, CT Coregistration- step 2 
Top 3 panels: CT perfusion with superimposed (red) 24 hr CT following co-registration; middle three 
panels: 24 hr CT at the same anatomic level; lower three panels: CT perfusion at the same anatomic 
level 
 
Figure 2-10 CTP, CT Coregistration- step 3 
Reformatted 24 hours CT (with the red colour overlay − top left eight panels) presented in a same 
window as the original 24 hour CT (lower right eight panels) and baseline CTP (lower left eight 
panels; CT perfusion angiography ( top right eight panels) 
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Figure 2-11 Reformatting of images after coregistration 
Reformatted 24 hours CT (with the red colour overlay turned off − top left eight panels) presented in 
a same window as the original 24 hours CT (lower right eight panels) and baseline CTP (lower left 
eight panels). CT perfusion angiography  (top right eight panels) 
 
 
Figure 2-12 ROIs for core, penumbra 
ROI of final infarct volume (Left) transposed to the penumbra/core ( middle. Green- penumbra; red- 
core) map; by applying thresholds either core or penumbra can be chosen (right)) 
 
2.3 Collateral grading: 
Patients with arterial occlusion in the Internal carotid artery (ICA) or proximal 
Middle cerebral artery (MCA) vessels had perfusion scans evaluated to determine 
the direction of blood flow distal to the vessel occlusion. 4-D angiographic 
appearances of the 4cm perfusion slab were displayed as a Maximum Intensity 
projection (MIP) image and evaluated in cine mode. The 4-D angiographic 
appearances permitted visualisation of arterial filling in normal and ischemic 
tissue beds in real time or at faster rates if needed adjusted by the operator. The 
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effect permitted the presence of contrast enhancement in distal portions of an 
arterial distribution to be seen prior to filling of the proximal portions and thereby 
confirming that flow in the relevant territory is truly collateral in nature. Without 
being able to confirm the retrograde direction of flow it would be impossible to 
say if CTA appearances were due to collateral filling and not simply due to 
delayed anterograde flow due to an incomplete arterial occlusion/stenosis. The 
use of perfusion data to confirm flow direction has been previously demonstrated 
using the same software packaging297. The effect is best appreciated when viewed 
in the cine mode, but can be appreciated using a series of screenshots taken at 2 
second intervals as seen in figure below (fig.2-13). 
 
Figure 2-13 CTP angiography for collateral grading 
4D CTP angiography demonstrating retrograde flow: Right MCA occlusion with perfusion scan MIP 
shown at 2 second intervals. The right MCA demonstrates delayed contrast filling, but the distal 
portion fills prior to proximal portion confirming that flow in ischemic area is retrograde and collateral 
in origin 
 
If retrograde flow was seen on CT Perfusion, collaterals were graded on baseline 
CTA qualitatively297. We defined collaterals as good (angiographic flow distal to 
occlusion), moderate (angiographic flow to ischemic territory but not distal to 
occlusion), or poor (contrast opacification only in distal superficial branches). We 
used a modified Miteff’s classification to incorporate terminal ICA, M1 and M2 
occlusion, whereas the original classification excluded M2 occlusion297. 
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2.4 Recanalisation 
Recanalisation was determined on follow up CT Angiogram at 24 hrs using a TIMI 
scale, a grading system adapted from cardiologists to describe recanalisation and 
reperfusion in revasculisation studies (Table 2-3). Recanalisation was defined as 
Thrombolysis in Myocardial Infarction (TIMI) grading 2- 3 in  CTA306 307. 
Thrombolysis in cerebral infarction (TICI) score was designed for conventional 
angiography, and dynamic function is crucial to use it accurately308. Since 
conventional CTA provide a single phased image, the TICI scale is unlikely to 
describe recanalisation more accurately than TIMI scale. Since introduction of 
endovascular therapies Modified TICI scale was recommended307. 
 Table 2-3 TIMI scale  
Grade TIMI 
0 No reperfusion 
1 Penetration without reperfusion 
2 Partial reperfusion 
3 Complete reperfusion 
 
2.5 Haemorrhage classification 
On 24h NCCT, we classified ICH as per European Cooperative Acute Stroke Study II 
(ECASS II) criteria,262 and SICH as any ICH with increase in NIHSS≥ 4 points262. 
Haemorrhagic transformation following ischemic stroke is classified into four types 
(Fig.2-14):  
Haemorrhagic infarction 1 (HI 1) - small petechiae along the margins of the infarct 
Haemorrhagic infarction 2 (HI 2) -confluent petechiae within the infarcted area 
but no space occupying effect;  
Parenchymal haematoma 1 (PH 1) - Blood clots in ≤30% of the infracted area with 
space occupying effect;  
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Parenchymal haematoma 2 (PH 2) -Blood clots in >30% of the infracted area with 
space occupying effect.  Any PH1 or PH2 were considered significant 
haemorrhage. 
 
Figure 2-14 ECASS II classification of ICH 
Examples from the ATTEST study imaging (from above left clockwise: HI1, HI2, PH1, PH2) 
 
Safe Implementation of thrombolysis in stroke Monitoring (SITS-MOST)  proposed 
that only PH type haemorrhage with deterioration in NIHSS≥4 is clinically 
significant309. 
2.6 Oedema classification 
Brain oedema classification was as adapted from IST-3 trial as no swelling (grade 
0), effacement of lateral ventricle (grade 1), effacement of lateral plus third 
ventricles (grade 2), or midline shift (grade 3. Table 2-4)310. In this thesis work, I 
used grades 2-3 as significant brain oedema. 
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Table 2-4 Brain swelling classification (adapted from IST-3 trial) 
 
 
 
2.7 Modified Rankin Scale 
The modified Rankin scale is an ordinal hierarchical grading from zero (no 
symptoms) to six (death) for measuring the degree of disability or dependence in 
daily activity (table 2-5). It is the most used functional outcome scale in stroke 
research studies. There is relatively lower inter-rater agreement compared with 
other scales311. Inter-observer reliability improved moderately with the structured 
mRS interview and video training system312. 
Table 2-5 Modified Rankin scale 
Scale Description 
0 No symptoms at all. 
1 No significant disability despite symptoms; able to carry out all 
usual duties and activities. 
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2 Slight disability; unable to carry out all previous activities, but 
able to look after own affairs without assistance. 
3 Moderate disability; requiring some help for more complex 
tasks (e.g. finances), but able to walk without assistance. Able 
to manage alone at home for at least 1 week. 
4 Moderately severe disability; unable to walk without assistance 
and unable to attend to own bodily needs without assistance. 
Able to be left alone for at least a few hours during the day. 
5 Severe disability; bedridden, incontinent and requiring 
constant nursing care and attention. 
6 Dead. 
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Chapter 3 Methods for Capillary Transit Time 
Heterogeneity (CTTH) work in Chapters 6, 7  
3.1 Introduction 
Using a multimodal imaging database from 3 different single centre studies, we 
derived the maps for several perfusion parameters. The study population was 
detailed in chapter 2. The perfusion parameters derived included: Cerebral 
blood flow (CBF), Cerebral blood volume (CBV), Mean transit time (MTT), Delay 
time (DT), Tmax, Capillary transit time heterogeneity (CTTH) and Coefficient of 
variation (COV) maps using vascular (parametric) method. Scans were read by 
one research fellow (BC) experienced in perfusion imaging, blinded to the 
clinical information and functional outcomes. MATLAB platform (2014 version) 
was used for image analysis (PGUI perfusion analysis software: centre for 
functionally integrative neuroscience CFIN, Aarhus University Hospital, 
Norrebrogade, Denmark). First, all the anonymised scans digital imaging and 
communications in medicine (DICOM) data was decoded to tailor to transfer into 
the dedicated pipeline developed locally in Brain imaging lab, Aarhus University, 
Denmark. These images were converted to Neuroimaging Informatics Technology 
Initiative (NIFTI) files. Then, masks were drawn for Infarct, manually in 24h 
followup non-contrast CT (NCCT) scans. Broadly the steps involved in deriving 
CTP parameters are below: 
 DICOM file Conversion to NIFTI 
 Baseline detection of contrast bolus arrival (automated) 
 Motion correction (automated): 2D approach was adapted  
 Check Motion Correction (manual): some slices where  motion artefact 
was detected, it was interpolated with the adjacent slice Concentration 
conversion (automated) 
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 Arterial Input function (AIF), venous output function (VOF) selection 
(Anterior cerebral artery (ACA) and sagittal sinus respectively were 
chosen manually) 
 Check baseline of concentration curves (manual) 
 Vessel removal for perfusion (PWI) Images (by applying threshold 
manually)  
 Deconvolution (automated) : standard SVD (s SVD), circular SVD (o SVD), 
Vascular(parametric) methods  
 Re-slice follow up NCCT to thicker (5mm) slices(automated) 
 Automatic segmentation (Grey matter (GM), white matter (WM), 
Cerebrospinal fluid (CSF) space) 
 Co registration (automated) of follow up NCCT to the acute NCCT at first 
followed by manual correction with acute CTP images. Co registration of 
CTP with follow-up NCCT was also done by automated method. By 
checking manually, whichever method co-registered best was used for the 
analysis. 
 Cleanup (automated) 
 Segmentation: Follow up NCCT mask for Infarct area (manual), TTP mask 
(ROI tool and manual adjustment if needed) 
3.2  Detailed steps 
Perfusion CT images were processed using MATLAB package (version 2014 Mat 
lab, Math works, https://de.mathworks.com/products/matlab.html)) to derive 
the CTP parameters. Motion correction of CTP images was carried out by a 2 
dimensional approach by a special filter. Motion correction was checked for each 
subject, and, if required, Interpolation of slices was carried out in some (n=20), 
but restricting to not more than 3 non contiguous slices for each patient (Fig.3-
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1). Interpolation of 3 slices, 2 slices in 4 subjects, one slice in 15 subjects was 
performed. 
 If interpolation is not possible due to excessive motion artefacts, they were 
excluded from the study (n=15).   
 
 
Figure 3-1 Motion correction of CTP images  
Top: left before motion correction right: after motion correction. Bottom: serial images of CTP after 
motion correction 
 
 A delay corrected deconvolution steps (standard SVD, circular SVD, vascular 
model) are then applied to generate the parametric maps MTT, CBF, CBV, DT, 
Tmax . In addition, CTTH, COV, OEFmax maps were obtained only in vascular 
model. The deconvolution applies an arterial input and venous output function 
which were selected manually. I selected Anterior cerebral artery (ACA) and 
  85 
 
vertical segment of Superior sagittal sinus respectively for Arterial Input function 
(AIF), Venous output function (VOF) with an ROI tool (Fig.3-2). Region of Interest 
(ROI) was chosen manually by reader (BC), software then identifies the 
reference voxels within these ROIs. This can be manually adjusted if needed 
(e.g. add more voxels, if required). An example of arterial, venous curves for a 
few subjects is shown in Fig. 3-3.  
 
Figure 3-2 AIF, VOF selection 
Left: curves (yellow-arterial, green-venous) after selection of voxels Right: ROIs placed on Anterior 
cerebral artery (ACA) and Sagittal sinus 
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Figure 3-3 AIF and VOF curves 
Arterial and venous curves in different subjects (Red curve is arterial and blue is venous). 
 
The software applies curve fitting by least mean squares to obtain time 
concentration curves for each voxel (Fig.3-4).The baseline curves were carefully 
inspected for each subject to adjust the start volume and end volume of the 
baseline before the uptake of the arterial curve (Fig 3-4).  I selected start 
volume (start of baseline) as 0 and end of baseline to be a minimum of 1. Some 
subjects (n=16) had no baseline (i.e. both start volume and end volume were 0 
with take off from start of the baseline) and therefore deconvolution was not 
possible; baseline unenhanced signal variation was not available to compare with 
voxels with substantial signal increase.  
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Figure 3-4 Concentration tissue curves 
Bottom graph shows the curves for each voxel and top graph is the cumulative curve. Small insert 
shows manual selection points of start and end values for baseline.  
 
I removed the peripheral vasculature by applying threshold for each subject 
individually (Fig.3-5). The distribution of threshold application for all the 
subjects is shown on histogram in the fig.3-6. An example of CTP images after 
vasculature removal is shown in Figure 3-7. 
 
Figure 3-5 Vasculature removal from CTP 
Pink colour is vasculature-manually threshold can be changed to obtain optimal vasculature 
removal. 
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Figure 3-6 Histogram of distribution of vascular thresholds 
 
 
Figure 3-7 Examples of CTP images after vasculature removal 
 
 
Separately, time to peaks (TTP) was outlined with ROI tool with manual 
adjustment if needed (Fig.3-8 &3-9). TTP maps are used to delineate the area of 
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hypoperfusion. From these outlined areas, other perfusion parameters were 
derived. CBV map is calculated from the area under the time enhancement 
curve for each voxel. Then central volume principle (CBF=CBV/MTT) is applied. 
Automatic segmentation of GM, WM, and CSF was also done.  
 
 
Figure 3-8 ROI drawing of TTP mask 
First ROI tool is drawn around the abnormal TTP zone (Top left and right) with manual adjustment 
if necessary (Bottom) 
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Figure 3-9 TTP masks after ROIs chosen in a subject 
 
Segmentation of total infarct volume in non contrast CT at follow up (n=169) was 
done manually outlining the hypo attenuation area (Fig.3-10).  Co-registration of 
acute NCCT to follow-up CT was conducted manually. Co-registration was 
assessed manually for satisfactory results A few scans were not properly gantry 
corrected. If acute scans were not properly gantry corrected, I manually co 
registered the CTP with follow up CT (n=15). An automated co-registration of 
CTP with follow-up CT was also carried out (Fig.3-11). A few were excluded that 
were not able to be co registered (n=2). The best co-registration mode (manual 
or automated) was chosen visually inspecting all the subjects. Co-registration of 
CTP with Follow up MRI scans was not adequate so those with follow up MRI 
(n=11) were excluded from the study. 
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Figure 3-10 CT Infarction ROI 
 masks are drawn manually for Infarct area on follow up CT  
 
 
Figure 3-11 Coregistration of Follow up CT and acute CTP 
Top left- follow up CT (in red) overlapped on acute CT. Bottom left- follow up CT. Top right- follow 
up CT (red) overlapping CTP image. Bottom right shows a dialogue box to change yaw, roll and 
pitch. 
 
Selection of automated or manually co registered images was chosen for each 
individual based on the best registration method by visually inspecting for each 
subject. There are some examples in figures below. In the first example (fig.3-
  92 
 
12) there is good correlation of both methods, in second example (fig.3-13) the 
manual co registration is  better than automated, in third (fig.3-14) automated 
is -better than manual) 
 
Figure 3-12 An Illustration of good coregistration of both manual and automated methods  
Top: acute CTP, middle:follow up NCCT manual, bottom-:follow up NCCT automated. Infarction 
masks are shown in pink, blue ROIs 
 
 
Figure 3-13 An Illustration of manual coregistration better than automated method 
Top: acute CTP Middle: follow up NCCT manual bottom: follow up NCCT automated. Infarction 
masks are shown in pink, blue ROIs 
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Figure 3-14 An Illustration of automated coregistration better than manual method 
Top: acute CTP Middle: follow up NCCT manual bottom: follow up NCCT automated. Infarction 
masks are shown in pink, blue ROIs 
 
Core, penumbra volumes are derived using Wintermark’s method (Core=CBV 
<2ml/100g/min, Penumbra= relative MTT>145%)141. Non bolus voxels where no 
contrast arrived during scan and values are undetermined (Fig 3-15) and non 
bolus voxels which are centred in CBV area (Fig 3-16), but also in White matter 
(WM) where signal to noise ratio (SNR) is low (Fig 3-17), are excluded from all 
the masks. This may have reduced CBV core mask significantly. Moreover, CBV 
mask may be scattered diffusely across the whole of brain. If so, I corrected by 
removing regions with CBV <1ml (Fig 3-18).  
MTT mask often included a non TTP area (Fig 3-19). Sometimes, the infarct (FI) 
is found to be outside the TTP area. To reduce this, we included MTT from TTP 
area plus Infarct area in follow up scan (FI) which is called “union mask”. An 
example of Core, penumbra, final infarct masks is shown in Fig 3-20. 
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Figure 3-15 Non bolus voxels 
Non-Bolus voxel regions shown on MTT maps. Top row-bolus arrival,    middle row-MTT is set long 
to show non bolus areas in red colour, bottom row follow up NCCT with infarction 
 
 
Figure 3-16 Non bolus mask 
final Infarct (Yellow ROI). non-bolus area (Light blue ROI).  CBV core (Red ROI) 
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Figure 3-17 Non bolus voxels (light blue) in White matter 
 
 
Figure 3-18 Scattered CBV voxels 
CBV (red) scattered diffusely in whie matter (blue). Left: Before excluding CBV<1ml .Right: after 
removing CBV<1ml voxels. 
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Figure 3-19 Final masks derived after the previous steps 
MTT (green), TTP (blue), Final Infarct (yellow) 
 
 
Figure 3-20 Final masks after fusion of MTT, FU Infarction 
Final Infarct (Yellow), core (red), penumbra (blue) masks  
 
Example figures with different maps (standard SVD, Vascular model) derived are 
shown in fig 3-21 & 3-22. 
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Figure 3-21 An example of standard SVD map 
CBF, CBV, delay metric and MTT maps are shown in anti clockwise from top left.  
 
 
Figure 3-22 An example of vascular model map 
Top row- CBF, MTT, CBV ; Middle row-  DT, CTTH, COV; Bottom row- OEF . 
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An example of CSF mask, mirror masks for Infarct, TTP masks is shown (fig. 3-
23). A 3 dimensional approach is used for mirroring masks in NCCT, and 2 
dimensional approaches were used for TTP masks. 
 
Figure 3-23 Mirroring of TTP, FU Infarct masks 
Brain (green), CSF (blue), infarct (yellow) and mirrored infarct (pink) , TTP (red) and mirrored TTP 
in contra lateral brain (blue). 
 
An example of Core, penumbra and final infarct masks drawn after the previous 
steps is shown in Fig 3-24. 
 
Figure 3-24 Core, penumbra and FU Infarction masks 
 Infarct ( red ROI), penumbra (orange voxels), and core (blue voxels) 
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An example of non-core, non-penumbra infarction is shown in Fig 3-25. 
 
Figure 3-25 An example of non-core-non-penumbral Infarct mask.  
Infarct masks shown in red ROIs on a grey scale MTT  
 
Finally, we obtained an excel sheet with median, mean values of CBF, CBV, MTT, 
CTTH and COV of all voxels in different tissue zones as described above. The 
values are from all the voxels in core, penumbra, noncore, non penumbra infarct 
tissue, and normal contra lateral brain.  
3.3 Study population of CTTH work 
From the 3 studies detailed in chapter 2, a total of 299 subjects have were 
eligible (MASIS n=83; POSH n=113; ATTEST n=103). 34 subjects were excluded: of 
which, 16 had no perfusion imaging done, 12 had non stroke diagnosis, and 5 
subjects had CTP done after thrombolysis.  Incomplete CTP was done in one 
subject .Scans with Jog mode (n=7) were included as maps appeared 
satisfactory. 
Out of remaining 265 subjects, 167 have core, penumbra maps available. 143 
subjects have a follow-up imaging (CT (n=132) and MRI (n=11)), 24 have no 
follow up imaging. I excluded subjects with follow up MRI as the co registration 
was not satisfactory.132 subjects have a follow up CT and perfusion maps were 
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available in all of these except 1 subject. This constituted the final study 
population (fig.3-26). 
 
 
 
 
 
 
 
 
 
 
 
Total subjects n=299 
 
 
 Perfusion maps (Core, penumbra volumes) available (n=167) 
 
Excluded (n=35) (Follow up MRI (n=11) no follow up 
Imaging (n=24)) 
 
 
 
Number with Follow-up CT (n=132)  
 
Excluded (n=98) 
(CTP poor quality (n=15) 
No baseline on CTP (n=16)) 
No perfusion lesion ( n=67) 
Total number with valid CTP 
(n=131) 
 
 
Figure 3-26 Flow chart of study population for CTTH 
work 
CTP performed in n=265 (ATTEST n= 94, MASIS n= 63, 
POSH n=108) 
 
Excluded 34 subjects: no 
CTP n=16; non stroke 
diagnosis n=12; CTP after 
tPA n=5; Incomplete CTA n=1 
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Chapter 4 Does the Penumbra Shrink over Time? 
Penumbra volume and collaterals in the first 6 
hours after acute ischemic stroke 
 
 
4.1 Introduction 
In animal focal ischaemia models, CBF thresholds for prediction of infarction 
differ over time; severe CBF reduction results in infarction within  a short time, 
while it takes longer for less severe CBF reduction to result in infarction 84. 
Conventionally, core is believed to grow over time at the expense of penumbra, 
and is understood to be a consequence of the dynamic interaction of multiple 
factors including peri-infarct spreading depressions and adverse neurochemical 
events313.  
Consistent with animal data on penumbra decline, the probability of favourable 
clinical outcome declines rapidly with increasing onset-to-treatment in IV 
Thrombolysis 261,314 , from onset-to-reperfusion time in endovascular 
reperfusion13,315. “Collateral failure” and consequent penumbral loss as a 
function of duration of ischaemia is assumed to be a major explanatory factor 
for this time dependence316.  
Clinical imaging observations are, however, not uniformly consistent with this 
explanation. Several human studies show persistence of imaging features 
accepted as consistent with penumbra for much longer across modalities 
including PET113,115 MRI215, MRI perfusion-diffusion mismatch 244,317 almost periods 
of up to 48h. Penumbra with Xenon CT represented a constant proportion (one 
third) of hypoperfused territory while core volume was variable from individual 
to individual within 6 hours of MCA occlusion318. In proximal arterial occlusion, 
good collaterals were associated with both favourable tissue and clinical 
outcomes, while time from onset was unrelated to either collateral grade or 
mismatch proportion297. In patients treated with endovascular therapy, the 
interaction of good collaterals and reperfusion, but not time from symptom 
onset to reperfusion, influenced penumbral tissue loss319. 
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I investigated the relationship of penumbra volume, collateral status and their 
interaction with time within 6 hours of stroke onset. Our hypothesis was that 
penumbra would generally shrink in size with time, and good collateral score is 
associated with existence of larger penumbra at later time points. 
4.2 Methods 
4.2.1 Study Population 
I selected data from subjects recruited at a single centre (Southern General 
Hospital, Glasgow) to one of three multimodal imaging studies during 2008-2013. 
Two studies were observational (one study  investigating feasibility of complex 
imaging, the multicentre Acute Stroke Imaging Study (MASIS)304, one study 
investigating Pathophysiology of acute post-stroke hyperglycemias in relation to 
brain perfusion and arterial patency (POSH, unpublished),) and one was a trial 
phase II randomised trial comparing alteplase and tenecteplase in stroke 
thrombolysis (ATTEST)303. In the two observational studies, all ischemic stroke 
patients aged >18 years and presenting < 6 hours after onset were eligible. 
Exclusion criteria were contraindications to iodinated contrast (allergy or eGFR 
<30ml/min).  Patients underwent NCCT, CT angiography (CTA) and CT perfusion 
at baseline (< 6hours) with follow-up CT and CTA (if occlusion was present on 
baseline imaging) approximately 24h later. Favourable outcome was defined as 
modified Rankin scale (mRS) 0-2 at final review (30 or 90 days, depending on 
individual study).  Endovascular treatment was not used. 
For this chapter, I selected subjects with a perfusion lesion and anterior 
territory arterial occlusion (ICA, M1, M2, or M3).   
Using data from three studies in acute ischaemic stroke patients <6h after onset 
imaged with multimodal CT, I measured core and penumbra volumes, collateral 
status, and target mismatch (defined as core volume<50ml, perfusion lesion 
volume>15ml, mismatch ratio>1.8). Patients were grouped by onset to imaging 
time (<3, 3-4.5, 4.5-6h). I explored correlates of penumbra proportion by 
multivariable linear regression. 
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4.2.2 Imaging acquisition 
All scans were performed on a Philips Brilliance 64 multi detector scanner. 
Whole brain NCCT was acquired first, (5 mm slice thickness FOV 218 x 218 mm, 
120 kv, 171 mA or 0·9 mm slice thickness, FOV 250x250  mm, 120 kV, 404 mA) 
followed by CTP with 40 mm slab coverage from the basal ganglia (8x5 mm 
slices, FOV 25 cm, 80 kVp, 476 mA, 2 second cycle time, 30 cycles) using a 50 ml 
contrast bolus administered at 5 mls per second (350 Xenetix) via a large-gauge 
cannula. A CTA covering aortic arch to the top of the lateral ventricles (0·67 mm 
slice thickness, 120 kV, 475 mA) was acquired during the first arterial past of 
contrast (Xenetix 350, 60 ml, followed by 30 ml of saline bolus, both given at 5 
ml per second). 
4.2.3 Imaging processing and analysis 
Imaging studies were anonymised, and analysed independently by two research 
fellows (BC, XH) blinded to treatment allocation after the recruitment 
completion to minimise the odds of recognising scans with treatment allocation. 
CT perfusion was processed offline using MiStar (Apollo Medical Imaging 
Technology, Melbourne, Australia) commercial software. Deconvolution of tissue 
enhancement curves and arterial input function (AIF) selected from the anterior 
cerebral artery was performed using modified singular value decomposition 
(SVD) with compensation for the effects of arterial delay and dispersion. Delay 
time (DT) was determined by a delay corrected SVD deconvolution by applying a 
series of delay time (DT) values, with actual delay time being minimum DT 
value, which produces Tmax=0320. Cerebral Blood Flow (CBF) and Cerebral Blood 
Volume (CBV) were calculated from the peak height and area under tissue 
enhancement curves respectively, and Mean Transit Time (MTT) = CBV/CBF.  
4.2.4 Penumbra definition 
Ischaemic core was defined as tissue with reduced CBF (relative CBF <40% of 
contra lateral hemisphere) and prolonged delay time (relative DT >2 sec); 
penumbra volume was defined as tissue with relative DT >2 sec but relative CBF 
≥ 40% of contra lateral148. I used Penumbra proportion ((penumbra volume/ total 
ischemic lesion volume) 100) throughout this paper. 
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4.2.5 Collateral scores 
If retrograde flow was seen on CTP as detailed in chapter 2, collaterals were 
graded on CTA qualitatively297. I defined collaterals as good (angiographic flow 
distal to occlusion), moderate (angiographic flow to ischemic territory but not 
distal to occlusion), or poor (contrast opacification only in distal superficial 
branches). I used a modified Miteff’s classification to incorporate terminal ICA, 
M1 and M2 occlusion, whereas the original classification excluded M2 
occlusion297. 
4.2.6 Target mismatch  
Target mismatch was defined as a perfusion lesion >15 ml with core volume < 50 
ml and mismatch between perfusion lesion and core >1.8321 . To account for the 
limited z axis (4cm) coverage of CTP, I reduced the 70ml threshold used by 
Endovascular Therapy for Ischemic stroke with perfusion-Imaging selection 
(EXTEND-IA)16 and MRI profile and response to endovascular reperfusion after 
stroke (DEFUSE-2)321 trials proportionately, by dividing the mean of (Co-
registered Infarct volume over 4cm/Total Infarct volume from whole brain NCCT) 
in the non-recanalised group. This figure was 0.715 (i.e. approximately 70% of 
total infarct is in the 4 cm slab covered by CTP). This was multiplied by 70ml, to 
yield an adjusted volume of 50ml to define target mismatch. 
4.2.7 Statistical analysis 
I compared the groups across 3 time epochs: <180 min, 180-270 min, and >270 
min from stroke onset to CTP acquisition time. I used chi-square test or Fisher’s 
test for categorical variables and Mann-Whitney tests for continuous variables. I 
conducted linear regression for the prediction of penumbra proportion. I used 
IBM SPSS Statistics 22 version for all the statistical analysis.  
 
4.3 Results 
From a total of 263 subjects, 180 had a visible perfusion lesion on perfusion 
imaging, 147 of whom had anterior territory occlusion (ICA=40, M1=60, M2= 39, 
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M3= 8); CTP was available in 144 subjects, who constituted the main analysis 
population. Collateral assessment was possible in 118 with retrograde flow on 
CTP-SI, who constituted the population analysed for relationship to collaterals 
(Fig.4-1). 28 patients with anterograde flow distally from occlusion were 
excluded from collateral grading as they would not represent true collateral 
circulation. In the main analysis group, the overall population had median age 74 
years (IQR 63-81) and median NIHSS 15(10-20). On initial imaging, median 
ASPECT score was 7 (5-9), median core volume 23ml (IQR 11-48), and median 
penumbra volume 42 ml (IQR 25-65). Occlusion was present in the ICA (or 
tandem) in 39 (27%), MCA M1 segment in 59 (41%), M2 in 38 (26%), and M3 in 8 
(5%).  Baseline characteristics in the subgroup of 118 with assessable collateral 
status did not differ from the overall study population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary material:   
 
 
 
 
Excluded without a 
perfusion lesion (n=83) 
Total subjects from 
3 studies (n=263) 
Assessed for site of occlusion 
(n=180) 
Excluded (n=33): 
a) Posterior territory occlusion 
(n=12) 
b) No occlusion (n=20) 
c) Not available (n=1) 
 
Excluded time to CTP 
unavailable (n=3) 
Anterior territory 
occlusion (n=147) 
 
Excluded no retrograde flow 
on CTP (n=29) 
 
Suitable for penumbral 
proportion comparison across 
time epochs (n=144) 
 
Subgroup with collateral 
grading available (n=118) 
 
Figure 4-1 Study population CONSORT diagram 
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Baseline clinical and imaging characteristics across time epochs (<3, 3-4.5, >4.5 
h) are detailed in Table 4-1.There were no significant differences in baseline 
characteristics. Across time epochs, neither proportions of penumbra (59%, 64%, 
75%  at <3, 3-4.5, >4.5h respectively, p=0.4; Figure 4-2), penumbra volumes ( 
41(22-58), 46 (32-69), 40 (26-76) at <3, 3-4.5, >4.5 h respectively, p=0.3; Figure 
4-2) nor poor collaterals (15/56 (27%), 14/47 (30%), 4/15 (27%) at <3, 3-4.5, 
>4.5h, p=0.9; Figure 4-2) differed significantly. 
Table 4-1 Baseline characteristics of study population (n=144) 
 Time to CT Perfusion (in minutes) 
0-180 
min(n=71) 
181-270 
min(n=58) 
>270min(n=15) p value 
Female (n, %) 28 (39.4%) 32 (55%) 5 (33%) 0.1 
Right side ischemia 
(n, %) 
32(46%) 32 (55%) 7 (47%) 0.55 
Age, years (median, 
IQR) 
72(62-79) 76(70-81) 71(61-80) 0.053 
NIHSS (median, IQR) 16(9-21) 14(10-19) 14.5(6.75-19) 0.34 
ASPECT score 
(median, IQR) 
7(5-9) 7(5-9) 6(5-7) 0.6 
ASPECT score 0-4 11(15%) 11(19%) 1(7%) 0.1 
ASPECT score 5-7 35(48%) 20(35%) 11(73%)  
ASPECT score 8-10 26(36%) 27(47%) 3(20%)  
Glucose 
(mmol/l)(median, 
IQR) 
6.6(5.7-8.2) 6.8(5.6-8.2) 5.9(5.3-6.7) 0.3 
Systolic Blood 
Pressure mmHg 
(median, IQR 
143(135-
162) 
149(137-
171) 
142(131-160) 0.5 
Previous Stroke or 
TIA (n,%) 
12/71(17%) 17/57(30%) 3/14(21.4%) 0.22 
Atrial fibrillation (n, 
%) 
29 (42%) 25 (47%) 3 (21%) 0.22 
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Diabetes 9 (13%) 6 (10%) 1(6.7%) 0.77 
Hypertension (n, %) 43 (61%) 34 (58.6%) 8 (53%) 0.8 
Hyperlipidemia (n, 
%) 
36 (51%) 29 (50%) 9 (60%) 0.77 
 Site of vessel 
occlusion 
    
 
 
ICA/tandem 
occlusion (n, %) 
19 (27%) 16 (27.6%) 4 (26/7%) 0.9 
 M1 (n, %) * 26 (36.6%) 26 (45%) 7 (47%)  
 M2 (n, %) * 21 (29.6%) 14 (24%) 3 (20%)  
 M3 (n, %)* 5 (7%) 2 (4%) 1 (6.7%)  
Core 
volume(ml)(Median, 
IQR) 
26 (11.5-
49.5) 
23 (14-48) 15 (11-38) 0.7 
Penumbra 
volume(ml)(Median, 
IQR) 
41 (22.5-58) 46 (32-69) 40 (26-76) 0.3 
Core proportion (%) † 41 (21-58) 36 (22-50) 25 (17-61) 0.4 
Penumbra proportion 
(%)† 
59 (41-79) 64 (50-78) 75 (39-82) 0.4 
penumbra/core ratio 
(Median, IQR)  
1.45(0.6-
3.6) 
1.8(1-3.6) 3(0.6-4.7) 0.3 
Target mismatch (n, 
%) 
39/70 (56%) 43/58 (74%) 10/15 (67%) 0.09 
Good collaterals (n, 
%) 
22/56 (39%) 17/47 (36%) 7/15 (47%) 0.9 
Moderate collaterals 
(n, %) 
19/56 (34%) 16/47 (34%) 4/15 (27%)  
Poor collaterals (n, 
%) 
15/56 (27%) 14/47 (30%) 4/15 (27%)  
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NIHSS: National Institute of Health Stroke Scale; ASPECTS: Alberta Stroke 
Program Early CT score; TIA: Transient Ischemic Attack; ICA: Internal Carotid 
artery; * Middle Cerebral Artery M1, M2, M3 segments; † proportion of core, 
penumbra in total perfusion volume. 
 
 
 
 
  
Figure 4-2 Core, penumbra volumes  in relation to collaterals and time 
Core, penumbra proportions and volumes (Panels A, B) and collateral proportion (Panel C) across 
time epochs. 
 
Median penumbra proportion was 45% with poor collaterals versus 72% with good 
or moderate collaterals (P<0.001); penumbra proportion was not clearly related 
to time to imaging (R2=0.003, p= 0.5; Figure 3) but a trend for divergent effects 
by collateral status was seen (slight increase in penumbra over time with good or 
moderate collaterals versus reduced with poor, R2=0.03 for both; p=0.08; Figure 
4-3).  
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Figure 4-3 Penumbra volume in relation with collaterals and time 
 Penumbra relationship with time (Panel A), and, with interaction of collaterals and time (Panel B). 
 
In univariate linear regression, potentially significant variables predicting 
proportion of penumbra (p <0.1) were: large artery (ICA or M1) occlusion, good 
or moderate collaterals, time*good or moderate v poor collaterals, diabetes and 
NIHSS.  Age, time to CTP, systolic blood pressure   and blood glucose were not 
significant predictors of Penumbra proportion (Table 4-2). 
 
Table 4-2 Univariate linear regression for predictors of penumbra proportion 
variable Β coefficient (95% CI) P value 
ICA or M1 occlusion -7(-14-0.4) 0.06 
Time to CTP 0.2(-0.3-0.07) 0.5 
(Good or moderate) versus 
poor collaterals 
22(14-29) <0.01 
Time* ((good or moderate) v 
poor collaterals) 
0.089 (-0.012-(0.2) 0.08 
Diabetes -11.37(-22-(-0.3) 0.043 
NIHSS -1.5(-1.9-(-1.05) <0.01 
Age 0.034(-0.28-0.34) 0.8 
Blood glucose -0.75(-0.18-0.37) 0.18 
Systolic blood pressure -0.089(-0.25-0.07) 0.2 
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 In multivariable regression, NIHSS, good or moderate collaterals versus poor 
collaterals remained independently significant predictors of penumbra 
proportion (Table 4-3). 
Table 4-3 Multivariate regression for predictors of penumbra proportion 
Variable Β Coefficient (95% CI) P value 
NIHSS -1.19-1.6-(-0.5) <0.01 
Good or moderate versus 
poor collaterals 
16(8.7-24) <0.001 
 
 
I analysed a sub-group of ICA and M1 occlusion patients (n=100) to explore 
whether the lack of variability in penumbra proportion also holds true in a more 
homogeneous group. Penumbra proportion was not clearly related to time to 
imaging (R2=0.009; p= 0.3. fig. 4-4), but a trend for divergent effects by 
collateral status was again seen (slight increase in penumbra over time with 
good collaterals versus reduced with moderate or poor, R2=0.04 for both; 
p=0.09. fig. 4-5). 
 
Figure 4-4 Penumbra in relation with time in proximal occlusion (ICA or M1) group 
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Figure 4-5 Collaterals and time relation with penumbra in proximal (ICA or M1) occlusion 
 
 
4.4 Discussion 
 
Our findings are consistent with previous reports showing persistence of an 
imaging-defined penumbra in humans, without apparent loss of volume that 
would explain the time-dependence of therapeutic benefit from reperfusion 
within the first 6h after stroke onset318. This was the case regardless of whether 
penumbra was assessed by absolute volume, volume relative to core, the 
proportion of patients with “target mismatch”, or the presence of favourable 
collateral flow patterns. The sustained presence of penumbra on imaging in 
human studies contradicts the understanding from animal studies of the 
penumbra as a dynamic and time-dependent phenomenon, and the observed 
short effective time window for clinical benefit from reperfusion in unselected 
populations26,261,315.  
While penumbral imaging may enhance trial efficiency by identifying an 
optimised “responder” population322, imaging-selection based trials target only a 
small proportion of patients (for example only 15% of  intravenously 
thrombolysed patients were randomised in recent CT perfusion-based selection 
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for a randomised trial of endovascular bridging therapy16) and generalisation to 
draw conclusions regarding penumbral behaviour is not possible. The utility of 
reperfusion based on imaging-defined characteristics rather than time has 
notably not been demonstrated in several randomised, controlled trials of 
intravenous thrombolysis up to 9h after onset of stroke249,269,323, in distinction to 
both observational studies of imaging-selected patients 321  and in recent trials 
of endovascular reperfusion270,271. Whether this failure relates to difficulties in 
implementing complex imaging analysis in multiple centres, an intrinsic 
difference between thrombolysis and mechanical thrombectomy, or is simply an 
artefact of patient selection, is unknown. 
  
Our main observation of interest was a potential divergent effect of penumbral 
proportion over time according to collateral status, with lower proportions of 
penumbra in later times being seen only among those with poor collateral flow. 
This observation challenges the concept of “collateral failure” as a general 
mechanism driving the loss of penumbral tissue over time, and instead suggests 
that the collateral status at initial presentation may define a group with a 
different natural history and much shorter time to intervene. These observations 
are consistent with previous studies. Bang and colleagues  studied the 
interaction of collaterals and perfusion-diffusion mismatch (perfusion lesion 
defined as Tmax ≥4 s) and found that neither collateral grading, nor mismatch 
lesion volumes correlated with time324. Poor collaterals were independently 
correlated with larger infarct growth. Jung and colleagues, in 44 subjects with 
M1 or M2 occlusion undergoing endovascular therapy within 6 hours and resulting 
in at least partial reperfusion, showed that elapsed time accounted for only a 
minor proportion of penumbra tissue (defined as Tmax≥6s) loss in good collateral 
grades but a larger proportion in poor collateral grades319. 
These observations imply that perfusion imaging within the first 6 hours after 
onset is unnecessary if collateral flow is moderate or good – the proportion of 
penumbra is unlikely to vary significantly among these patients: among those 
with poor collaterals, however, additional tissue imaging to define whether 
target mismatch (or similar tissue definitions) are present may be necessary 
prior to reperfusion therapies. 
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A wide variety of methods for collateral assessment have been proposed,325 and 
only limited study of the consistency of these competing approaches has been 
undertaken. The approach used here, modified from that of Miteff,297 requires 
time-resolved vessel imaging, and may be closer to the multiphasic CTA 
approach developed by Goyal and colleagues and deployed in the majority of 
patients recruited to the ESCAPE trial271. Whether single-phase CTA would yield 
equivalent findings in clinical use is unclear, and in addition, all of these 
collateral assessment methods are confined to occlusions of the terminal ICA or 
proximal MCA. Validation using other methods of collateral assessment and in 
other vascular territories will be important.  
 
Our conclusions are limited by the limited number of subjects, particularly after 
4.5 hours from symptom onset, and the limited range of onset-to-imaging times 
that were covered in our dataset. To our knowledge, this is the first CT 
perfusion study assessing the association of penumbra volume with time and our 
patient cohort is larger than MRI based studies reported previously319. We used 
validated thresholds 320,326 for core and penumbra, but thresholds for CT 
perfusion are not uniform, and their derivation is based on limited numbers147. In 
common with the majority of imaging studies, we have to infer the persistence 
of a presumed time-dependent imaging appearance from cross-sectional data 
rather than sequential imaging in each patient. Repeated imaging studies in the 
acute stroke population are logistically extremely difficult since patient care 
may be compromised, and in addition, radiation and contrast exposure limit the 
repeatability of CTP.  Our CT scanner had restricted brain parenchyma coverage 
of 4 cm, requiring us to modify the definitions of “target mismatch” based on 
whole brain volumes in large detector CTP16 or MRI studies for this more 
restricted brain coverage, but the 50ml core volume criterion, while obtained by 
the ratio of 4cm coverage volume to whole brain volume, has not been validated 
independently.  
In conclusion, we found no decrease in the proportion of CTP-defined penumbral 
perfusion within perfusion lesions, or the proportion of patients with target 
mismatch or favourable collateral patterns within the first 6 hours after stroke 
onset. A decline in proportion of penumbra with time was restricted to those 
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with poor collateral status. Given the strong effect of time on outcomes after 
reperfusion treatment, further investigations into the interaction between 
collaterals, penumbra and time is required 
4.5 Conclusions  
In a cross-sectional sample imaged within 6h, neither the proportions of 
penumbral tissue nor “target mismatch” varied by time from onset. A trend for 
reducing penumbra proportion only among those with poor collaterals may have 
pathophysiological and therapeutic importance. 
 
 
 
 
115 
 
 
Chapter 5 Interaction of Recanalisation, 
Intracerebral Haemorrhage and Cerebral 
Oedema after Intravenous thrombolysis 
 
5.1 Introduction 
Intravenous (IV) thrombolysis <4.5h after symptom onset significantly improves 
functional outcome, but carries increased risk of intra cerebral haemorrhage 
(ICH)10,120. Reperfusion is proposed to be necessary both for ICH 327 and vasogenic 
brain oedema42, the other major cause of early neurological deterioration after 
stroke. 
Both the third International Stroke Trial (IST-3)328, and pooled analysis of IV 
alteplase trials261, indicated slight excess of fatal symptomatic ICH (SICH) within 
7 days of treatment (2.7% in IST-3). IST-3328 also reported a small excess risk of 
fatal brain swelling (1.5%) within 7 days, and the Alteplase Summary of Medicinal 
Product Characteristics(https://www.medicines.org.uk/emc/medicine/308 section 4.4) 
states that “reperfusion of the ischemic area may induce cerebral oedema in the 
infarcted zone.” Vasogenic edema was associated with increased blood-brain 
barrier permeability after reperfusion in a rodent model329,330, but complex 
interactions of severity and duration of ischemia, and timing of reperfusion 
confound this possible relationship331. Space-occupying cerebral oedema is 
clinically associated with large artery occlusions that recanalise rarely with IV 
rtPA332, and no excess risk of brain oedema was reported in previous trials10,262. 
Different types of haemorrhage may have different mechanisms and clinical 
implications: hemorrhagic infarction type 1 &2  (HI1 or HI2262) may be an 
epiphenomenon of reperfusion with no adverse clinical implications, while, in 
contrast, parenchymal hematomas type 1 &2 with independent mass effect (PH1 
or PH2 262) are linked with clinical worsening and may be related to blood-brain 
barrier breakdown after reperfusion333. 
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Imaging features may interact with treatment. The Diffusion and perfusion 
Imaging evaluation for understanding stroke evolution (DEFUSE)15study and 
combined analysis of DEFUSE and the Echoplanar Imaging Thrombolysis 
Evaluation Trial (EPITHET) studies 334found increased risk of PH1 or PH2 ICH 
when reperfusion occurred in patients with “large core” (large volumes of 
severely hypoperfused tissue on MRI). Interaction of early reperfusion with other 
indices of severe ischemia (large DWI volumes 335, very low cerebral blood 
volume (CBV) on perfusion imaging336 or poor collaterals60)  has been reported to 
be associated with SICH after IV thrombolysis. The extent of vasogenic oedema 
may also interact with ischemic core volume (>50% hypodensity on CT was 
associated clinically with malignant brain oedema 337), and in an animal model  
reperfusion of large volumes of severely ischemic tissue (CBF <40%)  led to 
malignant oedema206 . 
Previous studies have not investigated the relationship of imaging characteristics 
(e.g. ischemic core volume), reperfusion, and their interaction with brain 
oedema and ICH after IV thrombolysis. We hypothesised that recanalisation in 
presence of a large core (large ischemic area) would be associated with 
significant haemorrhage, and persistent occlusion is associated with significant 
brain oedema. 
 
5.2 Methods  
 
5.2.1 Study population  
I collected data from subjects treated with IV rtPA <4.5 hours after onset 
recruited at a single centre to one of three multimodal imaging studies during 
2008-2013. Two studies were observational (one study  investigating feasibility 
of complex imaging, the multicentre Acute Stroke Imaging Study (MASIS)304, one 
study investigating Pathophysiology of acute post-stroke hyperglycemias in 
relation to brain perfusion and arterial patency (POSH, unpublished),) and one 
was a trial phase II randomised trial comparing alteplase and tenecteplase in 
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stroke thrombolysis (ATTEST)303. In the two observational studies, all ischemic 
stroke patients aged >18 years and presenting < 6 hours after onset were 
eligible. Exclusion criteria were contraindications to iodinated contrast (allergy 
or eGFR <30ml/min).  Patients underwent CT, CT angiography (CTA) and CT 
perfusion at baseline with follow-up CT and CTA (if occlusion was present on 
baseline imaging) approximately 24h later. Favourable outcome was defined as 
modified Rankin scale (mRS) 0-2 at final review (30 or 90 days, depending on 
individual study).  Endovascular treatment was not used. 
5.2.2 Image acquisition 
Scans were acquired on a Philips Brilliance 64 multi detector scanner. Whole 
brain NCCT (5 mm slice thickness FOV 218 x 218 mm, 120 kv, 171 mA or 0·9 mm 
slice thickness, FOV 250x250  mm, 120 kV, 404 mA) was followed by CTP with 40 
mm slab coverage from the basal ganglia (8x5 mm slices, FOV 25 cm, 80 kVp, 
476 mA, 2 second cycle time, 30 cycles) using a 50 ml contrast bolus 
administered at 5 mls per second (350 Xenetix) via a large-gauge cannula. CTA 
covering aortic arch to the top of the lateral ventricles (0·67 mm slice thickness, 
120 kV, 475 mA) was acquired during the first arterial passage of contrast 
(Xenetix 350, 60 mls, followed by 30 mls of saline bolus, both given at 5 ml per 
second) 
5.2.3 Image analysis 
Anonymised imaging studies were analysed independently by two researchers 
(BC, XH). CTP was processed offline using MiStar (Apollo Medical Imaging 
Technology, Melbourne, Australia). Deconvolution of tissue enhancement curves 
and arterial input function (AIF) selected from the anterior cerebral artery was 
performed using modified singular value decomposition (SVD) with compensation 
for the effects of arterial delay and dispersion. Delay time (DT) was determined 
by a delay-corrected SVD deconvolution by applying a series of delay time (DT) 
values, with actual delay time being minimum DT value, which produces 
Tmax=0320.  DT and Tmax are related but are not identical, and since DT is 
derived from a vascular transport model correcting for arterial delay and 
dispersion, thresholds are smaller than Tmax305. DT has demonstrated superior 
correlation with tissue at risk in recent studies326. Cerebral Blood Flow (CBF) and 
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Cerebral Blood Volume (CBV) were calculated from the peak height and area 
under tissue enhancement curves respectively, and Mean Transit Time (MTT) = 
CBV/CBF.  
5.2.4 Core, penumbra definition 
Ischemic core was defined as tissue with relative CBF <40% of contra lesional 
hemisphere and relative DT >2 sec; penumbra was defined as tissue with relative 
DT >2 sec but relative CBF ≥ 40% of contra lateral brain148. To account for 
limited z axis coverage of CTP, I reduced the 70ml threshold for large core used 
by EXTEND-IA148 and DEFUSE-2321 proportionately, by dividing the mean of (Co 
registered Infarct volume over 4cm/Total Infarct volume from whole brain NCCT) 
in the non-recanalised group: approximately 70% of the total infarct was  
covered by the CTP slab, therefore we considered large core to be >50ml. I 
evaluated baseline NCCT for ASPECT scores127. 
5.2.5 Collateral grading 
Collaterals on baseline CTA were graded if retrograde flow was seen on CTP 
source images (CTP-SI), 297 and defined  as good (vessels reconstitute distal to 
the occlusion), moderate (vessels seen partially in ischemic territory), or poor 
(contrast opacification seen only in distal superficial branches).I modified 
Miteff’s classification to incorporate M2 occlusion (the original classification 
excluded M2 occlusion)297. 
5.2.6 Haemorrhage, oedema classification 
On 24h NCCT, I classified ICH as per ECASS 2 criteria,262 and SICH as any ICH with 
increase in NIHSS≥ 4 points262. Any PH1 or PH2 were considered significant 
haemorrhage. Brain oedema was classified as per IST-3310 as no swelling (0), 
effacement of lateral ventricle (1), effacement of lateral plus 3rd ventricles (2), 
or midline shift (3): we defined grades 2-3 as Significant Brain Oedema  (SBE). 
Recanalisation was defined as Thrombolysis in Myocardial Infarction (TIMI) 
grading 2- 3 at 24 hour  CTA306 307.  
As an exploratory analysis, early major neurological improvement (NIHSS 0 or 1, 
or improvement by ≥8 points by 24h) was taken as a biomarker of early 
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reperfusion338, and outcomes were compared among three groups – i) no 
recanalisation ii) recanalisation but no early improvement (presumed late 
recanalisation) and iii) recanalisation and early improvement (presumed early 
recanalisation).  Early neurological improvement independent of recanalisation 
status can predict 3m outcome339. Although recanalisation can be diagnosed with 
using early neurological improvement, there are a number of patients who have 
no recanalisation but ENI. This was proposed likely to be due to other biological 
factors such as collateral supply340. 
I compared groups by recanalisation and ischemic core volume, using chi-
squared tests or Fisher’s exact tests for categorical variables, and Mann-Whitney 
tests for continuous variables. I evaluated the independent effect sizes of 
recanalisation, core volume and their interaction on imaging and clinical 
outcomes using logistic regression. I used IBM SPSS Statistics (version 22) for the 
statistical analysis.  
 
5.3 Results 
Of 263 subjects, 159 had anterior circulation stroke with vessel occlusion pre-
treatment; we excluded 24 subjects presenting >4.5h after onset, and 12 in 
whom 24h CTA was not evaluable, leaving 123 subjects. Collateral grading was 
available in a subset of 106 subjects. 
Median age was 74 years (IQR 62-80), median NIHSS 15 [IQR 9-20], and median 
symptom onset to treatment time 180min (IQR 151-210). Occlusion site was ICA 
or M1 in 84 (68%). Recanalisation on 24h CTA was seen in 80 (66%) (Tandem or 
proximal ICA 30%, M1 74%, M2 87% and M3 50% (Table 5-1)). Mean time interval 
from treatment to follow up imaging was 27.5 hrs (SD ±7). Detailed baseline 
characteristics are presented in Table.5-2.  Tenecteplase was used in 31 patients 
and alteplase in 92. 
Table 5-1 Recanalisation rates grouped by occlusion site Iin comparison with Interventioanl 
Manageement of Stroke (IMS-3) study 
 Our study- 
Recanalisation (TIMI 2 
or 3)* 
IMS-3 rtPA treated 
group341 
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Tandem/ICA (n=30) 9/30 (30%) 56% proximal ICA 
28% Tandem ICA 
M1(n=54) 40/54 (74%) 80% -86% 
M2(31) 27/31 (87%) 78% 
M3(8) 4/8 (50%) 100% (M3 & M4) 
*cumulative p value <o.o1 IMS 3 Interventional Management of Stroke 
 
Table 5-2 Baseline characteristics of study population (n=123) 
Variables Recanalised (n=80) Occluded 
(n=43) 
P* 
Age (median (IQR), years) 73 (63-81) 74 (62-79) 0.8 
Male (n, %) 48 (60%) 21 (48.8%) 0.1 
NIHSS baseline (median, IQR) 15(9-19) 14(9-20) 0.6 
Onset to treatment time 
(median , IQR, min) 
175(145-210) 190(165-206) 0.6 
ASPECT score (median, IQR) 
7(5-9) 
7(5-9) 0.9 
Occlusion Site:   <0.01 
                ICA/tandem (n, %) † 9 (11.3%) 21 (48.8%)  
M1 (n, %) † 40 (50%) 14 (32.6%)  
M2 (n, %) † 27 (33.8%) 4 (9.3%)  
M3 (n, %) † 4 (5%) 4 (9.3%)  
Cardio-embolic (n, %) ǂ 34(47.9%) 16 (39%) 0.7 
TACI (n, %) § 54 (67.5%) 30 (69.8%) 0.7 
Atrial Fibrillation (n, %) 35 (47.9%) 14 (33.3%) 0.17 
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Diabetes (n, %) 8 (10%) 5 (11.6%) 0.7 
History of Stroke or Transient 
Ischemic attack (n, %) 
14 (18%) 7 (16.3%) 1.0 
Hypertension (n, %) 45 (56.3%) 26 (62%) 0.5 
Smoker (n, %) 23 (28.8%) 14 (32.6%) 0.3 
On anti platelets (n, %) 42 (52.5%) 24 (55.8%) 0.8 
Imaging  outcomes in relation to recanalisation within small or large core 
groups (n=122)ǁ 
 Core small(<50ml) (n=95) Core large(>50ml) 
(n=27) 
p 
ICA or M1 
occlusion
† 
57(69%) 26(96%) <0.001 
Poor (vs.  
good or 
moderat
e) 
collatera
ls  
9/78(11.5%) 12/22(54.5%) <0.01 
Poor 
outcome 
(mRS 3-6 
at 30 or 
90 days) 
51(54%) 24(89%) 0.001 
 Recanal Occluded P Recanalise Occlud P value 
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ised 
(n=63 ) 
(n=32) value d (n=16) ed(n=1
1) 
 
Any ICH 
(n, %) 
19 (30%) 4 (12%) 0.06 8 (50%) 4 (36%) 0.5 
 
HI1 or 
HI2 (vs. 
no ICH, 
PH1, 
PH2) 
14 (22%) 3 (9.4%) 0.16 7 (44%) 3 (27%) 0.4 
Type of 
haemorr
hage# 
     0.25 
No ICH 
(n, %) # 
44 (70%) 28 (87%) 0.35 8 (50%) 7 
(63.6%) 
 
HI1 (n, 
%) # 
5 (8%) 2 (6%)  3 (19%) 3 (27%)  
HI2 (n, 
%) # 
9 (14%) 1 (3%)  4 (25%) 0 (0%)  
PH1 (n, 
%) # 
1 (1.6%) 0 (0%)  0 (0%) 1 (9%)  
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PH2 (n, 
%) # 
4 (6%) 1 (3%)  1 (6%) 0 (0%)  
Any 
oedema 
(n, %) 
19 (31%) 15 (47%) 0.13 12 (75%) 8 (73%) 0.9 
Oedema 
type** 
     0.38 
No 
oedema 
(n, %)** 
44 (70%) 17 (53%) 0.17 4 (25%) 3 (27%)  
Effaceme
nt of 
lateral 
ventricle 
(n, %)** 
16 (25%) 13 (40%)  3 (19%) 4 (36%)  
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Effaceme
nt of 
lateral 
and 3rd 
ventricle 
(n, %)** 
2 (3%) 0 (0%)  6 (37.5%) 1 (9%)  
Midline 
shift (n, 
%)** 
1 (1.6%) 2 (6.3%)  3 (19%) 3 (27%)  
SICH (n, 
%) # 
4 (6%) 1 (3%) 0.5 0 2(18%) 0.07 
Significa
nt ICH 
(n, %) 
5 (8%) 1 (3%) 0.36 1 (6%) 1 (9%) 0.8 
SBE (n, 
%) †† 
3 (5%) 2 (6%) 0.7 9 (56%) 4 (36%) 0.3 
Poor 
outcome 
(mRS>2) 
(n, %) 
20 (47%) 22 (69%) 0.04 13 (81%) 11 
(100%) 
0.13 
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* Chi-square test or Fisher test  for categorical variables, Mann-whitney  test for 
continuous variables 
ASPECT score: Alberta stroke Early CT Score 
† ICA-Internal Carotid artery, M1,M2,M3- branches of Middle cerebral artery 
ǂ Cardio embolic versus other aetiologies (large artery atherosclerosis, lacunar 
stroke, unknown cause) 
§ Total anterior circulation Infarction(TACI) versus other stroke types 
ǁ one subject out of total study population (n=123)did not have core size 
available  
#Haemorrhage classification according to ECASS-2 criteria 
** Brain oedema classification by IST-3 criteria 
††SBE: Significant Brain Oedema 
 
Most haemorrhages were HI1 or HI2 (28 (23%)) and there were few PH1 or PH2 (8 
(6%)). There was a trend for recanalisation to be associated with any ICH (28 
(35%) v 8 (18%); p=0.06), predominantly HI1/HI2 (22 (27.5%) v 6 (14%); p=0.08), 
while incidence of PH1/PH2 did not differ (6 (7.6%) v 2 (4.6%); p=0.5. Fig.5-1). 
Oedema of any grade was less frequent with 24h recanalisation, although not 
significantly (32 (40%) v 23 (53%); p=0.15) and significant brain oedema was not 
related to recanalisation (12 (15%) v 6 (12%); p=0.8. Fig.5-2). 
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Figure 5-1 Types of haemorrhage in occluded vs. recnalised small or large core groups 
 (HI1/2: Haemorrhagic Infarction type1 or 2; PH1/2: Parenchymal haematoma type 1 or 2; No ICH: 
No Intra cerebral haemorrhage; Recan: Recanalised; Occl: Occluded) 
 
 
Figure 5-2 Types of oedema in occluded vs. recanlaised small or large core groups  
(SBE: Significant Brain Oedema; Non-SBE: Non significant Brain Oedema; Recan: Recanalised; 
Occl: Occluded) 
 
Neither significant oedema (12/92 alteplase-treated versus 6/31 tenecteplase-
treated, OR 0.6, 95% CI 0.2-1.8; p=0.4), nor significant haemorrhage (8/92 
alteplase-treated versus 0/31 tenecteplase-treated, p=0.2; odds ratio not 
calculable) was associated with thrombolytic agent. 
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After adjusting for 24h recanalisation, large core (>50ml) was associated with 
both haemorrhage and oedema, most notably with SBE, although no significant 
relationship with PH1/PH2 ICH or SICH was evident. Recanalisation was also 
associated with a trend towards any ICH, particularly HI1/2 ICH, but not to 
oedema (Table 5-3). Regression analysis did not identify significant interaction 
of large core and 24h recanalisation for any outcome (Table 5-3). Recanalisation 
was associated with significantly reduced odds of death or dependence (mRS 3-
6) at day 30 or 90, while large core volume was associated with increased odds 
of these outcomes.
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Table 5-3 Regression for association of large core and recanalisation, and their interaction for imaging and clinical outcomes 
 Any ICH* HI1 or HI2† 
 
Significant 
ICH* 
 
SICHǂ Any 
oedema 
 
SBE§ 
 
Good  90d 
mRS (0-2) 
Large core (OR 
(95% CI); p) 
 
4 (1.6-
9.5); 
p=0.003 
2.9 (1.13-
7.8); 
p=0.03 
 
1.2 (0.23-
6.5); p=0.8 
1.6 (0.3-
8.5); p=0.6 
5.4 (2-14); 
p<0.01 
17.4 
(5.3-57); 
p<0.01 
0.15 (0.04-
0.5); p=0.03  
Recanalisation 
(OR (95% CI); 
p) 
 
2.3 (0.97-
5.5); 
p=0.06 
 2.5 (0.9-
6.9); 
p=0.08 
1.7 (0.33-
8.8); p=0.5 
0.8 (0.17-
3.8); p=0.8 
0.5 (0.27-
1.18); 
p=0.13 
1.45 
(0.4-
4.9); 
p=0.55 
2.8 (1.2-6.8); 
p=0.02 
Large core * 
Recanalisation 
0.34 
(0.05-
0.7 (0.09-
6); p=0.8 
0.25 
(0.007-9); 
p=1ǁ 1.7 (0.2-
11); 
3(0.2-34) 
 p=0.37 
p=0.99# 
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(OR (95%CI); 
p) 
2.2); 
p=0.26 
p=0.45 p=0.56 
* ICH Intra cerebral haemorrhage, † Hemorrhagic infarction type 1 or 2, ǂ Symptomatic Intra cerebral haemorrhage, 
§ Significant Brain Oedema, ǁ Since 0% of recanalised group in large core has SICH, the corresponding odds ratios 
cannot be calculated,# since 100% of occluded group in large core have poor 90dmRS, the corresponding odds ratios 
cannot be calculated. 
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Early neurological improvement occurred in 36 patients: 45 had recanalised by 
24h but did not exhibit early major improvement, and 38 showed no 
recanalisation and no early improvement. Oedema and hemorrhagic outcomes 
were generally lower and day 90 mRS  is better in the group with presumed early 
recanalisation, but did not differ significantly between the late recanalisers and 
those with no recanalisation (Table 5- 4). Different types haemorrhage and 
oedema in each of these groups is shown in bar chart (fig. 5-3 & 5-4). 90 day 
modified Rankin scales are shown on grotto bars comparing these groups in fig. 
5-5. 
Table 5-4 Comparison of early improvers vs. non-early improvers 
 Early 
improvemen
t (n=36) 
No early 
improvement/Recanalise
d (n=45) 
No early  
improvement/Non
-recanalised 
(n=38) 
P 
value
§ 
Any ICH 5 (14%) 19 (42%) 9 (24%) 0.014 
Significan
t ICH 
1 (3%) 5 (11%) 2 (5%) 0.3 
SICH* 0 3 (7%) 3 (8%) 0.25 
Any 
oedema 
7 (19%) 24 (53%) 21 (55%) 0.002 
SBE 2 (5.6%) 10 (22%) 6 (16%) 0.11 
Good 90d 
mRS 
22 (63%) 12 (27%) 10 (26%) 0.001 
ICH: Intra cerebral haemorrhage 
*SICH as per ECASS-2 criteria 
SBE: Significant brain oedema 
§ chi-square values 
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Figure 5-3 Type of haemorrhage in early improvers vs. non early improvers 
  
 
Figure 5-4 Types of oedema in early improvers vs. non early improvers 
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Figure 5-5 90 day modified Rankin scales in early improvers vs. non early improvers 
 
5.4 Discussion 
 
Recent focus on potential hazards of IV rtPA highlights limited data on the 
interaction of patient characteristics, especially ischaemic tissue volumes, 
reperfusion and the pathophysiology of haemorrhage and brain oedema. Few 
patients have been studied with detailed brain imaging334, only a proportion of 
whom have received thrombolytic therapy; animal models206,342  may not 
recapitulate the human situation, and other data derived from series of  late 
endovascular intervention343.  
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Our cohort allowed the study of interactions between 24h recanalisation, 
perfusion characteristics and incidence of both ICH and early brain oedema. We 
found ICH incidence comparable to previous literature, for example ICH of all 
kinds seen in 34% (48% in ECASS-II262), and SICH in 5.7% (7.7% in a meta-analysis 
IV thrombolysis 264).  Incidence of early vasogenic brain oedema of any degree 
(45%)  and  SBE (6.8%)  are comparable to reported figures for oedema329 and SBE 
(4% in IST-3)328 that used similar definitions, although other definitions yield 
variations in incidence 344. Recanalisation rate (66%) in our study was identical to 
that reported in the IMS-3 rtPA treated group, as were recanalisation rates by 
occlusion site341.  
The major predictor of ICH and SBE in our study was the presence of a large 
“core”. This is consistent with a rodent study in which infarct volume, but not 
reperfusion, was associated with oedema345.  Literature on reperfusion and post-
ischemic oedema in non-human primates examined only early time points (< 6 
hours) of unclear clinical relevance84,206,346. Recanalisation in our study, in 
contrast, was associated only with a trend towards HI1/2 ICH. Neither 
recanalisation, large core nor their interaction was associated with clinically 
relevant PH1/2 ICH. DEFUSE15 reported potential interaction of large core and 
early reperfusion in provoking SICH, and defined the “malignant profile” based 
on MRI features similar to the CTP features in our study. Of 6 DEFUSE subjects 
with the “malignant profile,” 3 experienced (uniformly fatal) SICH. The 
combined EPITHET and DEFUSE studies334  included only 27 “malignant profile” 
patients, of  whom 6/9 who reperfused developed PH1/2 ICH, compared to 2/18 
without reperfusion. Despite similar patient numbers, we were unable to 
replicate this interaction. Since perfusion characteristics may better define ICH 
risk than diffusion-weighted MRI347, it seems unlikely that this is due to a 
difference between MRI and CT-based tissue viability assessment methods. 
As an exploratory analysis, we assessed major early clinical improvement as a 
biomarker of early reperfusion. This group had significantly fewer ICH or oedema 
events and greater probability of favourable 90 day outcome. The incidence of 
significant ICH or oedema did not differ between those with presumed late 
recanalisation and those without recanalisation, but it is not possible to exclude 
a relationship between late recanalisation and adverse imaging outcomes. 
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Good clinical outcome was strongly associated with 24h recanalisation (OR 2.8 
(1.2-6.8); p=0.02) and was less likely with large core (OR 0.15 (0.04-0.5); 
p=0.03), consistent with previous observations348, but there was no significant 
interaction between these variables in predicting good 90 day outcome. This is 
consistent with the known prognostic value of both variables 348,349, but also with 
the lack of interaction between endovascular treatment effect and CTP 
features.350 
Our study has limitations. As a single centre, retrospective analysis, independent 
replication in other settings is desirable. The small number of clinically 
significant hemorrhagic and brain swelling outcomes inevitably lead to wide 
confidence intervals around the effect estimates, encompassing the possibility 
that recanalisation may be related to either significant oedema or ICH, and 
means that conclusions must be cautious: nonetheless, with a larger number of 
outcome events we were unable to replicate earlier reports of an association 
with ICH, as discussed above. No classification of brain oedema has been 
reported consistently in clinical studies, and different classification methods 
may yield different incidence. The timing of brain imaging for outcome 
assessment in our dataset (mean 27.5h after IV thrombolysis) is too early to 
detect maximal brain swelling, but while this might underestimate the severity 
of brain oedema, it seems unlikely to underestimate the incidence of significant 
brain oedema based on data that indicate that 95% of cases progressing to 
malignant MCA infarction were identifiable on 24h CT344. CTP analysis was based 
on validated thresholds, but  standardisation is not yet agreed147. Since we had 
access to angiographic outcome data only at approximately 24h, we could not 
discriminate early from late recanalisation, which may carry different risks of 
ICH,351 although we undertook exploratory analyses using early clinical 
improvement as a biomarker for this. We used TIMI 2-3 (partial or complete 
recanalisation) since even partial restoration of flow might be expected to 
impact on adverse complications, whereas TIMI 3 would be more strongly related 
to favourable clinical outcomes, which was an endpoint of secondary interest in 
this study. The overall recanalisation rate at 24h in our study (66%) matches that 
reported by the IMS-3  (65%) based on a 24h CTA endpoint, with comparable 
individual occlusion site recanalisation rates 341 ,offering further reassurance 
about external validity.  
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Our findings indicate that 24h recanalisation itself is not significantly associated 
with early vasogenic oedema, or significant haemorrhage, questioning the 
widespread attribution of these outcomes to “reperfusion injury.” The 
association of large core with both significant oedema, and also poor outcome in 
spite of recanalisation, is consistent with recent clinical trial strategies that 
have sought to exclude such patients from reperfusion therapies. Observational 
data cannot define risk: benefit ratio, however, and it is important to bear in 
mind that excluding “large core” patients might represent an efficient clinical 
trial strategy, but that risk: benefit balance in this group remains to be 
determined: treatment in this group may still be associated with net benefit.  
 
5.5 Conclusions  
Among patients treated with IV rtPA, 24h recanalisation was not independently 
associated with significant early (24h) vasogenic oedema or significant 
haemorrhage, although incidence of HI/HI2 ICH was higher. Large ischemic core 
was associated with both significant brain oedema and poor outcome. There was 
no interaction of recanalisation and large core lesions for any imaging outcomes. 
Early major clinical improvement as a marker of probable early reperfusion was 
associated with lower incidence of both significant haemorrhage and oedema. 
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Chapter 6 Explore Capillary transit time 
heterogeneity (CTTH) within different 
components of the tissue – core, penumbra, 
‘non-core-non-penumbra’ infarct, normal brain 
 
6.1 Introduction 
Capillary Transit time Heterogeneity (CTTH) values may reflect better on the 
micro-vascular flow regulation, providing a more accurate measure of tissue 
oxygenation (CMRO2). The response to impaired capillary level tissue oxygen 
delivery (e.g. hyperaemia) is to modify inflow to capillary beds in order to 
homogenise transit time; therefore transit time heterogeneity may be an index 
of impaired capillary level oxygen delivery. Normal increase in CTTH 
theoretically could hamper an efficient oxygen extraction to the brain tissue. 23  
Resting Brain has high heterogeneity of flow velocities200. This limits net oxygen 
extraction due to functional shunting.  Normally neural activation gives rise to 
an increase in local brain tissue perfusion by recruiting previously non perfused 
capillaries 352. The capillary perfusion becomes homogenous200,353,354. This is 
shown to counteract the inherent reduction in OEF as CBF increases23,355, which 
is likely inherent property of passive microvasculature354  . However, as brain 
diseases affect micro vascular regulation, a pathological non homogenous 
perfusion pattern arises. As a consequence of this transit times through 
capillaries vary more (existence of high flow and low flow capillaries) and leads 
to less oxygen availability for extraction23. This abnormal capillary micro 
vascular regulation has been reported in diseases such as brain tumours, 
Alzheimer’s dementia, acute ischaemic stroke, small vessel disease 184,185,355,356. 
Preliminary results in humans show that both CBF and CTTH must be known to 
explain OEF in patients with Cerebrovascular disease355. 
CBF, CBV, and a delay metric (Tmax, MTT, TTP, DT) are used to predict brain 
tissue at risk in acute ischaemic stroke. Regional availability of oxygen in brain 
tissue (CMRO2) is traditionally inferred from the magnitude of CBF and the 
concentration of oxygen in arterial blood. CBF is sensitive to regional levels of 
neuronal activity (i.e. neurovascular coupling357). The extent and duration of 
CBF reduction predicts the development of permanent infarction in acute stroke 
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26. The microscopic distribution of the CBF is rarely considered. It has been 
proposed that heterogeneity of capillary transit times affects oxygen extraction 
efficiency23,185.  Therefore, cerebral blood flow, oxygen binding to haemoglobin, 
and capillary flow heterogeneity can influence oxygen delivery23. Flow 
heterogeneity, along with CBF, can be derived from the slope of the 
deconvolved tissue curve177. Extending the classic flow diffusion equation, 
capillary blood mean transit time (MTT) and capillary transit time heterogeneity 
(CTTH) combined determines the maximum OEF (OEF max) that can be achieved 
for a given tissue oxygen tension. The putative effects of increased CTTH were 
reported in stroke, traumatic brain injury, and dementia in a series of papers by 
Ostergaard et.al.184,358,359. There is a need for robust estimation of CTTH, MTT, 
OEFmax to test the above hypotheses further. This will inform to what extent 
CBF or CTTH, or both contribute to tissue oxygen availability. 
With reduced cerebral perfusion a mildly elevated CTTH and MTT leads to 
increased oxygen extraction in compliant normal vasculature. Coefficient of 
variation COV (COV =CTTH/MTT)) remains unchanged. In micro vascular 
dysfunction (due to erythrocyte clogging), constriction of pericytes leads to 
severely increased CTTH.  This leads to critical shunting of oxygenated blood in 
capillary bed with reduced CBF. Severe increased CTTH can make reperfusion 
futile if CTTH fails to normalise after recanalisation 355. This is due to too fast 
transit times due to restoration and increase of CBF and hence reduced OEF. 
Severe increased CTTH is followed by decreased CTTH (homogenisation) as a 
result of stepwise capillary occlusions360. This represents “no-flow” phenomenon 
361. Hypoperfused cerebral tissue with extreme flow homogenisation has been 
shown to correlate with final infarct21,187 . COV may predict infarction better 
than CTTH alone by removing inherent dependency of CTTH & MTT. A low COV 
predicted infarction if no recanalisation. Severe CTTH heterogenisation as well 
as homogenisation would entail high risk of infarction of hypoperfused brain 
tissue, where as mildly elevated CTTH represents tissue with low risk of 
infarction360. 
We hypothesize that CTTH values significantly differ between the cerebral tissue 
compartments (core, penumbra, non-core-non-penumbra Infarct & normal brain) 
and hence CTTH can differentiate the tissue states better than conventional 
perfusion parameters (i.e. Cerebral Blood Flow (CBF), Cerebral Blood Volume 
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(CBV), Mean Transit Time (MTT)). This is of particular importance in the 
infarcted brain tissue that is neither in core nor in penumbra (non-core-non-
penumbra Infarction).  
The purpose of the study was to derive CTTH values and compare these values in 
different hypoperfused cerebral tissue compartments (core, penumbra,’ ‘non-
core-non-penumbral’ tissue, contra lateral normal brain) in acute ischaemic 
stroke. 
 
6.2 Methods 
 
Using multimodal imaging from three studies from a single centre as described in 
previous chapters, I analysed multi parametric maps derived from acute CT 
perfusion (CTP). A novel parameter, CTTH was measured along with Cerebral 
Blood Flow (CBF), Cerebral Blood Volume (CBV), and Mean Transit Time (MTT) in 
a voxel wise method using a vascular (parametric) model (VM). A 24 hour follow 
up Non contrast CT (NCCT) was read for drawing final Infarction masks.  
Core and penumbra were defined using Wintermark’s method (Core=CBV 
<2ml/100g/min, Penumbra= relative MTT>145%). Scans were read by one 
Research fellow (BC) experienced in perfusion imaging, blinded to the clinical 
information and clinical outcomes. MATLAB 8.4 platform was used for image 
analysis. After detailed stepwise post processing as described in chapter 3, 
finally concentration time curve for each tissue voxel is derived. 
A delay corrected deconvolution steps (standard SVD, circular SVD, vascular 
model) are then used to calculate the parametric maps (MTT, CBF, CBV, Tmax 
and TTP). Additionally, CTTH, Coefficient of variation (COV), OEF maps was 
obtained in vascular model. Coefficient of variation (COV) is a measure of the 
dissimilarity between the parametric capillary transit time heterogeneity (CTTH) 
and mean transit time (MTT) maps.  
Time to peak map (TTP) was outlined with ROI tool with manual adjustment if 
needed for abnormal TTP. TTP maps were used to delineate the area of 
abnormal perfusion. From these outlined areas, the other parameters were 
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derived. Non bolus voxels where no contrast arrived were excluded from masks. 
CBV voxels were diffusely scattered, hence we corrected exuding voxels with 
CBV<1ml as explained in chapter 3. MTT mask often included a non TTP area. 
Sometimes, the infarction is found to be outside the TTP area. To reduce this, 
we included MTT from TTP area plus Infarct area in follow up scan (FI) which is 
called “union mask”. 
CBV map is calculated from the area under the time enhancement curve for 
each voxel. Then Central volume theorem (CBF=CBV/MTT) is applied. Automatic 
segmentation of grey matter (GM), white matter (WM), Cerebrospinal Fluid (CSF) 
was done. The normal contra-lateral hemisphere was used to calculate relative 
(normalised) CBF, MTT. This was chosen as mirrored ROI of TTP map. ROIs from 
follow-up NCCT infarct volume, segmentation masks (GM, WM) and mirrored 
normal contra lateral side were placed on the parametric maps derived from all 
the methods. The individual voxel values were recorded on excel sheet. Mean 
and median values of all voxels for each parameter was produced after the 
initial steps as described above. 
Mean (±SD), median (±IQR) values of different tissue level parameters (CTH, 
COV, CBF, CBV, and MTT) was compared using Kruskal- Wallis for comparing 
median values.  
 
 
6.3  Results 
Study population for the work on CTTH work was explained in chapter 3. Base 
line clinical characteristics of this group are shown in Table 6-1. 
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Table 6-1 Baseline charactersitics of subjects included for final anlysis (n=132) 
Age (years) Mean 70 (SD ±12)  Median 73(IQR 18) 
NIHSS Mean 13 ( SD ±7)  Median 12 (IQR 10) 
Systolic BP (mmHg) Mean 146 (SD ±20)  Median 144 (IQR 
28) 
Capillary blood glucose 
(mmol/l) 
Mean 6.9 (SD ±2)  Median 6.6 (IQR 
2.2) 
Hypercholesterolemia 65 (50%) 
smoker 47 (36.4%) 
Male gender 76 (59%) 
Cardiac disease 29 (24%) 
Atrial fibrillation 43 (34%) 
Diabetes 15 (11.6%) 
Hypertension 72 (56%) 
Penumbra volume Mean 54 ml(SD ±35.8)  Median 53.9 
ml (IQR 60) 
Core volume Mean 5.5 ml (SD ±6.8)  Median 2.9ml 
(IQR 7) 
 
An example of vascular model map (fig.6-1) and SVD map (fig.6-2) generated are 
shown. 
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Figure 6-1 Example of maps derived in vascular model 
Top row:  left CBF, middle MTT, right CBV    Middle row: left  Delay time, middle CTTH, right COV.   Bottom row:  Left OEF  
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Figure 6-2 An example of SVD maps 
 CBF, MTT, Delay time and CBV maps are shown clockwise from top left side
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An illustration of the ROIs showing infarct, a core and penumbra mask is shown in fig. 6-3. 
 
Figure 6-3 An example of ROIs for core, penumbra and FU Infarct 
 (Infarct Yellow, Penumbra Blue, Core red). 
 
In Table 6-2 the perfusion parameter values in different compartments (core, penumbra, and ‘non-core-non-penumbra (NC/NP) 
infarction and normal brain) have been compared for significance.
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Table 6-2 The perfusion parameters in different tissue zones (core, penumbra, 'non-core-non-penumbra' infarction and normal contralateral brain) 
 Core mask 
(n=115) 
Penumbra mask 
(n=130) 
NC/NP Infarct 
mask (n=116) 
Contra lateral  
Brain mask 
(n=132) 
P (Parametric 
Repeated 
measures 
ANOVA) 
Median MTT  (seconds 
median, IQR) 
  
9.6 (5.6) 
 
 
10.9 (3.7) 
 
 
4.7(1.74) 
 
 
3.9 (1.1) 
 
 
<0.01 
 
 
Median CTTH (seconds 
median, IQR) 
 
 
9.3 (4.7) (4.68) 
 
 
10.8 (3) 
 
 
5.1 (1.9) 
 
 
4.2 (1.16) 
 
 
<0.01 
 
 
Median COV (seconds 
median, IQR ) 
 
 
0.98 (0.075) 
0 
0.97 (0.045)) 
 
 
1.05 (0.6) 
 
1.05 (0.3) 
 
<0.01 
 
 
Median CBF 
(ml/100gm/min) 
(median, IQR ) 
 
 
 
6.8 (4.2) 
 
 
 
14.4 (4.7) 
 
 
 
31.3 (19) 
 
 
 
34 (12) 
 
 
<0.01 
 
 
Median CBV  
(ml/100g/min)(median, 
IQR ) 
 
0.7 (0.2) 
 
 
0.73) 
2.3 (0.6) 
 
 
 
2.6 (0.9) 
 
 
2.39 (0.05) 
 
 
<0.01 
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Between two group comparisons of median values of perfusion parameters using 
non parametric comparison (Friedman test) showed p values <0.001. I compared 
the values of each parameter between core, penumbra; between penumbra, 
NC/NP and between NC/NP, normal brain. Only Coefficient of Variation (COV) 
did not reach significance between NC/NP and normal brain (p=0.5). Box plots 
for comparing each parameter (CTTH, MTT, CBV and CBF) in these 
compartments is shown in fig.6-4, 6-5, 6-6 & 6-7.  
Median of CTTH (median of voxels) value is 13.13 s in penumbra that Infarcted 
and 10.5 s in penumbra that rescued (non parametric p <0.001). 
 
 
Figure 6-4 Box plot of median CTTH in different tissue zones 
NC/NP: non-core-non-penumbra.  Y axis is CTTH time in seconds. 
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Figure 6-5 Box plot of median MTT in different tissue zones 
 NC/NP: non-core-non-penumbra. Y axis is CTTH time in seconds. 
 
 
Figure 6-6 Box plot of median CBV in different tissue zones 
NC/NP: non-core-non-penumbra. Y axis is CTTH time in seconds. 
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Figure 6-7 Box plot of median CBF in different tissue zones 
NC/NP: non-core-non-penumbra. Y axis is CTTH time  in seconds.  
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6.4 Discussion 
The delay metrics Tmax, MTT are affected by transit time heterogeneity 
properties362.  It is speculated that this shortcoming may have affected the 
predictive ability of existing transit time metrics223,363. CTTH, COV might 
represent missing step towards distinguishing tissue with benign oligaemia from 
salvageable tissue. I have successfully processed the CTTH values from a large 
cohort of CT perfusion scans. CTTH values are significantly different in tissue 
compartments; however, from the results above, it is not clear that they 
discriminate core from penumbra. In our cohort CTTH and MTT are correlated. 
CTTH co varies with MTT as hypoperfusion contributes to elevated CTTH364. It 
may mean that CTTH is only giving the same qualitative information about 
perfusion as a prolonged MTT, whereas CBF, CBV values are clearly different in 
core and penumbra. Median CBF (median of voxels) is 6.8 ml/100g/min (IQR 4.2) 
in core and 14.4 ml/100g/min (IQR 4.7) in penumbra. Median CBV is 0.7 
ml/100g/min (IQR 0.2) in core and 2.3 ml/100g/min (IQR 0.6) in penumbra. The 
inverse relationship between CBF and CTTH in our study is consistent with the 
theory that increased blood flow would homogenise capillary flow200. In a study 
of 23 healthy human controls using DCE-MRI, average CTTH of 0.93s (IQR 1.33s) 
was seen in putamen grey matter365.  In subjects with carotid stenosis, there is 
marked difference in ipsilateral brain (CTH 4.2 s) and contra-lateral brain (CTTH 
1.8s). CTTH values are much higher than healthy volunteers. In anaesthetised 
rats, resting brain CTTH was 1-1.3 s, while activation decreased it to 0.2-0.7 
s366. 
Accurate and reproducible estimation of CTTH in voxel-wise calculation is 
necessary. CTTH values are likely to be between 10-20 seconds in compliant, 
passive micro vasculature in penumbra364. Earlier human studies investigated the 
relationship of intra-voxel flow heterogeneity and tissue fate using perfusion 
weighted MRI21,187. These studies did not quantify capillary heterogeneity but 
reported intra-voxel deviations of relative flow distribution compared to normal 
tissue. Similar to our results, Engedal et al, using perfusion weighted MRI, 
showed mean CTTH of 12 sec (SD +/-7.6), mean COV of 1.0 ( SD +/- 0.2), CBF 21 
(SD +/- 20) ml/100ml/min and MTT 13 sec ( SD +/- 11 ) in the cerebral tissue 
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with prolonged MTT of > 5 sec (i.e. hypoperfused tissue). The subjects in their 
study included: all patients who presented within 6h of symptom onset with 
acute, non-lacunar, ischaemic stroke with a NIHSS score ≥4 (European multi 
centre database); all Ischaemic stroke patients eligible for IV thrombolysis 
(regional database).  A low COV (i.e. extreme homogenisation) was strongly 
associated with Infarction in absence of recanalisation at 24hrs. COV may predict 
infarction better than CTTH alone by removing inherent dependency of CTTH & 
MTT and therefore expected to remain constant during changes in perfusion 
pressure. Mildly elevated CTTH positively predicted functional outcomes360. 
CTTH values in our cohort are slightly higher, they all had stroke with varying 
vascular risk factors. Hence CTTH values are higher with large variance (COV).   
Increased volumes of mildly elevated CTTH (10-20 sec) positively predicted 
favourable clinical outcome in acute ischemic stroke with a LVO364. However, 
there is no correlation between mildly elevated CTTH and final infarct volume.  
I have not looked at individual patients with carotid occlusion and how it 
influences CTTH. We do not have information on different brain tissues (deep 
grey matter, white matter, grey matter).  
Our study has limitations with small cohort of patients with only ischaemic 
stroke (i.e. not homogenous population). The study subject cohorts were 
different in three non randomised studies leading to heterogeneous population. 
There is no external validation for the methodology in deriving the novel 
parameters (CTTH, COV). Approximation of flow patterns to the flexible two-
parameter gamma function is widely used in micro vascular research. 
Nevertheless, this approximation might not be appropriate in disease conditions 
such as ischaemia. No experimental studies directly compared CTTH with OEF 
measured by PET. We have used perfusion thresholds as per Wintermark’s 
criteria. The core, penumbra measurements may not be replicable with other 
criteria using different perfusion parameters and thresholds. Other valuable 
exercise would have been to have derived thresholds for CTTH along with other 
parameters in core, penumbra tissues (with core meaning the hypoperfused 
tissue correlating with final infarction if recanalised, penumbra meaning 
hypoperfused tissue correlating with final infarction if non recanalised). 
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6.5 Conclusions 
 
I successfully derived new perfusion parameters CTTH, COV using the vascular 
model. Although CTTH values did not differ significantly in tissue zones (core, 
penumbra), this needs to be tested in large number of subjects with further 
validation work. 
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Chapter 7 What are the clinical characteristics of 
subjects with ‘non-core-non-penumbral’ 
infarction? 
 
7.1 Introduction 
Infarction of acutely silent tissue (non-core-non-penumbra) was previously 
described in literature367. This was shown to negatively impact clinical outcome.  
In the classic core/penumbra model, both the core and the penumbra contribute 
to the clinical deficit and together constitute the symptomatic tissue.  Imaging 
studies have shown that combined volumes of core and penumbra correlate 
better with acute clinical scores, and that salvage of penumbral tissue is 
associated with improvement in clinical scores368 . So called ‘Oligaemia’ is found 
surrounding hypoperfused tissue which is assumed to be clinically silent and not 
at risk of infarction. Bang et al, reported occurrence of new DWI lesions after 1 
week in >50% of anterior circulation strokes predominantly involving areas 
initially affected by only mild hypoperfusion369.  Infarction of silent tissue is 
plausible in circumstances such as cerebral blood flow in oligaemia falls below 
penumbral and then infarction threshold367. This can happen for example in 
hypotension when cerebrovascular autoregulation is negatively affected in 
leptomeningeal collaterals. Embolisation of clot into distal branch of occluded 
artery could contribute to infarction of acutely silent, contiguous brain tissue. 
Delayed tissue damage from inflammation was also proposed as contributory for 
infarction of acutely silent tissue370. In unexplained early neurological 
deterioration (<24 hrs after stroke onset) subjects an infarct growth beyond the 
initial penumbra was shown to be larger than matched controls with no early 
neurological detarioration371. Cerebral pericyctes which regulate capillary 
diameter during functional activation are susceptible in conditions such as age, 
hypertension and diabetes359. Even if blood flow to a given region of brain is 
adequate to the oxygen needs, a mal distribution of flow (Capillary flow 
heterogeneity, CTTH) can lead to variations in oxygen extraction.  
We hypothesised that pre-stroke co morbidities may reflect a propensity for 
extension of infarction beyond the defined compartments (core, penumbra). We 
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further hypothesised that extension of infarction may reflect capillary 
dysfunction that would be evident in abnormal CTTH.  
Using the similar subjects and methods as detailed in chapter 7, I investigated 
the subjects with ‘non-core,-non –penumbral’ infarction to evaluate any 
differences in clinical characteristics such as vascular risk factors. 
 
7.2 Methods 
 
I used the same dataset and methods as in chapter 7. Wintermark’s validated 
thresholds (Core=CBV <2ml/100g/min, Penumbra= relative MTT>145%) for core, 
penumbra were applied.  Most subjects were found have an infarction outside 
the core and penumbra tissue (hence we called non- core-non-penumbral 
infarct). The median volume of NC/NP infarction on follow-up CT was 2.3 ml, 
hence we decided to use this value as cut off. We defined a threshold of >2.3ml 
as significant non-core-non-penumbra (NC/NP) Infarct brain volume.  
 I compared the groups (non-core-non-penumbral infarction >2.3 vs. ≤ 2.3ml) for 
a demographic data, clinical scores, and map-derived volumes using appropriate 
categorical or numerical statistical test for comparison. I called the group with 
non-core-non-penumbra infarct volume >2.3 as ‘non-core-non-penumbra 
Infarction’ groups in discussion. 
7.3 Results 
Median time of symptom onset to CTP imaging was 188 min (IQR 83). Mean time 
was 198 min (SD +/-69). The volumes of total penumbra, salvaged penumbra, 
non-core-non-penumbra infarction and Infarction on CT slices co-registered to 
CTP space; proportions of salvaged penumbra, non-core-non-penumbra 
infarction (with infarction volume in CT slices co registered to CTP space) and 
non-core-non-penumbra (with total penumbra volume) are shown in Table 7-1. 
Clinical, Imaging characteristics of the subjects with NC/NP ≤ 2.3ml vs. >2.3 ml 
is shown in Table 7-2. 
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Table 7-1 Volumes of Salvaged Penumbra, Infarction and 'non-core-non-penumbra' infarction 
Penumbra 
volume 
median(IQR)    
 
Infarction in 
CTP co 
registered 
CT slices 
median(IQR)    
 
Salvaged 
penumbra 
median(IQR)    
 
Salvaged 
penumbra/total 
penumbra (%) 
Non-core-non-
penumbra-
infarction/Infarction 
in CTP co-registered 
CT slices (%) 
NC/NP  
median 
(IQR) 
NCNP/penumbra 
(%) 
54 ml (23-
84) 
9.9 ml (0-
39) 
33.7 ml (12-
56) 
73 (30-92) 20 (9-40) 2.33 
ml 
(0.7-
8.5) 
6 (1-21) 
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Table 7-2 Clinical, Imaging characteristics of the subjects with NC/NP =< 2.3 ml vs. >2.3 ml 
 NC/NP FI ≤2.3ml 
(N=64) 
NC/NP FI >2.3ml 
(N=65) 
P value (mann-
whitney) 
Female n/N (%) 28/64 (44%) 25/65 (38%) 0.6 
Smoker n/N (%) 20/64 (31%) 27/65 (41%) 0.3 
Hypertension n/N 
(%) 
34/64 (53%) 38/65 (58%) 0.6 
 
Diabetes n/N (%) 5/64 (8%) 10/65 (15%) 0.3 
Atrial fibrillation 
n/N (%) 
19/63 (30%) 23/60 (38%) 0.35 
Cardiac Disease 
n/N (%) 
14/ 59 (24%) 15/62 (24%) 1 
Capillary blood 
glucose (mmol/l) 
median (range) 
6.5 (5.7-7.6) 6.8 (5.6-8.1) 0.4 
Systolic BP 
(mean+-SD) 
147 (21) 147 (20) 0.9 
Age 
median(years, 
range) 
73 (63-80) 72 (61-79) 0.26 
NIHSS median 
(range) 
9 (6-15) 16 (10-19) <0.01 
OTT* (minutes, 
mean+-SD)  
181 (46) 183 (49) 0.8 
Median CTTH 
(seconds) 
4.1 (3.6-4.9) 4.3 (3.8-4.8) 0.5 
Core volume 
median (ml,  IQR) 
2.1 (4.7) 6.1 (8.7) <0.001 
Penumbra volume 
median (ml, IQR) 
38.7 (65) 62 (52) 0.011 
Follow up infarct 
median volume in 
CT co registered 
to CTP space (ml, 
IQR) 
9.9 (16.8) 57.6 (45.8) <0.001 
NC/NP infarct 
median volume 
(ml, IQR) 
0.7 (1.4) 8.2 (14.5) <.0001 
OTT Onset to treatment time;  NIHSS National Institute of Health 
stroke Scale ; CTTH Capillary transit time heterogeneity 
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Out of the total subjects with recanalisation status available (n=100), 55 
subjects have recanalised (i.e. achieved TIMI grade 2 or 3). Box plot of median 
CTTH values are shown in fig.8-2 comparing median CTTH in penumbra which 
has infarcted (13.2 s, IQR 4) and penumbra that is rescued (10.35 s, IQR 1.7) in 
only recanalised subjects.  
 
Figure 7-1 Box plot of median CTTH values in penumbra infarcted vs. rescued in recanlised 
subjects. (Y axis represents CTTH (sec)). 
 
 
7.4 Discussion 
‘Non-core-Non-penumbral’ infarction group has larger hypoperfused area 
(penumbra volume 62ml vs. 39ml, (p=0.001)) leading to larger final infarction 
volume (57 ml vs. 9.9ml). This could be due to infarction of oligaemic tissue 
surrounding the penumbra. The accurate separation of benign oligaemia with 
penumbra is a challenge260. The use of blood flow threshold levels to define 
salvageability of brain tissue and to predict infarct growth is affected 
conceptually by collateral supply, peri-infarct depolarisations and dynamic 
nature of penumbra.  These same factors could lead to growth of penumbra into 
regions of oligaemia367.  
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Perfusion thresholds can be time dependent to differentiate the tissue zones, 
with for example even smaller reductions in CBF can lead to infarction at later 
time from stroke onset372. The proportion of “noncore non penumbra infarction” 
constituting the infarction in CTP slices is on average 20% in our study, whereas 
in a study of anterior circulation Ischemic stroke non-core-non-penumbra 
infarction constituted 11%260. In their study, substantial volume (arbitrarily 
considered >1ml) was seen in 7/34 (21%; up to 8ml) of patients, representing on 
average 11% (up to 83%) of final Infarction volume in the 2 slices of CTP260 .In our 
study, median volume of non-core-non-penumbral infarction was 2.3ml (up to 
8.5ml, similar to Alawneh et al260 group). 
Clinical characteristics did not differ in between those with NC/NP volume >2.3 
ml or <2.3 ml, presumably due to inherent bias in distinguishing with median 
volume. In Alawneh et al study CT perfusion protocol consisted of 2 contiguous 
10mm slices (20mm thickness), where as in our study CT perfusion slice was 
40mm thickness. In their study, 1ml of acutely silent but Infarcted tissue volume 
was arbitrarily considered significant. Our median volume for arbitrarily dividing 
significant to non significant infarction of “non core non penumbra tissue” is 
similar to their group after correcting for the limited brain coverage.  Higher 
NIHSS and larger penumbra volumes were seen in the group with NC/NP volume 
>2.3 ml.  
Median penumbra volume saved in our cohort was 33.7 ml (average 77% of 
penumbra is rescued). Alawneh et al study in 34 CTP subjects with mean Onset 
to imaging time of 136 min, showed salvaged penumbra median volume of 59ml 
(85% penumbra rescued)260.  
The lack of clear association of non-core-non-penumbra infarction with CTTH 
might simply reflect smaller number of subjects. It is potentially difficult to 
reliably measure CTTH in such small volumes. Median CTTH value is relatively 
higher in the penumbra tissue that has infarcted in comparison to the penumbra 
that is rescued after recanalisation.  This may suggest the theory that higher 
CTTH value despite reperfusion leads to Infarction355. Sudden increase in CBF 
after reperfusion in capillaries with too fast flow would lead to low OEFmax. 
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Our study has limitations.The CT perfusion images has limited brain coverage 
and hence cannot be certain if the volumes for infarction and tissue parameters 
correlate to a whole brain imaging. Since all subjects had non-core-non-
penumbra infarction, we arbitrarily divided into two groups using median volume 
(2.3 ml) as cut off, but this has bias in understanding the difference between 
those with larger infarction in this region to those with small infarction. The 
CTTH values for the NC/NP tissue region itself is not derived but the overall 
CTTH value for the subjects with or without NC/NP infarction is derived. This 
does not give true information on CTTH variability in the region of interest as 
such. Our study has limitations with small cohort of patients with only ischaemic 
stroke (i.e. not homogenous population). The study subject cohorts were 
different in three non randomised studies leading to heterogeneous population. 
There is no external validation for the methodology in deriving the novel 
parameters (CTTH, COV). Approximation of flow patterns to the flexible two-
parameter gamma function is widely used micro vascular research. Nevertheless, 
this approximation might not be appropriate in disease conditions such as 
ischaemia. No experimental studies directly compared CTTH with OEF measured 
by PET. The core, penumbra values are derived with Wintermark’s thresholds. 
The thresholds may not replicable with other perfusion parameters and 
thresholds.  
7.5 Conclusions 
I did not identify any significant difference of CTTH values in subjects with non-
core-non-penumbra infarction tissue; however this is very novel method and 
needs further work with validation. An analysis in larger group of subjects would 
be helpful in better understanding of the role of CTTH in “non-core-non-
penumbra” infarction. This parameter can potentially be a key factor in 
determining tissue fate; perhaps this is the missing link for inadequate 
prediction with current transit time metrics.  
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Chapter 8 Is secondary transfer for stroke 
thrombolysis optimal? - Comparing outcomes 
between two hospitals with different model of 
care and with the rest of UK 
 
   
8.1 Introduction 
Intravenous thrombolysis in ischemic stroke is beneficial if given within 4.5 hours 
of symptom onset 373 120, with benefits being highly time-dependent261. Despite 
being recognised as recommended treatment supported by the highest level of 
evidence in national and international guidelines for more than a decade, IV 
thrombolysis is not universally available at all hospitals where stroke patients 
are admitted. Consequently, patients with acute stroke may be transferred to a 
stroke centre in order to be treated. The outcomes of patients accessing a 
primary stroke centre directly have not been compared to those transferred 
secondarily from a referring hospital. 
Bias from the source of patient referral was reported, with more patients aged 
>80 were referred from primary care, whereas, those referred from Emergency 
departments were <80 years374. Factors including older age, high blood glucose, 
stroke severity,   pre-stroke disability, and blood pressure are significant 
prognostic factors 375,376, and several of these (notably age and severity of 
stroke) interact with time to presentation261.  Longer time from symptom onset 
to treatment is associated with poorer outcomes based on clinical trials263,377.  
Registry based studies show heterogeneity in patient outcomes based on regional 
differences or socioeconomic status378,379. Risk adjusted inpatient mortality was 
higher among patients from lower income areas380. The inverse relationship of 
socio-economic status and stroke outcomes was reported in a secondary analysis 
of a study investigating quality of stroke services in Scottish hospitals381. Patients 
from deprived regions are more likely to be dependent or death at 6 months 
compared to affluent regions.  Analysis from the Safe Implementation of 
Thrombolysis in Stroke (SITS) register identified different treatment biases in UK 
and non-UK SITS countries 382: UK SITS-MOST patients had more severe stroke  
(median NIHSS 14.5 vs. 12), accounting for differences in outcome (48% of UK 
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patients achieved independence (modified Rankin Score 0-2) compared to 55% of 
non-UK). Provision of all relevant processes of care reduces medical 
complications after stroke383. A prospective cohort English study has shown that 
patients admitted to higher levels of organisation are more likely to receive high 
quality care and reduced mortality384. Implementation of centralised stroke 
services has trade off between improved, focussed stroke care with longer travel 
times and potentially delays in stroke treatments. Centralisation of stroke 
services has shown improved length of stay, improved time to scan and in some 
improved mortality385,386. 
Glasgow city population has been recognised to have poor health status 
compared to rest of the UK (“Glasgow effect” 
https://en.wikipedia.org/wiki/Glasgow_effect). The model of stroke care can 
influence patient outcomes. In Glasgow, Southern General Hospital (SGH) has 
transfer from peripheral hospital model, whereas, Western Infirmary Glasgow 
(WIG) has local thrombolysis only model. We sought to explore the potential 
impact of different referral systems for IV thrombolysis by exploring SITS registry 
data for two different hospitals in the same city; and to compare outcomes in 
these hospitals against those seen in the rest of the UK.  
Our hypothesis was that SGH taking referrals from poorer part of Glasgow, and 
wider geographical catchment will have poorer outcomes compared to a local 
hospital in Glasgow. We also believe that peripheral hospital referrals contribute 
to poorer outcomes. In addition, we were also interested to compare the 
outcomes in direct admissions with secondary transfers SGH. 
 
8.2 Methods  
I undertook a retrospective, observational study comparing outcomes in 
different geographical regions using SITS registry data. The Safe Implementation 
of Thrombolysis in Stroke (SITS) registry was established as part of the 
conditional European licence for alteplase in order to confirm clinical trial 
findings in routine practice 387.  The SITS platform is an internet –based 
interactive stroke registry, which serves as a tool for structured data entry and 
is an instrument for centres to compare their own treatment results with 
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national and global performance. SITS is an ongoing, prospective, academic-
driven, multinational register for centres using thrombolysis for the treatment of 
acute ischemic stroke. After increased time window to 4.5 hrs since publication 
of  ECASS III120 , there was a concern that increased time window would lead to 
delays and potentially increased haemorrhage and mortality with treatment 
delays. SITS registry was aimed to assess the implementation of prolonged time 
window for thrombolysis, to investigate whether the increased time window has 
resulted in prolongation of admission-to-treatment time, and to evaluate 
treatment safety and functional outcome in a large patient cohort. 
I analysed data from the SITS registry for all thrombolysed stroke patients from 
May 2003 to March 2013. I collected separate data for two hospitals within 
Glasgow (Southern General Hospital SGH, Western Infirmary Glasgow WIG) and 
for the rest of the UK (excluding these two hospitals). SGH provide IV 
thrombolysis service to secondary transfers from a wide geographical area in 
South of Glasgow with a population catchment of over 500,000 population and 
admitting patients from over 6 district general hospitals. Victoria Infirmary (VIC) 
is a closely linked hospital to SGH and therefore transfers from this hospital or 
direct admissions to SGH are considered primary SGH admissions and remaining 
admissions as peripheral referrals (or secondary SGH admissions) for the analysis. 
WIG has catchment of 225,000 population of own and other referrals from north 
of Glasgow hospitals. Since year 2015 the Stroke service has been redesigned in 
Glasgow. VIC, WGI hospital services have moved to SGH. 
Outcomes:  
The 90 day modified Rankin score (mRS) was analysed as a dichotomised 
variable, defining good outcome as mRS 0-2. We analysed death at 90 days, the 
incidence of SITS Monitoring Study (SITS-MOST)-defined symptomatic intra-
cerebral haemorrhage (Parenchymal haematoma type 2 (PH2) or remote 
Parenchymal haematoma type 2 (PHR2) with deterioration in NIHSS of ≥4 or 
death)388 and clinically relevant significant haemorrhage (Parenchymal 
Haematoma type1 or 2 or Remote Parenchymal Haematoma type 1 or 2). 
Statistical analysis:  
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Sample size calculation was not performed as this study was a non randomised 
comparison of groups. Unadjusted comparisons between SGH, peripheral 
referrals to SGH, WIG, and rest of the UK (r UK) were done using Kruskal-Wallis 
test for numerical variables and chi-square or Fisher’s tests for categorical 
variables, as appropriate. Data were analysed without and with adjustment for 
baseline prognostic factors, and onset to treatment time (OTT) was specifically 
tested. We carried out univariate and multivariate logistic regression for the 
outcomes with hospital site as an explanatory variable and adjustment for other 
variables. The variables entered in regression models are detailed in table 
below. Variables with p value <0.1 on univariate regression were entered into 
multivariate logistic regression. Onset to treatment time (OTT) was forced in if 
not already significant in univariate regression. The variables included in the 
regression models were: Age, pre-stroke modified Rankin score (0-1 vs. 2-5), 
Onset to treatment time, Baseline NIHSS, systolic BP, Capillary blood  glucose 
(mmol/l), Weight (kg), Oxford stroke type (TACI v other), female gender, 
Hypertension, Hyper lipidemia, Smoking, Diabetes, Atrial Fibrillation, congestive 
heart failure, Previous stroke, Stroke aetiology(Embolic v other) and hospital 
locations.   
As adjustment for baseline prognostic variables does not necessarily capture all 
relevant factors, I additionally undertook propensity score matching389 
(comparison of SGH, rUK groups) using nearest neighbourhood method with R 
statistics.  The variables used for matching between UK and SGH were: Age, 
NIHSS, Diastolic BP, Capillary blood Glucose (mmol/l), Hypertension, Diabetes, 
Hyper lipidemia, Smoking, Atrial fibrillation, Previous Stroke, Congestive Heart 
failure, Pre stroke modified Rankin score (0-1 vs. 2-5), Antiplatelet use, Stroke 
type (Embolic v Other), Oxford stroke classification(TACI v Other). As there are a 
large number of covariates, conventional matching would have been difficult 
and would have resulted in dropping a large number of cases. Propensity score 
matching summarize many covariates into a single score. 
I used SPSS 21 for descriptive, binary logistic regression analysis for the main 
outcomes in both before matching (SGH, peripheral transfers, WIG and r UK) and 
after matching (SGH, peripheral transfers, r UK cohorts). I also then measured 
the risk of death within 90 days between sites by log rank test and Cox’s 
proportional hazards regression method.  
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8.3 Results:  
Out of 11120 patients who received IV thrombolysis, 7504 had 90 day modified 
Rankin score available (fig.8-1). Baseline characteristics of study population are 
illustrated in Table8-1. 
 
Figure 8-1 Study population CONSORT diagram  
(SGH- Southern General Hospital, WIG-Western Infirmary Glasgow, r UK- rest of the UK)  
 
11410 
Total entries 
of subjects 
11120 
IV tPA  given 
7504 
Available 90d 
mRS 
649  
SGH 
554 
WIG  
6301 
rUK 
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Table 8-1 Baseline characteristics of study population 
 
  
SGH  
(n=307) 
 
Peripheral 
referrals  
(n=342) 
 
WIG (n=554) 
 
rUK (n=6301) 
 
P value 
Median age 
(IQR), years 
72 (61-79) 70 (62-78) 71.5(61-79) 72(62-79)  
0.4 
 
Female  
gender ( %, n) 
 48% 
(145/302) 
 46% (15/338) 48% (264/554) 45% 
(2824) 
0.4 
 
 
Median NIHSS 
(IQR) 
14 (7-20) 15 (9-20) 11(6-18) 
 
13(8-19) <0.01 
 
Pre stroke 
mRS  (0-1) (%, 
n ) 
80%(236/2
93) 
 89%(294/329)   
83.4%(462/554) 
 
 87.4% 
(5207/5957)  
 
 
 
0.001 
mRS0 66.9% 
(196/293) 
72.9% 
(240/329) 
65.7% 
(364/554) 
72.9% 
(4343/5957) 
<0.001 
mRS 1 10.2% 
(40/293) 
16.4% (54/329) 17.7% (98/554)  14.5% 
(864/5957) 
 
mRS 2 10.2% 
(30/293) 
9.1% (30/329) 10.5% (58/554) 8% (478/5957)  
mRS3 9.2% 1.5% (5/329) 6.1% (34/554) 4.3%  
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(27/293) (258/5957) 
mRS 4 0 0 0 0  
mRS5 0 0 0 0.2% (14/5957)  
Hypertension ( 
%, n) 
 60%, 
(180/299) 
 62% (207/333)  61.9%, 
(341/551) 
 
57.7%,   
(3527/6108)  
 
0.1 
Diabetes (%, 
n) 
14% 
(41/300) 
12% (41/336) 13% 
(72/553) 
14% 
(867/6194) 
0.7 
Hyper 
lipidemia (%, 
n) 
19% 
(58/299) 
23% (77/336) 38% 
(209/549) 
35% 
(2031/5765) 
 
 
<0.01 
Smoker (%, n) 28% 
(84/297) 
25% (84/331) 30.5% 
(167/548) 
20% 
(1151/5799) 
 
 
<0.01 
Atrial 
Fibrillation (%, 
n) 
35% 
(104/308) 
26% (86/335) 30.6% 
(169/552) 
24% 
(1455/6069) 
 
 
<0.01 
Congestive 
Heart failure 
(%, n) 
3.3% 
(10/300) 
5% (17/336) 7.8% 
(43/552) 
5% 
(306/6085) 
0.018 
Previous 
stroke (%, n) 
20% 
(60/299) 
14.6% (49/336) 18% 
(98/540) 
12.2% 
(756/6183) 
 
 
<0.01 
On 54% 44% (148/335) 52.4% 
(290/553) 
40.3% 
(2502/6216) 
<0.01 
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antiplatelet 
(%, n) 
(163/300)  
On anti 
hypertensives 
(%, n) 
51% 
(152/299) 
49% (165/336) 60.2% 
(333/553) 
48% 
(2943/6115) 
<0.01 
 
 
 
Median 
capillary 
blood 
glucose(IQR), 
mmol/l 
6.4 (5.5-
7.6) 
6.3 (5.6-7.6) 6.1 (5.3-7.3) 
 
6.4 (5.6-7.8) <0.01 
 
 
Median 
Systolic blood 
pressure(IQR), 
mmHg 
149 (135-
163) 
149 (131-164) 141 (126-159) 149 (133-163)  
<0.01 
Median 
Diastolic blood 
pressure 
(IQR),mmHg 
77 (67-85) 75 (65-86) 77 (69-86) 80 (70-90)  
 
 
 
<0.01 
 
TACI (%, n)¶ 56% 
(166/296) 
60% (198/333) 41% (226/5520 47.6% 
(2909/6114) 
<0.01 
PACI (%, n)¶ 35% 
(103/296) 
28% (93) 36.8% (203) 36.7% (2246)  
POCI (%, n)¶ 1.4% (4) 1.2% (4) 1.3% (7) 0.3% (20)  
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LACI 9%, n)¶ 8% (23) 11.4% (38) 21% (116) 15.4% (939)  
Large vessel 
atherosclerosi
s (%, n)* 
34.5% 
(99/287) 
33% (107/326 53%(272/513) 44.6% 
(2453/5500) 
<0.01 
Cardioembolic 
(%, n)* 
52% (150) 50% (162) 33.9% (174) 27.4% (1506)  
Lacunar (%, 
n)* 
4% (14) 3% (9) 9%(46) 10.8% (594)  
Unknown/Unc
ertain (%, n)* 
10% (29) 13% (43) 4% (21) 17.2% (947)  
Onset to Door 
Time(IQR),min 
70 (50-96) 97 (64-139) 
 
120 (90-150) 150 (120-165)  
<0.01 
 
 
 
 
Onset to 
Treatment 
Time(IQR),min 
145 (115-
175) 
173 (145-195) 
 
170 (145-190) 180 (160-205)  
<0.01 
 
Door To 
Imaging 
time(IQR),min 
33 (20-50) 28 (15-49) 
 
15 (9-27) 15 (8-22)  
<0.01 
Door To 
Treatment 
time 
(IQR),min 
68 (50-94) 66.5 (47-95) 
 
40 (25-55) 60 (47-95) <0.01 
  167 
 
167 
 
 
¶ Oxford stroke classification (TACI-Total anterior circulation Infarct; PACI-Partial anterior 
circulation Infarct; LACI-Lacunar Infarction; POCI-Posterior circulation Infarct 
 
*Stroke aetiological classification using TOAST criteria 
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Unadjusted important clinical outcomes (Haemorrhage, functional outcome at 90 
days and death) are illustrated in Table.8-2. 90 day modified Rankin score 
distribution is shown in grotto bars in Fig. 8-2. 
 
 
Table 8-2 Un-adjusted improtant clinical outcomes in different hospital groups 
 SGH 
(n=307) 
Peripher
al 
referrals 
(n=342) 
WIG 
(n=554) 
UK 
(n=6301) 
P value 
SITS-MOST 
SICH 
haemorrha
ge (n, %) 
2/260 
(0.8%)  
4/269 
(1.4%) 
12/539 
(2.2%) 
77/5784 
(1.3%) 
 
0.3 
 
Significant 
haemorrha
ge (PH1 or 
PH2 or 
PHR1 or 
PHR2) (n, 
%) 
27/293 
(9%)  
29/327 
(9%) 
54/542 
(10%) 
456/601
7 (7.6%) 
0.18 
 
 
 
 
Death 
(n/N, %) 
66/302 
(22%) 
90/338 
(26%)  
90/554 
(16%) 
 
1227/63
01 
(19.5%) 
 
0.001 
 
unfavourab
le 90day 
mRS  
(2-6) 
 (n, %) 
240/302 
(80%) 
266/338 
(80%) 
371/554 
(67%) 
 
3936/63
01 
(62.5%) 
 
 
<0.01 
Poor 90 
day mRS 
(3-6) (n, %) 
179/302 
(59%)  
219/338 
(65%) 
264/554 
(48%) 
2928/63
01 (46%)  
<0.01 
 
SITS-MOST Safety in Stroke Thrombolysis Monitoring study, SICH-
Symptomatic Intra cerebral Haemorrhage 
PH1, PH2 - Parenchymal haemorrhage type 1, type 2 respectively, 
PHR1, PHR2- Remote Parenchymal haemorrhage type 1 & 2 
respectively  
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Figure 8-2 90 day modified Rankin scales in different hospitals 
mRS is classified into 0,1,2,3,4,5 and 6 (death). 
 
 
8.3.1 Regression analysis 
Univariate regression and multivariate regression analyses for the poor 90 day 
outcome (modified Rankin score 3-6) are illustrated in Table 8-3 and 8-4 
respectively. 
 
 
Table 8-3 Univariate regression for poor 90 day modified Rankin score (mRS3-6) in all study 
population 
Variables OR(95%CI) P value 
Age (years) 1.04(1.03-1.04) <0.01 
Onset to 
Treatment 
Time(OTT, min) 
0.99(0.99-1.003) 0.2 
Pre stroke mRS 0-
1 
0.26(0.22-0.3) <0.01 
NIHSS 1.18(1.17-1.19) <0.01 
Systolic Blood 
pressure(mmHg) 
1(0.99-1.003) 0.63 
6% 
7% 
17% 
19% 
15% 
14% 
16% 
19% 
20% 
14% 
19% 
16% 
18% 
19% 
15% 
13% 
9% 
11% 
14% 
10% 
10% 
8% 
2% 
4% 
22% 
27% 
16% 
20% 
SGH  
Peripheral 
referrals 
WGH 
UK 
0 1 2 3 4 5 dead 
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Capillary blood 
Glucose (mmol/l)  
1.1(1.08-1.12) <0.01 
Weight(kg) 0.99(0.98-0.99) <0.01 
Female gender 1.28(1.17-1.4) <0.01 
Hypertension 1.27(1.15-1.4) <0.01 
Diabetes 1.4(1.23-1.6) <0.01 
Hyper lipidemia 0.97(0.8-1.07) 0.5 
Smoking 0.78(0.7-0.8) <0.01 
Atrial fibrillation 1.67(1.5-1.8) <0.01 
Congestive Heart 
failure 
1.8(1.5-2.2) <0.01 
Previous stroke 1.24(1.08-1.4) <0.01 
TACI vs. Other 
(Oxford 
classification)§ 
3.3(3 -3.7) <0.01 
Embolic vs. other 
stroke types ¶ 
1.36(1.2-1.5) <0.01 
r UK (reference)   
SGH  1.7(1.3-2.12) <0.01 
Peripheral 
referrals 
2.12 (1.7-2.6) <0.01 
WIG 1.05 (0.88-1.25) 0.6 
 
§ Oxford stroke classification 
¶ TOAST classification  
 
 
 
 
Table 8-4 Multivariate regression for poor 90 day modified Rankin score (mRS3-6) 
Variables OR (95%CI) P value 
Age 1.03(1.023-1.32) <0.01 
NIHSS 1.18(1.17-1.2) <0.01 
Capillary blood 
glucose (mmol/l) 
1.07(1.05 -1.1) <0.01 
  171 
 
171 
 
 
 
In multivariate regression analysis, adjusted (for all variables with p<0.1) poor 
90 day outcome (mRS >2) remained significantly higher in SGH (OR 1.7 (1.26-
2.3); p<0.01), peripheral referrals (OR 2.22 (1.7-2.9); p<0.01) and WIG (OR 1.3 
(1.06-1.6), P=0.014) compared to rUK. Increasing age, higher baseline NIHSS, 
pre-stroke mRS score 0-1, higher capillary blood glucose, longer onset to 
treatment time independently predicted the poor outcome (see table 6-4).  
Univariate regression for death at 90 days is shown in Table 8-5. Multivariate 
regression for death at day 90 is shown in Table 8-6. 
 
 
Table 8-5 Univariate regression for death at 90 days in all study population 
 0R(95%CI) P value 
Age (years) 1.06(1.05-1.07) <0.01 
Onset to 
Treatment 
Time(OTT, min) 
0.999(0.998-
1.001) 
0.3 
Pre stroke mRS 0-
1 
0.336(0.3-0.4) <0.01 
NIHSS 1.14(1.13-1.15) <0.01 
Systolic BP 
(mmHg) 
1.002(1-1.005) <0.06 
Capillary blood 
Glucose (mmol/l) 
1.11(1.08-1.13) <0.01 
Weight (Kg) 0.986(0.98-0.99) <0.01 
Female gender 1.09(0.97-1.22) 0.14 
Hypertension 1.25(1.1-1.4) <0.01 
Pre-Stroke mRS 0-1 0.3(0.25-0.36) <0.01 
Onset to treatment 
time (min, forced) 
1.002(1.001-1.003) <0.01 
rUK (reference)   
SGH  1.7 (1.26-2.3) <0.01 
Peripheral 
referrals 
2.22 (1.7-2.9) <0.01 
WIG 1.3 (1.06-1.6) 0.014 
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Diabetes 1.46(1.25-1.7) <0.01 
Hyper lipidemia 0.99(0.87-1.12) 0.88 
smoking 0.6(0.52-0.72) <0.01 
Atrial fibrillation 1.9(1.68-2.16) <0.01 
Congestive Heart 
failure 
2.1(1.67-2.6) <0.01 
Previous stroke 1.24(1.06-1.46) <0.01 
TACI vs. Other 
(Oxford 
classification)§ 
2.7(2.4-3.1) <0.01 
Embolic vs. other 
stroke types ¶ 
1.5(1.3 -1.7) <0.01 
rUK (reference)   
SGH plus VIC 1.15 (0.8-1.5) 0.3 
Peripheral 
referrals 
1.5 (1.17-1.9) 0.001 
WIG 0.8 (0.6-1) 0.065 
 
§Oxford classification 
¶TOAST classfication 
 
 
 
 
 
Table 8-6 Multivariate regression for death at 90days 
Variables OR(95%CI) P Value 
Age (years) 1.05(1.04-1.06) <0.01 
NIHSS 1.14(1.12-1.15) <0.01 
Capillary Blood glucose 
(mmol/l) 
1.09(1.06-1.12) <0.01 
Pre-Stroke mRS 0-1 0.54(0.45-0.65) <0.01 
Hypertension 0.8(0.7-0.9) <0.05 
Onset to treatment time 
(min; forced) 
1.002(1.000-1.004) 0.03 
r UK (reference)   
SGH plus VIC 1.06 (0.76-1.5) 0.7 
Peripheral referrals 1.46 (1.08-1.98) 0.013 
WIG 0.92 (0.7-1.2) 0.56 
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In multivariate regression (Table 8-6), adjusted Death was only significantly 
higher in, peripheral referrals (1.46 (1.08-1.98), p=0.013) but not SGH direct 
admissions (Odds ratio 1.06, 95%CI, 0.76-1.5, p=0.7), WIG (0.92 (0.7-1.2); 
p=0.56) compared to rUK. Higher Age, higher NIHSS, higher capillary blood 
Glucose, and longer onset to treatment time were positively associated, and pre 
stroke mRS (0-1), Hypertension negatively with death in multivariate regression 
(Table 8-6).  
8.3.2 Survival analysis  
Death occurred in 61 patients in SGH, 88 patients in Peripheral referrals, 86 
patients in WIG, and 1169 patients in rUK. No day of death was available in 68 
patients who were “imputed” to death at day “90”.The Log-rank test and Cox 
proportional hazards regression for death at day 90 comparing SGH, peripheral 
referrals, rUK, WIG are shown below (Fig.8-3, 8-4 & Table.8-7).  
 
 
Figure 8-3 Log rank test comparing hospitals (Log-Rank p<0.01) 
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Figure 8-4 Cox's proportion Hazard function 
 
 
Table 8-7 Cox's regression analysis for death at 90 days 
Variable Hazard Ratio (95% CI)  P value 
Age 1.039 (1.034-1.045) <.001 
NIHSS 1.1 (1.1-1.12) <0.01 
Pre stroke mRS (0-1) 0.68 (0.6-0.79) <0.01 
Capillary blood glucose 
(mmol/l) 
1.07 (1.05-1.09) <0.01 
rUK (reference)   
SGH  1.16 (0.9-1.5) 0.26 
Peripheral referrals 1.6 (1.3-2) <0.001 
WIG 1.09 (0.9-1.36) 0.45 
 
 
In addition, the causes of death in different sites are illustrated in figure 8- 5.
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Figure 8-5 Cuases of death in the hospitals  
(1= SGH  2= Peripheral referrals to SGH   3=WIG  4=UK) 
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8.3.3 Propensity score matching of SGH with UK subjects  
565 subjects were matched between SGH and rUK. Distribution of propensity 
score matching is shown in fig. 8-6 &8-7. The variables used for matching has 
been described in the methods section.  Univariate and multivariate regression 
analysis for poor outcome and death at 90 days are shown in Tables 6-8 to 6-11. 
Post matching, SGH has significantly increased poorer outcome (OR 1.6 (1.1-2.3); 
p=0.013), death (OR 1.8 (1.15-2.7); p=0.008), than rUK; peripheral referrals also 
have higher poorer outcome (OR 2.1 (1.4-3); p<0.01), death (OR 2.1 (1.4-3); 
p=0.01) than rUK.  
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Figure 8-6 Propensity score distribution before matching (        SGH, -------- UK) 
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Figure 8-7 Propensity score distribution after matching ( SGH, -------- UK) 
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Table 8-8 Univariate regression for poor outcome at 90 days (mRS>2) in SGH, UK post 
matched groups 
Variables 0R(95%CI) P value 
Age (years) 
 
1.04(1.03-1.05) <0.01 
Onset to treatment time 
(IQR, min) 
 
1.003(1.0-1.006) 0.04 
Pre-Stroke mRS0-1 0.23(0.14-0.365) <0.01 
NIHSS  
 
1.17(1.15-1.2) <0.01 
Systolic Blood pressure 
(mmHg) 
 
1.001(0.99-1.007) 0.64 
Capillary blood Glucose 
(mmol/l) 
 
1.13(1.06-1.2) <0.01 
Weight (kg) 
 
0.986(0.978-0.994) <0.01 
Female gender 
 
1.5(1.2-1.9) 0.001 
Hypertension 
 
1.3(1.006-1.6) 0.04 
Diabetes 
 
2(1.4-3) <0.01 
Hyper lipidemia 
 
1.06(0.79-1.4) 0.7 
Smoking 
 
0.7(0.5-0.9) 0.01 
Atrial Fibrillation  
 
1.28(0.99-1.676) 0.06 
Congestive Heart Failure 
 
1.05(0.5-2.06) 0.9 
Previous stroke 1.78(1.26-2.5) 0.001 
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TACI v other stroke types 
(Oxford classification) 
3.34(2.6-4.3) <0.01 
Embolic v other stroke 
types 
1.3(1.01-1.63) 0.036 
rUK (reference)   
SGH  1.37 (1.02-1.85) 0.03 
Peripheral referrals 1.76 (1.32-2.36) <0.01 
 
 
Table 8-9 Multivariate regression for poor outcomes at 90 days (mRS>2) in SGH, UK post 
matched group 
Variables OR(95%CI) P Value 
Age (years) 1.03(1.02-1.04) <0.01 
NIHSS 1.18(1.15-1.2) <0.01 
Capillary blood Glucose 
(mmol/l) 
1.1(1.02-1.2) 0.01 
Onset to treatment time 
(min) 
1.004 (1.001-1.008) 0.023 
Pre-Stroke mRS (0-1) 2.65 (1.58-4.44) <0.01 
Previous Stroke 1.52 (1.006-2.28) 0.047 
rUK (reference)   
SGH  1.6 (1.1-2.3) 0.013 
Peripheral referrals 2.1(1.46-3) <0.01 
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Table 8-10 Univariate regression for death at 90 days in SGH, UK post matched groups 
Variables 0R(95%CI) P value 
Age (years) 
 
1.07(1.05-1.08) <0.01 
Onset to treatment time 
(min) 
 
1.002(0.99-1.006) 0.2 
Pre stroke mRS 0-1 
 
0.34(0.3-0.6) <0.01 
NIHSS 
 
1.13(1.1-1.16) <0.01 
Systolic Blood pressure 
(mmHg) 
 
1.008(0.99-1.013) 0.08 
Capillary blood Glucose 
(mmol/l) 
 
1.14(1.076-1.25) <0.01 
Weight (kg) 
 
0.98(0.97-0.99) <0.01 
Female gender 
 
0.9(0.67-1.25) 0.4 
Hypertension 
 
1.4(1.03-1.9) <0.05 
Diabetes 
 
1.72(1.16-2.5) <0.01 
Hyperlipidemia 
 
1.07(0.75-1.5) 0.7 
Smoking 
 
0.57(0.39-0.8) <0.01 
Atrial Fibrillation  
 
1.74(1.27-2.36) <0.01 
Congestive Heart Failure 
 
1.46(0.67-3.2) 0.34 
Previous stroke 
 
1.05(0.7-1.5) 0.78 
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TACI v other stroke types 
(Oxford classification) 
2.5(1.8-3.5) <0.01 
Embolic v other stroke 
types 
1.4(1.02-1.86) <0.05 
rUK (reference)   
SGH  1.7 (1.15-2.5) 0.007 
Peripheral referrals 2.1 (1.5-3) <0.01 
 
 
Table 8-11 Multivariate regression for death at 90 days in SGH, UK post matched groups 
Variables OR(95%CI) P Value 
Age 1.05(1.03-1.07) <0.01 
NIHSS 1.13(1.09-1.16) <0.01 
Capillary blood Glucose 
(mmol/l) 
1.11(1.04-1.9) 0.002 
Onset to treatment time 
(min) 
1..006 (1.002-1.01) 0.008 
r UK (reference)   
SGH  1.8 (1.16-2.7) 0.008 
Peripheral referrals  2.1 (1.38-3.2) 0.001 
 
 
 
 
8.4 Discussion  
Different systems have been evaluated to increase access to IV thrombolysis, 
including “telemedicine” (TEMPIS390), “scan in a van”325, “helicopter transfer” 
391. Differences in patient outcomes after IV thromobolysis according to system 
of care have been less investigated. The issues raised by transfer of patients 
between healthcare facilities with different access to treatments have been 
highlighted by endovascular thrombolysis, where an interplay of transfer times 
and in-hospital efficiency (expressed as door to needle  time for IV thrombolysis) 
dictates the boundaries that determine appropriate care pathways (direct 
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transfer to an endovascular centre – the “mother ship” paradigm – or initial local 
thrombolysis initiation and subsequent transfer – the “drip and ship” paradigm). 
The risk factors and service characteristics differed in many important respects 
across groups. Within the Glasgow services, differences in patient characteristics 
likely reflect different population health states in the areas served by different 
hospitals, although they likely also reflect different physician behaviour, access 
to complex imaging, and other organisational features (note lesser severity at 
WIG, different risk factor profiles etc). The secondary transfer cases include 
referral bias and patient selection by the tertiary hospital in addition to transfer 
delay.  
Is there a “Glasgow Effect”? 
The Glasgow population shows a higher prevalence of several adverse prognostic 
markers, high prevalence of co- morbidities, and greater degree of pre-stroke 
dependence.  
The “Glasgow effect” (https://en.wikipedia.org/wiki/Glasgow_effect) describes 
an unexpectedly poor health and life expectancy of the population of Glasgow 
compared to the rest of the UK, that cannot be explained by poverty alone392,393 
. Although socio-economic status, cultural factors and other health related risk 
factors all undoubtedly contribute this phenomenon, it remains elusive as to why 
these health inequalities exist.  In multivariable analysis, independent predictors 
of poor outcome - increasing age, higher baseline NIHSS, higher pre-stroke 
modified Rankin scale, higher capillary blood glucose, and longer onset to 
treatment time – were the same as found by other studies375,394. West of 
Scotland stroke thrombolysis patients from all three groups, however, had 
significantly poorer outcomes compared to the rest of the UK independent of 
other factors. Mortality, excluding the secondary transfer cases, did not differ 
significantly from the rest of the UK in either conventional or propensity-
matched analyses. It is possible that the poorer outcome, defined as day 90 mRS 
score of 0-2, reflects general co-morbidities of the west of Scotland population 
that are not adequately detected by the conventional vascular risk factor profile 
and demographics available from this dataset. Data on frailty, co-morbidities 
and social deprivation were not available, but are likely highly relevant to 
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functional outcomes (e.g. Charlson co-morbidity index395). The pre-stroke 
estimated mRS was also significantly worse among west of Scotland patients 
(mRS≥2 was seen in 20% of SGH, 17% WGI compared to 13% in the rest of the UK. 
Modified Rankin score of 3 was found in 9.2% in SGH, 6.4% in WGI and 4.3% in 
UK).  
Is secondary transfer of patients associated with poorer outcome? 
Secondary transfer patients differed by good pre-morbid mRS and longer onset 
to treatment time, but even after adjusting for other predictors, functional 
outcomes were poorer among those transferred from outside Glasgow and 
mortality was higher, in both multivariable and propensity-matched analyses.  
The poorer outcome among these patients cannot be clearly explained from the 
available data. Causes and timing of death exhibit no clear pattern, the majority 
of deaths in all groups resulting from initial cerebral effects of stroke. 
Repatriation to the parent hospital was determined by patient status and was 
not dictated by administrative policies. Almost all parent hospitals had 
dedicated stroke units throughout the study period. 
Our study has several limitations. We compared disproportionate subject 
numbers using non-randomised subjects in a registry database. I did not 
calculate sample size as this was a non-randomised comparison. Propensity score 
matching was carried to adjust for large covariates but this method can have 
bias. Nevertheless, the results are similar with or without propensity score 
matching suggesting validity. Registry database can have limitations with entry 
errors and missing information. We have missing information and particularly 
missing 90d modified Rankin score. There are several imaging parameters that 
can influence the outcomes (e.g. ASPECTS score), which we do not have 
information for adjusting. Although other factors were adjusted this may still be 
inadequate in terms of baseline population characteristics. Comparing the 
outcomes between direct stroke admissions to DGH referrals can be done 
perhaps in different way to what I have done in this thesis. All DGH referrals to 
both the Glasgow hospitals can be compared to the direct admissions to both 
hospitals in non randomised way. However, we proposed to explore the 
geographical factors (larger catchment in SGH) and also socio-economic factors 
(poorer populations in SGH catchment), hence used the comparison between 
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hospitals, and compared only direct admissions with DGH referrals to SGH only. 
In Univariate logistic regression there are many parameters tested for the 
clinical outcomes. All the parameters that were significant in univariate 
regression were chosen for multivariate regression. The issue with this method 
is, too many variables can cancel each other’s effect for a smaller sample size 
(over fitting model) and the results could be confounded. 
8.5 Conclusions 
 Poorer 90 day outcomes after thrombolysis occurred frequently at a hospital 
that accepted secondary transfer patients compared to a hospital in the same 
city that did not routinely take such patients. Adjusted mortality was 
significantly higher in peripheral referrals versus direct SGH admissions, WIG 
compared to rest of UK. These poorer outcomes were accounted for by the 
secondary transfer patients.  
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Chapter 9 : Summary of chapters: Exploration of 
Perfusion Imaging; Applicability of Capillary 
transit time heterogeneity (CTTH) in perfusion 
Imaging; Stroke outcomes in different Care 
settings 
9.1 Introduction 
Stroke outcomes are heterogeneous and several predictive factors have been 
shown to influence, some of which are related to patient factors and some are 
to tissue Imaging. Majority of thesis chapters explored imaging related factors 
relevant to tissue outcomes in Ischaemic stroke, and to complement this I have 
also conducted a clinical outcome comparison between two hospitals and to rest 
of the UK using SITS stroke database. Here, I have summarised the Imaging 
chapters and clinical outcomes chapter and how they complement each other in 
the sections below.  
9.2 Imaging factors 
CT Perfusion can provide cerebral blood flow values and with the severity of CBF 
reduction, the brain tissue outcome can be predicted. A severely reduced CBF 
would lead to tissue infarction. The animal models have consistently shown that 
increasing time from a large vessel occlusion, the size of irreversibly damaged 
brain tissue increases in size. This was shown to be due to infarction of the 
penumbra spreading from the core, if there is no restoration of blood flow. The 
lepto-meningeal collateral failure was also thought to contribute to this 
expansion of irreversibly ischaemic tissue313.  The intra venous thrombolysis 
clinical studies in humans also showed that benefit from treatment drops with 
increasing time reaching to no benefit after 4.5 hours261. These trials used only 
plain CT imaging for patient selection. The heterogeneous Imaging factors (such 
as location of vessel occlusion, lepto-meningeal collateral status, core, 
penumbra volumes) were not included in these human trials. However, several 
human advanced imaging studies showed that penumbra can persist in significant 
proportion in some patients up to longer time delays than 4.5 hours. This is 
shown to be useful in patient selection for later time window thrombolysis trials 
such as EXTEND and thrombectomy trials such as DEFUSE 3251,273. Failure of 
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collateral flow is associated with infarct growth is observed in recent 
thrombectomy trials316.  
In this thesis, I have explored whether the penumbra volume reduces with 
increasing time and particularly tested if good vs. poor collaterals can influence 
this. Within 6 hours of symptom onset, the penumbra volume did not change 
significantly with increasing time under 6 hours across a cross section of 
patients. However, a divergent effect with trend for penumbra volume 
decreasing with increasing time in patients with poor collaterals was seen. 
Similar to our findings, Miteff et al showed that good collaterals are associated 
with large penumbra by limiting expansion of core297. Good collaterals are shown 
to be associated with favourable clinical outcomes in earlier clinical 
studies292,396. Due to this overwhelming evidence, subjects with poor collateral 
status or large “core” were excluded from a landmark thrombectomy trial271. 
Fast progressors (Subjects with fast Infarct growth) have poor collaterals and 
hence greater need for speedy and earlier intervention in comparison to slow 
progressors (Subjects with slow Infarct growth) who have good collaterals 397. 
The Imaging outcomes after ischemic stroke also influence patient outcomes. 
Haemorrhage and oedema after ischemic stroke have negative influence in 
patient outcomes. The stroke complications haemorrhage and cerebral oedema 
can be predicted from patient and baseline imaging factors. In this thesis, I 
investigated perfusion imaging factors (e.g. core volume), recanalisation status 
and how they interact in relation to haemorrhage and oedema outcomes. Plain 
CT can help in excluding stroke mimics and can show early ischaemic signs. 
Measuring the extent of early ischemic signs with ASPECT score can be valuable 
in predicting the extent of Ischemia and risk of malignant oedema and 
haemorrhage398,399. However, plain CT does not give information on perfusion 
status, collaterals and of course on recanalisation. Previous studies showed 
increased risk of symptomatic haemorrhage if reperfusion occurred in a large 
ischaemic area (i.e. large core)334. However, interaction of recanalisation and 
core tissue in both oedema and haemorrhage outcomes after IV thrombolysis was 
not previously studied. We hypothesised that recanalisation of a large ischaemic 
core would cause significant haemorrhage and non-recanalisation would lead to 
significant oedema.  In my study, a large core volume was associated with any 
haemorrhage and significant brain oedema, and recanalisation with any 
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haemorrhage. However, interaction of core size, recanalisation was not 
associated with haemorrhage or oedema.  Oedema, haemorrhage was less seen 
in early improvers (recanalised) compared to no improvers (late recanalised) or 
no improvers (non-recanalised). 
Although several CT perfusion parameters have been validated, there is no 
standardisation of what parameters and what thresholds best define the brain 
tissue into core, penumbra. Moreover, micro vascular capillary heterogeneity is 
not incorporated and homogeneity is assumed in the standard perfusion models. 
Capillary transit time heterogeneity (CTTH) was hypothesised and in this thesis 
using CT perfusion images, CTTH was at first derived through a complex model; 
once successful, CTTH was then explored in studying two main Imaging aspects; 
does CTTH differ significantly in core, penumbra and non-core-non-penumbra 
tissue (i.e. Does CTTH vary significantly in penumbra and non-core-non- 
penumbra infarction); does the subjects with non-core-non-penumbra tissue 
infarction have different risk factors and patient demographics; whether CTTH 
values vary significantly in this group. This information would complement other 
patient outcome factors in previous chapters. Although the CTTH work did not 
provide any definitive answers, we were successful in deriving the Capillary level 
parameter in CT perfusion complementing MR perfusion capillary level work and 
paving the way for larger studies using CT perfusion images. 
9.3 Stroke care model and/ or Organisational factors: 
The literature on stroke patient outcomes comparison in different stroke care 
models is limited. Hyper-acute stroke Units covering a larger geographical area 
could lead to treatment delays and also lead to bias in treating even most severe 
strokes if transferred from smaller centres. Transferred patients contributed to 
higher risk of poorer outcomes in hospital registry study400.  Also, patient 
demographics such as socio-economic status which is not captured routinely 
could contribute to patient outcomes. Repatriation of patients from one hospital 
to other hospital may compromise continuity of care and lead to poor functional 
outcomes.  In this thesis, stroke outcomes were compared between two 
hospitals in Glasgow (with a different geographical catchment and socio-
economic status) and with the rest of the UK. Referrals from small hospitals to 
Southern General hospital had poorer outcomes and increased mortality 
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compared to the direct admissions. This was not fully explained by the onset to 
treatment time. This may due to other factors as mentioned above, such as 
socio-economic status, lack of continuity of care as these patients were more 
likely to be repatriated soon after acute stroke. 
 Imaging selection can potentially assist decision making in patients requiring 
inter hospital transfer. If perfusion parameters identify poor collateral and large 
core, then reperfusion has to happen very quickly to be beneficial and reduce 
risk of ICH. Transfer of such patients beyond a time threshold could potentially 
be avoided and local delivery of thrombolytic therapy may be the best option 
available. Conversely, slow progressor with good collateral patients could be 
selected for transfer and endovascular treatment. Imaging triage could be a 
mechanism for improving the quality of regional stroke networks to minimise 
futile inter hospital transfer. 
In conclusion, in this thesis, I have explored Ischaemic Stroke outcomes 
encompassing advanced imaging and stroke care models. 
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